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ABSTRACT 
 
Joshua Gregory Gober: Rational Engineering of Cytochrome P450 Enzymes 
(Under the direction of Eric Brustad) 
 
Cytochrome P450s, which typically catalyze oxidation reactions via an iron-oxo species, 
have recently been reported to cyclopropanate alkenes in the presence of diazoacetate reagents 
through formation of an iron carbenoid. Stereoselective enzymes for carbenoid insertion into aryl 
olefins have been reported; however, engineering selective variants for all of the possible 
isomers of the reaction remains a challenge. Earlier work with a model P450 (P450 BM3) 
reported a highly activating mutation of a conserved active site threonine to alanine that resulted 
in dramatic improvements in enantioselectivity and diastereoselectivity for the model reaction of 
styrene with ethyl diazoacetate. This work demonstrates that by incorporating this single 
mutation into a diverse panel of a dozen P450s from various microorganisms, enantioselective 
and diastereoselective catalysts can be quickly identified for all isomers in the reaction of styrene 
with ethyl diazoacetate. 
This work also demonstrates the utility of intermolecular, P450-mediated olefin 
cyclopropanation for selective, late-stage modification of complex natural products. In this study, 
a diverse set of engineered P450s were found to catalyze cyclopropanation of dehydroalanines 
(Dhas), which are commonly found in natural products. P450s involved in the biosynthesis of a 
pyridine-containing thiopeptide, thiomuracin GZ, were found to catalyze cyclopropanation of 
thiomuracin derivatives engineered to display Dhas at key residues. This work presents a strategy 
iv 
for chemoselective and stereoselective modification of complex natural products using a rational 
engineering approach. 
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CHAPTER 1: NON-NATURAL CARBENOID AND NITRENOID INSERTION 
REACTIONS CATALYZED BY HEME PROTEINS 
 
Introduction 
In recent years, the use of biocatalysts to synthesize optically pure organic molecules has 
garnered considerable interest for use in pharmaceutical and industrial applications. Enzymes are 
especially attractive because they offer advantages of high selectivity and mild, sustainable 
reaction conditions. Traditional enzyme engineering efforts have focused on adapting natural 
biocatalysis. For example, directed evolution has proven to be a valuable tool to enhance the 
organic solvent tolerance, pH stability, and thermostability of enzymes for use under industrially 
relevant reaction conditions.1 In addition, directed evolution as well as rational and 
computational design are now widely used to expand the scope of native enzymes to include 
synthetic substrates of medicinal and fine chemical importance. Despite the increasing interest in 
using enzymes as tools for synthesis, adapting reactions discovered through chemical ingenuity 
remains challenging, and many synthetic transformations have no biological counterpart. This 
vacancy in the field has compelled researchers to develop strategies to adapt protein scaffolds for 
new reactivity. Historically, a number of approaches have been applied to engineer protein 
pockets to carry out non-native chemical transformations. For example, protein cavities have 
been engineered to bind non-natural transition states using in silico tools such as Rosetta, or 
_________________________ 
1Edited with permission from: Gober, J. G.; Brustad, E. M. “Non-natural carbenoid and nitrenoid 
insertion reactions catalyzed by heme proteins.” Curr. Opin. Chem. Biol. 2016, 35, 124-132. 
Copyright © 2016 Elsevier Ltd. 
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through immunization with transition state analogs to generate catalytic antibodies.2,3 
Alternatively, natural active sites may show weak but fortuitous activity for side reactions that 
share mechanistic features with the enzyme’s native chemistry.4 These promiscuous functions 
can often be optimized by evolution in both nature and in the lab when enzyme variants are 
interrogated against reaction conditions where new reactivity may provide a selective advantage. 
In addition to promiscuous reactivity driven directly by protein scaffolds, recent efforts 
have sought to take advantage of alternative reaction landscapes mediated by enzyme cofactors. 
(Note: The term cofactor is used to broadly encompass protein-bound accessory molecules 
including cofactors, coenzymes, prosthetic groups, and metal ions). In nature, cofactors serve to 
augment the reactivity of proteins beyond limitations imposed by the canonical amino acids. In 
many cases, cofactors have served as inspiration for the design of synthetic small molecule 
catalysts that mimic or expand on cofactor function. For example, about 60 years ago, in research 
aimed at elucidating the mechanistic basis of thiamine (vitamin B1) catalysis, Breslow correctly 
identified that the central thiazole moiety of thiamine forms a stabilized N-heterocyclic carbene 
(NHC) that is responsible for catalysis.5 This seminal discovery proved to be a launching point 
for a new field of chemistry aimed at developing synthetic NHCs for organocatalysis, among 
other applications. In a complementary fashion, taking inspiration from this resulting synthetic 
creativity, Müller and coworkers have gone on to show that thiamine-dependent enzymes 
catalyze a number of non-natural, NHC-dependent reactions including asymmetric benzoin 
condensation and Stetter reactions.6 
Transition metals offer intriguing targets for expanding protein function due to their 
diverse range of reactivity and their ability to function on a wide range of substrates. Indeed, 
since the 1970s, a variety of techniques have been developed to introduce non-natural 
17 
metallocofactors into protein cavities to generate novel biocatalysts.7,8 Remarkably, while 
approximately one third of all proteins are metalloproteins, little effort has focused on 
determining whether or not natural protein-bound transition metal centers possess the diverse 
reactivity observed with similar synthetic transition metal complexes.  
Heme proteins have served as sources of inspiration for synthetic chemists due to the 
diverse range of activities exhibited by these proteins. For example, cytochrome P450s, many of 
which use a high-valent iron-oxo species to oxidize unactivated C-H bonds, have motivated 
many research groups to design small molecule catalysts that mimic features of these powerful 
catalysts. Conversely, biological engineers are now taking lessons learned from synthetic 
metalloporphyrin chemistry to augment the chemical capabilities of protein-bound heme 
molecules. Small molecule metalloporphyrins have been shown to catalyze P450-like oxidation 
reactions, and in addition, mechanistically related carbenoid and nitrenoid transfer reactions 
using reactive intermediates that bear significant structural and electronic similarity to the native 
P450-oxenoid (Figure 1.1). Here, I highlight recent work demonstrating that in the presence of 
synthetic reagents, numerous heme proteins, including P450s and globins, catalyze a broad array 
of abiological carbenoid and nitrenoid transfer transformations, opening new avenues for the 
construction of complex carbon-carbon, carbon-nitrogen, and other bonds using chemistry that 
has not previously been explored by Nature. 
Carbenoid transfer reactions 
Enzymatic olefin cyclopropanation 
Cyclopropanation via carbenoid transfer to olefins is a hallmark reaction catalyzed by 
synthetic metalloporphyrins and other organometallic complexes. In 2013, Arnold and 
colleagues reported that the iron porphyrin of heme proteins is able to carry out similar non- 
18 
 
Figure 1.1. Reactive intermediates involved in metalloporphyrin catalyzed transformations. 
Cytochrome P450BM3 (PDB 2IJ2, top left) and myoglobin (PDB 1MBN, top right) contain the 
cofactor iron protoporphyrin IX (heme). Non-natural reactions catalyzed by P450BM3 and 
myoglobin were inspired by biomimetic small molecule catalysts such as metal 
tetraphenylporphyrins that have been shown to catalyze transformations that proceed through 
carbenoid and nitrenoid intermediates similar in structure to the reactive oxenoid intermediate 
that drives native cytochrome P450 catalysis. 
 
natural metallocarbenoid chemistry.9 Diverse heme scaffolds including free hemin, horseradish 
peroxidase, myoglobin, cytochrome c, and cytochrome P450BM3 (BM3), all catalyzed the model 
cyclopropanation of styrene using ethyl diazoacetate (EDA) as a carbene precursor, producing 
four diastereomeric products (two cis and two trans, Figure 1.2A and Table 1.1, Entry 1) albeit 
with low yield. Intriguingly, BM3, a cytochrome P450 (P450) that has proven robust for enzyme 
engineering applications, showed altered diastereoselectivity (37:63; cis:trans) when compared 
to free hemin (6:94), providing evidence that product distribution can be controlled by the 
architecture of the heme-binding pocket. 
metalloporphyrin reactive intermediates
M
O
metal carbenoid
C-H alkylation,
cyclopropanation
metal nitrenoid
C-H amination,
aziridination
metal oxenoid
C-H hydroxylation,
epoxidation
R
M
C
R
M
N
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Figure 1.2. Selectivity, structural insight, and application of P450-catalyzed cyclopropanation. 
(a) Chiral gas chromatography traces show the stereoselectivities obtained in the reaction of 
styrene and ethyl diazoacetate using variants of the model P450BM3 and variants generated in a 
diversity-oriented P450 library. (b) Structural comparison of wild type CYP119 (cyan, PDB 
1F4T) and CYP119-T213A/C317H (green, PDB 5bv5) shows that mutation of the axially-
ligating cysteine to histidine causes considerable changes to the orientation of the heme cofactor 
within the active site. (c) An engineered P450BM3 variant BM3-Hstar allows for the synthesis of a 
levomilnacipran precursor in high yield and excellent stereoselectivity. 
 
Enzymatic cyclopropanation was improved by screening a panel of 92 pre-engineered 
BM3 variants that had been isolated over the course of past directed evolution efforts aimed at 
expanding native P450 biocatalysis. Of the ~ 10 active variants that were identified, most 
displayed hemin-like product distributions favoring formation of trans-cyclopropanes; however, 
a few variants displayed altered preference for cis-cyclopropanes. 
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Table 1.1. Summary of carbenoid- and nitrenoid-mediated transformations 
catalyzed by heme-containing enzymes 
Carbenoid-mediated 
Entry Substrate(s) Product Protein(s) Reference(s) 
1 
  
cytochrome P450; 
myoglobin 
9-14, 16 
2 
  
cytochrome P450; 
myoglobin 
17-18 
3 
  
myoglobin 19 
4 
  
myoglobin; 
YfeX 
20-21 
Nitrenoid-mediated 
Entry Substrate(s) Product Protein(s) Reference(s) 
5 
  
cytochrome P450 29 
6 
  
cytochrome P450; 
myoglobin 
22, 24-25 
7 
 
 
cytochrome P450 23 
8 
  
cytochrome P450 26 
9 
  
cytochrome P450 27-28 
 
Sequence analysis of highly active BM3 variants revealed that, in addition to other 
mutations, each contained the same Ala mutation in place of a highly conserved active site Thr 
(T268A). Remarkably, grafting the T268A mutation alone into wild type BM3 transformed the 
enzyme into a highly active and trans-selective cyclopropanation catalyst (Figure 1.2A, 323 total 
turnover (TTN), 1:99 dr, 96 % ee). Mutations were also capable of tuning product distribution. 
Site saturation mutagenesis performed individually on active site residues of a moderately cis-
selective variant, BM3-CIS (13 mutations from wild type; 71:29 dr and 94% ee), led to the 
isolation of a variant with a single point mutation (BM3-CIS-T438S) that enriched production 
21 
(Figure 1.2A, 293 TTN, 92:8 dr, 97% ee) of a cis-cyclopropane diastereomer that is challenging 
to make using traditional synthetic cyclopropanation catalysts. 
Since this initial report, metallocarbenoid-mediated cyclopropanation has been shown to 
be a general feature of the P450 family of enzymes.10,11 Brustad and coworkers recently explored 
the generality of enzyme-catalyzed cyclopropanation by tapping into natural P450 diversity (this 
work is described in more detail in Chapter 2).11 A library of over one dozen wild type P450s 
(24% average sequence identity to BM3) and their corresponding T268A mutation (found to be 
activating in BM3) was constructed and screened in the reaction of styrene with EDA. All of the 
wild type P450s were active, and over half of the enzymes from the library experienced an 
increase in activity and/or selectivity in the presence of the Ala mutation. Notably, from this 
small, diversity-oriented library, individual protein scaffolds were identified that provided 
selective enrichment for each of the four possible cyclopropane stereoisomers (Figure 1.2A). 
Under biological conditions, carbenoid insertion is outcompeted by native P450-mediated 
monooxygenation (providing epoxides from olefins). Similar to monooxygenation, carbene 
precursor activation requires initial single-electron reduction of the resting state Fe3+-heme. 
During native P450 catalysis, substrate binding leads to an increase in the heme iron reduction 
potential, facilitating electron transfer from biological reductants such as NAD(P)H. Non-natural 
substrates such as styrene, however, may not efficiently induce the conformational changes 
necessary to drive this process. Accordingly, an anaerobic environment and strong reductants, 
such as sodium dithionite, are required to provide useful levels of in vitro enzymatic 
cyclopropanation. Several groups have shown that the activity of P450s for non-native chemistry 
can be significantly improved by tuning the inner coordination sphere of the iron center. Arnold 
and Brustad demonstrated that mutation of the conserved axial Cys ligand of P450s to Ser 
22 
provided a new variant (denoted cytochrome P411 due to a distinctive shift in the carbon 
monoxide-bound heme Soret band from 450 nm to 411 nm) that was incapable of carrying out 
monooxygenation chemistry and fortuitously showed enhanced activity towards enzymatic 
carbenoid-insertion reactions.12 The mutation increased the resting state heme reduction potential 
from ~ − 420 mV to ~ − 290 mV (in the wild type BM3 backbone, all potentials versus standard 
hydrogen electrode) resulting in thermodynamically favorable P411 reduction by NAD(P)H (− 
320 mV). Enhanced activity by P411s enabled whole-cell cyclopropanation reactions for the 
preparative-scale synthesis of phenyl cyclopropanes (27 g/L; 48,800 TTN), and lyophilized cells 
performed well without major loss of stereoselectivity, providing an operationally facile 
biocatalytic platform for cyclopropane synthesis. 
Wang et al. have gone on to show that a number of altered proximal ligation states are 
accommodated within expressed P450s.13 Notably, a Cys-to-His mutation in BM3-T268A 
greatly increased cyclopropanation activity and expanded substrate scope to include an electron-
deficient olefin that can be used as an intermediate in the synthesis of the antidepressant 
levomilnacipran (Figure 1.2B and C). Further directed evolution via iterative site saturation 
mutagenesis led to the isolation of a new catalyst, BM3-Hstar, which catalyzed the reaction in 
92% yield, 96% de, and 92% ee. BM3-Hstar exhibits an impressive rate of cyclopropanation, 
achieving 80% yield in 10 mins, and remains active and stereoselective in the presence of 
oxygen. BM3-Hstar was used to prepare, in whole cells, a small library of levomilnacipran 
derivative precursors in high yields and moderate to very good selectivities.14 Analysis of an X-
ray crystal structure of a thermostable P450, CYP119, bearing the Cys-to-His mutation showed 
that substantial structural rearrangements were required to accommodate the altered heme-
23 
ligation state (Figure 1.2B).15 Accordingly, these destabilizing axial mutations may not be 
accessible in all P450 scaffolds. 
Expanding beyond cytochrome P450s, Fasan and coworkers have shown that myoglobin 
(Mb), which natively contains a His-ligated heme, can also be engineered to produce highly 
functional cyclopropanation catalysts.16 Using a limited diversity active site library in which 
residues in the distal pocket of Mb were mutated to Ala, Val, Phe, or Trp, beneficial mutations 
were identified that when combined produced a remarkable variant (Mb-H64V/V68A) that 
catalyzed the cyclopropanation of styrene with EDA in >99% de, >99% ee, and > 10,000 TTN, 
indicating that protein-based, carbenoid-insertion catalysts can achieve synthetically relevant 
activities and selectivities. The engineered Mb variant maintained high diastereo- and 
enantioselectivity on a variety of substituted styrenes, and mechanistic investigations performed 
on electronically tuned styrenes provided evidence that an electrophilic heme-centered carbenoid 
is generated during the catalytic cycle. 
Enzymatic X-H carbenoid insertion reactions 
In addition to carbenoid-mediated olefin cyclopropanation, iron porphyrins are also able 
to catalyze carbenoid insertion into O-H, N-H, and S-H bonds. By screening a small panel of 
BM3 cyclopropanation catalysts, Wang et al. identified one variant, H2-5-F10, that was able to 
catalyze the N-H insertion reaction of EDA and aniline in 47% yield (Table 1.1, Entry 2).17 
Using H2-5-F10 as a catalyst, electron-rich anilines gave moderate to high yields, but alkyl 
amines were poor substrates for the reaction. Substitutions to the para- position of aniline were 
well tolerated; however ortho- substitutions and increased steric bulk with respect to the carbene 
precursor resulted in decreased yields. 
24 
Fasan and coworkers have demonstrated that myoglobin variants can also catalyze N-H 
and S-H insertion reactions (Table 1.1, Entries 2 and 3).18,19 For example, Mb-H64V/V68A, 
previously engineered to be a highly active and selective cyclopropanation catalyst, was also a 
very robust catalyst for carbenoid insertion into anilines. Substitutions at the ortho-, meta-, and 
para- positions were well tolerated, as were both electron withdrawing and electron donating 
groups. In the reaction of aniline with ethyl diazoacetate, Mb-H64V/V68A catalyzed formation 
of the single N-H insertion product in > 99% yield and ~3000 TTN at high substrate loading. 
Mb variants were also screened in the S-H insertion reaction of thiophenol with ethyl 
diazoacetate (Table 1.1, Entry 3).19 Mb-L29A and Mb-L29A/H64V showed a greater than two-
fold increase in activity for the model reaction compared to wild type Mb. Thiophenols 
containing electron donating and electron withdrawing groups at the ortho-, meta-, and para-
positions as well as benzyl, alkyl, and cycloalkyl mercaptans worked well in the reaction. Yields 
of 60% to > 99% could be achieved on select substrates using low catalyst loading (0.2 mol%). 
The reaction of ally(phenyl)sulfane and ethyl diazoacetate was used to probe the mechanism of 
S-H insertion. A [2,3]-sigmatropic rearrangement was observed, which is consistent with a 
stepwise mechanism that proceeds via a sulfonium ylide intermediate (Figure 1.3A). The 
observed enantioselectivity suggests that the sulfonium ylide is associated with the heme or the 
active site prior to protonation.   
Enzymatic olefination of carbonyl compounds 
Phosphonium ylides are known to react with aldehydes to generate E or Z olefins. Fasan and 
associates have shown that both hemin and Mb variants are active olefination catalysts in the 
reaction of benzaldehyde with ethyl diazoacetate in the presence of either triphenylphosphine or 
triphenylarsine oxophiles (Table 1.1, Entry 4).20 The choice of triphenylphosphine and its 
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Figure 1.3. Proposed mechanisms for some carbenoid- and nitrenoid-mediated transformations 
catalyzed by heme-containing enzymes. (a) The S-H insertion reaction of ally(phenyl)sulfane 
and ethyl diazoacetate catalyzed by myoglobin variants is proposed to involve a sulfonium ylide 
intermediate that undergoes a [2,3]-sigmatropic rearrangement to furnish the final product. (b) 
The olefination of aryl aldehydes catalyzed by myoglobin variants is proposed to involve a 
phosphonium ylide that reacts in a Wittig-like process to yield α,β-unsaturated esters. (c) Allylic 
amination catalyzed by engineered P450BM3 variants is proposed to proceed through initial 
sulfimidation of an allylic sulfide using p-toluenesulfonyl azide followed by a [2,3]-sigmatropic 
rearrangement and reductive cleavage to give the chiral protected allylic amine. 
 
 
 
(a)
(c)
(b) 
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congeners in addition to mutations within the protein scaffold had an impact on conversion and 
diastereoselectivity. Aromatic aldehydes with electronic and steric substitutions could be used in 
the reaction without compromising selectivity; however, substitutions to the α-position of the 
carbene precursor were not tolerated. Similar to sulfonium ylide formation in S-H insertion 
reactions, the proposed mechanism for aldehyde olefination involves attack of an electrophilic 
iron carbenoid by triphenylphosphine to generate a phosphonium ylide (Figure 1.3B). The ylide 
is then proposed to react with an aldehyde to form an oxaphosphetane intermediate that 
rearranges to yield the olefin and triphenylphosphine oxide. The selectivity-determining step 
likely occurs during formation of the oxaphosphetane. The phosphine oxide byproduct however, 
was found to be inhibitory, limiting total conversion to < 50%. 
Hauer and coworkers have gone on to show that some heme-containing enzymes also 
catalyze carbonyl olefination in the absence of an oxophile (Table 1.1, Entry 4).21 From a screen 
of concentrated and fractionated E. coli lysate, four heme-containing proteins were found to 
catalyze the olefination of benzaldehyde with ethyl diazoacetate in the absence of 
triphenylphosphine. YfeX, an E. coli protein of unknown function, was found to be the most 
active of the screened enzymes. Overexpression of YfeX in E. coli resulted in a > 2 fold increase 
in product formation in whole cells (440 mgL-1hr-1). Distinct from Mb-catalyzed olefination, in 
the absence of an oxophile, a nucleophilic carbene has been hypothesized to attack the aldehyde 
directly, forming an iron oxetane intermediate which rearranges to form the alkene and the native 
P450 monooxygenation intermediate, Compound I. The proposed formation of Compound I is 
supported by the observation of non-productive alkene epoxidation byproducts. 
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Nitrenoid transfer reactions 
Enzymatic intramolecular C-H amination 
Shortly after reporting P450-mediated cyclopropanation, Arnold and coworkers went on 
to show that many of the same P450-scaffolds also catalyzed metallonitrenoid insertions, 
including the intramolecular C-H amination of benzylic carbons.22 In this work, a panel of Cys- 
and Ser-ligated BM3 variants was screened for C-H amination of 2,4,6-triethylbenzene-1-
sulfonyl azide (Table 1.1, Entry 6). While the wild type enzyme was poorly active, mutations 
previously identified as activating for P450-mediated cyclopropanation (T268A and C400S) 
substantially enhanced enzymatic C-H amination. Substoichiometric quantities of NADPH or 
sodium dithionite as reductants supported activity, providing evidence that the active ferrous-
heme is regenerated during the catalytic cycle. Activity was inversely correlated with C-H bond 
strength when free hemin was used as a catalyst, yielding a racemic mixture of the benzosultam 
products. Intriguingly, highly active P411-based catalysts did not show the same dependence on 
bond strength and catalyzed the reactions with considerable asymmetric induction. These data 
suggest that the enzyme active site influences both stereoselectivity and reactivity in 
intramolecular C-H aminations. In an exciting follow up, Hyster et al. have shown that P450 
active sites can also tune the regioselectivity of C-H aminations.23 Using 2,5-
diisopropylbenzene-1-sulfonyl azide as a model substrate, P411 screening and subsequent active 
site directed evolution led to the isolation of variants enriched for C-H amination at the 
homobenzylic carbon (Table 1.1, Entry 7), providing evidence that enzymatic nitrenoid insertion 
reactions can also target less activated C-H bonds. 
Intramolecular C-H amination via Cys-ligated BM3 variants has been further confirmed 
by Fasan and colleagues, who examined a series of benzenesulfonyl azide substrates in order to 
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better understand the requirements for C-H activation.24 Altering electronics on the benzene ring 
did not appreciably affect catalysis; however, increased steric bulk was shown to be an important 
factor to achieve high activity. It has been suggested that larger substituents may help orient the 
C-H bond in close proximity to the metallonitrenoid intermediate in a manner that favors C-H 
insertion. The Fasan lab also showed that a number of heme proteins, including catalase, 
horseradish peroxidase, myoglobin, and hemoglobin, all catalyze intramolecular benzylic C-H 
amination using benzenesulfonyl azide substrates.25 In addition, these authors have demonstrated 
that alternative organoazide nitrene precursors, including carbonazidates, also function in P450-
mediated C-H amination reactions, providing an enzymatic source to synthetic precursors for 
valuable 1,2-amino alcohols (Table 1.1, Entry 8).26 
One limiting feature in P450-mediated nitrenoid insertions is the non-productive over-
reduction of the sulfonyl azide precursor to yield the corresponding sulfonamide. Through their 
investigations, Singh et al. observed that the T268A mutation in BM3 (generally activating in 
carbenoid and nitrenoid insertions), also substantially reduced formation of this byproduct.24 In 
native P450 catalysis, this conserved active site threonine plays a pivotal role in proton transfer 
events that are important for monooxygenation. Mutation to Ala likely favors productive C-H 
amination by decreasing the rate of off-path, non-productive protonation of the metallonitrenoid 
intermediate, thereby improving the efficiency of the desired nitrenoid insertion. 
Enzymatic intermolecular sulfimidation 
It is well known that the active oxenoid intermediate (Compound I) responsible for P450-
mediated monooxygenations, can also react with aryl sulfides to generate sulfoxides. 
Analogously, Farwell et al. have recently shown that P450-centered metallonitrenoids can mimic 
this process to generate sulfimides in an asymmetric fashion.27 A number of BM3 variants were 
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shown to be active in the reaction of tosyl azide (as a nitrene precursor) with thioanisole (Table 
1.1, Entry 9). While Cys-ligated enzymes were poorly active, substantial product formation 
(>300 TTN) was observed for Ser-substituted P411BM3 variants. Importantly, similar to other 
carbenoid and nitrenoid insertion chemistries described here, the composition of the heme-
binding pocket plays an important role in substrate orientation as selective scaffolds were 
identified for the enriched production of either sulfimide enantiomer. 
To date, substrate scope in enzymatic sulfimidation reactions remains quite limited. 
Hammett analysis comparing rates of enzymatic sulfimidation on electronically tuned 
thioanisoles produced a linear free energy relationship indicative of a buildup of partial positive 
charge on the sulfide during the rate-limiting step.27 These data suggest that the electronics of the 
aryl sulfide also play a key role in determining the overall yields of sulfimidation products. In 
addition, while a number of sulfonyl azide nitrene precursors of varied size were examined in 
this reaction, only tosyl azide provided productive sulfimidation. Limitations in nitrene precursor 
scope in this and other enzymatic nitrenoid insertion reactions remains poorly understood. 
In a clever follow up to this initial work, Prier et al. have adapted enzymatic 
sulfimidation for the selective synthesis of chiral amines.28 By using a substrate walking 
approach in combination with directed evolution, the authors were able to isolate a P411 variant 
that demonstrated sulfimidation on phenyl crotyl sulfide (Figure 1.3C). Allylic sulfimides are 
known to undergo stereospecific [2,3]-sigmatropic rearrangements to yield protected allylic 
amines. Whole-cell sulfimidation of phenyl crotyl sulfide in the presence of tosyl azide using an 
optimized P411 scaffold led to the formation of the corresponding allylic amine in 77% yield, 
2200 TTN, and 68% ee upon reductive workup. Enantioselectivity for the resulting allylic 
amines, while moderate, were attenuated in comparison to stereoselectivities achieved during 
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sulfimidation of alkyl sulfides. The difference in observed selectivities using alkyl sulfides and 
allylic sulfides of comparable size suggests that enantiopurity may erode during the sigmatropic 
rearrangement. 
Enzymatic intermolecular aziridination 
Nitrenoid-mediated aziridination reactions of olefins bear mechanistic similarity to both 
carbenoid-mediated cyclopropanation and oxenoid-mediated epoxidation reactions. In nature, 
aziridine biosynthesis is accomplished through nucleophilic substitution reactions. Accordingly, 
enzymatic aziridination via nitrene transfer would provide a novel strategy for synthesizing these 
synthetically relevant functionalities in a manner not previously observed in biology. Based on 
their earlier success, Arnold and coworkers screened a variety of P411 enzymes that previously 
demonstrated C-H amination and/or sulfimidation activity for the nitrenoid-mediated 
aziridination of substituted styrenes.29 Using tosyl azide as a nitrene precursor, one variant, 
denoted P-I263F, demonstrated considerable activity (>150 TTN) on a number of p-substituted 
styrenes. Electron-rich styrenes provided ring-opened products due to favorable hydrolysis of the 
aziridine product, but less electron-rich substrates including styrene and p-methylstyrene 
provided the desired aziridine product in moderate yield. Initial yields were limited by non-
productive reduction of the metallonitrenoid intermediate yielding sulfonamide byproducts; 
however, aziridination activity and selectivity were further improved via directed evolution using 
site saturation mutagenesis targeted to the substrate-binding pocket. One variant, P-I263F-
A328V-L437V, showed excellent enantioselectivity (99% ee) on p-methylstyrene and improved 
yields due to reduced formation of the sulfonamide byproduct. Impressively, good to excellent 
selectivity was maintained on a variety of substituted styrenes, although complete erosion of 
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stereochemistry was observed in reactions with α-methyl styrene and p-methoxystyrene due to 
ring opening of the aziridine with water. 
Conclusion 
Engineering enzyme scaffolds that carry out non-natural chemical transformations has 
been a longstanding goal of protein chemists in an effort to combine lessons learned from 
synthetic chemistry with the selectivity and evolvability imparted by genetically encoded 
biocatalysts. Since the initial report of protein-mediated carbenoid insertion in 2013, rapid 
progress has been made with regards to increasing the synthetic repertoire of heme proteins to 
include a variety of metallocarbenoid and nitrenoid transfer reactions. Importantly, researchers 
have shown that the heme cofactor provides reactivity that can be tuned by the protein scaffold 
using well-established protein engineering and directed evolution techniques. It is reasonable to 
suspect that, under the right conditions, other synthetic transformations that exploit these reactive 
intermediates as well as alternative chemistries driven by synthetic iron porphyrins, may 
similarly be accessible using heme proteins as catalysts. For example, expanding heme protein 
catalysis to include intermolecular carbenoid and nitrenoid insertion into unactivated C-H bonds 
– advancing on the early intramolecular C-H amination work highlighted here – would mark a 
significant achievement and would accelerate the late-stage diversification of small molecules. 
The outlook for the continued expansion of synthetically useful metallo- and organocofactor-
catalyzed reactions is promising given the wealth of transformations mediated by synthetic 
transition metal complexes and organocatalysts. Using chemistry as a guide, the identification of 
promiscuous reactivity in heme and other natural, protein-bound catalysts may provide a rapid 
means of expanding the reactive landscape available to protein engineers. 
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CHAPTER 2: MUTATING A HIGHLY CONSERVED RESIDUE IN DIVERSE 
CYTOCHROME P450S FACILITATES DIASTEREOSELECTIVE OLEFIN 
CYCLOPROPANATION2 
 
Introduction 
One approach to uncovering new modes of enzyme catalysis is to use man-made reagents 
that provide access to reactive intermediates not typically found in nature.1 For example, 
intermolecular metal-catalyzed cyclopropanation is a well-characterized reaction that allows 
functionalization of olefins with a variety of synthetic carbene precursors. Cyclopropanes are 
valuable synthetic targets due to their presence in natural products and pharmaceuticals as well 
as their use as synthetic intermediates that undergo stereoselective ring-opening 
transformations.2-5 A variety of transition metal complexes, including metalloporphyrins similar 
to the native prosthetic group hemin, have been applied for this transformation, but the design of 
competent catalysts that demonstrate high diastereo- and enantioselectivity has remained 
challenging.6-14  
Recent work by Arnold and Fasan has shown that heme-containing proteins, including 
members of the cytochrome P450 family of enzymes (P450s) and myoglobin, promote the 
promiscuous cyclopropanation of styrenes in the presence of diazoacetates.15-17 In contrast to free 
hemin, which produces a racemic mixture of predominantly trans-cyclopropanes with low total  
 
______________________ 
2Edited with permission from: Gober, J. G.; Rydeen, A. E.; Gibson-O’Grady, E. J.; Leuthaeuser, 
J. B.; Fetrow, J. S.; Brustad, E. M. “Mutating a Highly Conserved Residue in Diverse 
Cytochrome P450s Facilitates Diastereoselective Olefin Cyclopropanation.” ChemBioChem 
2016, 17 (5), 394-397. Copyright © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
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Figure 2.1. Styrene cyclopropanation with ethyl diazoacetate catalyzed by P450 variants. Chiral 
GC traces are aligned to provide a visual representation of product distributions. 
 
turnover number (TTN), several native heme proteins exhibit weak to moderate stereoinduction 
and modest catalytic efficiency. 
Engineering efforts on cyclopropanation catalysts derived from myoglobin and the bacterial 
P450BM3 have resulted in increased activity and have led to the facile isolation of highly trans-
selective enzymes. For example, an engineered myoglobin with two mutations from wild type 
showed near-perfect selectivity in the cyclopropanation of styrene with ethyl diazoacetate (EDA) 
producing the 1S,2S isomer with >99% conversion.15 Mutations have also been shown to affect 
activity. While wild type P450BM3 is a weak cyclopropanation catalyst (< 5 TTN), a single active 
site mutation, T268A, improved TTN ~ 65 fold and produced a highly selective variant for the 
1S,2S isomer (99:1 dr, 97% ee; Figures 2.1 and 2.2 and Table 2.1).16 Together these studies 
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demonstrate that the architecture of heme-binding pockets can be leveraged to improve 
selectivity in intermolecular cyclopropanation reactions.  
Despite these efforts, engineering biocatalysts selective for thermodynamically unfavorable 
cis-diastereomers remains a challenge. Cis-selective catalysts for the cyclopropanation of styrene 
with EDA have been identified by screening a library of P450BM3 variants possessing diverse 
active sites (see P450BM3-CIS-T438S, Figure 2.1 and Table 2.1);16,18 however, these catalysts 
contained a large number of mutations (> 10), most of which were acquired over a decade of 
directed evolution. Identifying similar trajectories in other, non-cis-selective scaffolds would 
require considerable engineering and screening efforts. In addition, minor substitutions on 
styrene lead to attenuated or even reversed selectivity (vide infra).16,18 The difficulty in 
engineering cis-selective enzymes illustrates the challenge of using a single protein scaffold to 
alter both diastereo- and enantioselectivity. 
Figure 2.2. Active site of substrate-free 
P450BM3 (PDB: 2IJ2). Conserved residues 
T268, F393, and C400 are colored green, and 
the heme cofactor is colored purple. 
 
We hypothesized that we could access 
stereoselective cyclopropanation catalysts by 
sampling a diverse library of natural P450 
active sites and by introducing strategic 
mutations informed by previous P450BM3 
engineering efforts. In P450BM3, a single mutation, T268A, significantly improves activity and 
selectivity, and the majority of highly active P450BM3 variants contain this mutation (Figures 2.1 
and 2.2 and Table 2.1).16 Because this threonine is highly conserved, we reasoned that this 
mutation might affect cyclopropanation activity and selectivity in other scaffolds. Here we show 
37 
that a small library composed of thirteen diverse P450s and their corresponding alanine variants 
allows for the rapid identification of selective biocatalysts for all four diastereomers of the 
cyclopropanation reaction. 
Results 
Given the ubiquity of P450s in nature, numerous gene sequences are known that encode 
scaffolds that catalyze a range of oxidative and reductive transformations on a wide variety of 
substrates. The vast number of P450s that have been characterized or hypothesized based on 
genome mining makes the selection of viable sequences a non-trivial endeavor. To guide our 
search, we used the bioinformatics tool Deacon Active Site Profiler 2 (DASP2), which allowed 
us to maximize diversity by identifying scaffolds that share motifs necessary for function (e.g. 
the heme ligating cysteine, Figure 2.2) among sequences that share little overall sequence 
identity (See Supporting Information).19-21 From the DASP2 search we identified hundreds of 
unique P450 sequences as potential candidates for library design. The library was further 
narrowed down to enzymes that fit at least two of the following criteria: 1) P450s derived from 
bacterial origin or previously produced in Escherichia coli (to facilitate heterologous 
expression), 2) P450s of known structure (to aid future protein engineering), and 3) sequences 
that shared <20% sequence identity to P450BM3 (to maximize active site structural variation). Our 
final library comprised sixteen P450s, including P450BM3, with diverse activities and substrate 
scopes (Tables S2.1 and S2.2 and Supporting Information text). The average sequence identity 
across the entire library is 24%, and the maximum identity is 46% (P450PikC and P450eryF; 
Figures S2.1 and S2.2). Each enzyme contains the conserved active site threonine, with the 
exceptions of P450eryF and CYP122A2, which contain an alanine and a serine respectively at this 
position (Figures S2.1 and S2.3). The genes of the wild type P450s and their corresponding 
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alanine variants were synthesized by Gen9 Inc. Of the thirty-one wild type and ThrAla 
constructs under investigation, 25 proteins were successfully purified in sufficient quantity for 
screening (Figure S2.4 and Table S2.1). 
Table 2.1. Activities and stereoselectivities of P450 variants for the reaction of styrene 
with ethyl diazoacetate. 
 
 
catalyst yield TTNa dr (cis:trans) ee cis [%]b ee trans [%]c 
Hemin 16 79 13:87 -2 -4 
P450BM3 1 7 12:88 0 -2 
P450BM3-T268A 67 338 1:99 -18 -97 
P450BM3-CIS-T438S 62 311 93:7 -97 -79 
P450BioI 27 135 12:88 8 13 
P450BioI-T238A 48 241 71:29 95 -24 
P450cam 41 207 88:12 -43 9 
P450cam-T252A 30 151 71:29 -86 -5 
P450eryF (A245) 70 349 89:11 -99 -19 
CYP142 49 246 44:56 -84 -6 
CYP142-T234A 54 272 90:10 -97 -14 
CYP164A2 7 34 14:85 5 2 
CYP164A2-T260A 70 350 18:82 -82 -9 
CYP107N1 7 36 9:91 0 -4 
CYP107N1-T251A 48 238 9:91 -3 -3 
P450nor 5 27 12:88 -6 -3 
P450nor-T243A 13 66 10:90 -3 -2 
P450EpoK 49 247 11:89 -15 -22 
P450EpoK-T258A 44 219 18:82 -25 -14 
P450PikC 50 249 8:92 -2 3 
P450PikC-T247A 46 231 7:93 -15 32 
P450RhF 52 258 9:91 -3 -2 
P450RhF-T275A 34 171 12:88 -11 -2 
P450TxtE 37 187 10:90 6 -2 
P450TxtE-T250A 45 225 10:90 -2 -2 
P450TylH1 48 242 13:87 16 8 
P450TylH1-T279A 50 251 10:90 1 -28 
a TTN = total turnover number. b (1S,2R) – (1R,2S). c (1R,2R) – (1S,2S). TTNs and stereoselectivities 
determined by chiral GC analysis.  
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Table 2.2. Substrate scope for most selective variants from the P450 library 
 
 
yield TTNa dr (cis:trans) ee cis [%]b ee trans [%]b 
4a      
hemin 16 79 22:78 0 -3 
P450BM3-T268A 68 342 1:99 33 93 
P450PikC-T247A 50 248 25:75 11 -49 
P450BM3-CIS-T438S 19 95 8:92 8 90 
P450eryF (A245) 30 149 42:58 -5 -37 
P450BioI-T238A 54 271 87:13 -96 8 
CYP142-T234A 47 234 89:11 94 0 
4b      
hemin 18 90 17:83 0 n.d.c 
P450BM3-T268A 65 326 1:99 -40 n.d.c 
P450PikC-T247A 55 276 11:89 -4 n.d.c 
P450BM3-CIS-T438S 61 305 75:25 -79 n.d.c 
P450eryF (A245) 41 204 73:27 -93 n.d.c 
P450BioI-T238A 43 214 66:34 88 n.d.c 
CYP142-T234A 48 241 91:9 -96 n.d.c 
4c      
hemin 6 30 13:87 -1 n.d.c 
P450BM3-T268A 39 195 13:87 -36 n.d.c 
P450PikC-T247A 41 205 9:91 0 n.d.c 
P450BM3-CIS-T438S 59 297 35:65 71 n.d.c 
P450eryF (A245) 17 85 73:27 -81 n.d.c 
P450BioI-T238A 14 70 30:70 59 n.d.c 
CYP142-T234A 34 171 90:10 -96 n.d.c 
aTTN = total turnover numbers. bstereochemistry unassigned; negative sign indicates opposite enantiomer 
is formed. cnot determined; baseline separation could not be achieved. TTNs and stereoselectivities 
determined by chiral GC analysis. 
 
 
All of the wild type P450s screened were active catalysts for the cyclopropanation of styrene 
with EDA, though to varying extents (Table 2.1). The threonine to alanine mutation, which was 
previously found to strongly activate P450BM3 variants,
16 induced similar enhancements in three 
scaffolds (P450nor, CYP107N1, and CYP164A2) that showed weak native activity (< 50 TTN) 
but experienced three to ten-fold increases in TTN upon mutation (Table 2.1). For example, wild 
type CYP164A2 displayed negligible activity (34 TTN), whereas CYP164A2-T260A produced 
cyclopropanes in 70% yield (350 TTN). 
Nine of the wild type P450s showed considerable activity (> 200 TTN) even in the absence of 
the mutation, indicating that it is not absolutely required for high activity (Table 2.1). In some 
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scaffolds, a small but significant decrease in activity was observed upon mutation, with P450cam-
T252A and P450RhF-T274A showing 27% and 33% decreases, respectively. Interestingly, wild 
type P450eryF, which contains an alanine in place of the highly conserved threonine, was the most 
active wild type P450 and one of the most active enzymes screened (349 TTN).  
Most of the variants were trans-selective and showed hemin-like product profiles. A subset, 
however, possessed notable stereoselectivity (Table 2.1). P450PikC-T247A and P450BM3-T268A 
showed impressive trans-diastereoselectivity (93:7 and 99:1 dr, respectively) and moderate to 
excellent enantioselectivity (32% and 97% ee) for the 1R,2R and 1S,2S isomers, respectively. 
The selectivity of P450BM3-T268A is consistent with previous reports.
16 In both variants, the 
threonine to alanine mutation improved enantioselectivity. Interestingly, five P450s in the library 
were cis-selective, including a few that were highly enantioselective for the 1R,2S and 1S,2R 
isomers. Wild type P450cam produced the 1R,2S enantiomer (88:12 dr) with moderate 
enantioselectivity (43%), which improved to 86% ee (71:29 dr) in its T252A variant. P450eryF, 
which natively contains the active site alanine, and CYP142-T234A showed strong preference 
for the 1R,2S isomer, catalyzing the reaction with ~90:10 dr and ≥97% ee. Substituting the 
conserved threonine with alanine had a drastic effect on P450BioI, transforming the trans-
selective scaffold into a highly cis-selective catalyst with unprecedented enantioselectivity 
among biocatalysts for the 1S,2R isomer (95% ee, 71:29 dr). Notably this simple, limited 
diversity library produced selective variants for all four possible ethyl-2-
phenylcyclopropanecarboxylate diastereomers (Figure 2.1, Table 2.1). 
To assess how selectivity translates to other substrates, we briefly explored the substrate scope 
of our most selective variants compared to previously engineered trans- and cis-selective 
P450BM3 variants (P450BM3-T268A and P450BM3-CIS-T438S, respectively).16 We screened variants 
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against styrenes with substituents at the α-vinyl position (1b) and with electron donating or 
withdrawing substituents on the aromatic ring (1c and 1d, respectively.) Tolerance to 
substitutions varies widely depending on the protein scaffold (Table 2.2). Trans-selective 
scaffolds, P450BM3-T268A and P450PikC-T247A, identified using styrene as a model substrate, 
retained moderate to high activity and trans-diastereoselectivity on all substrates tested. 
Conversely, the cis-selective enzymes demonstrated more variability. For example, P450BM3-CIS-
T438S, retained cis-selectivity against methoxy-substituted styrene 1c, but became a trans-
selective enzyme when presented with electron withdrawing substituents and increased 
branching on the olefin. P450BioI-T238A showed improved cis-selectivity in the presence of α-
methyl styrene (1b); however, substitutions on the styrene ring lead to diminished or reversed 
diastereoselectivity. CYP142-T234A, however, remains highly cis-selective and displays high 
enantioselectivity (>90% ee) for all substrates tested. Despite the difficulties in predicting trends, 
using only a small P450 library, moderate to high selectivity for encumbered cis-diastereomers 
was observed for each model substrate. 
Discussion 
Interestingly, the most active and stereoselective variants presented in this study contained the 
mutation of the active site threonine to alanine, and the mutation tended to increase activity 
and/or selectivity in over half of the enzymes screened. This highly conserved residue is located 
in the kinked region of the I-helix (Figure S2.3) and has been proposed to facilitate proton 
delivery, activation of molecular oxygen, and the stabilization of other catalytic intermediates.22 
In cysteine-ligated BM3 variants the T268A mutation is required for cyclopropanation activity, 
which initially led us to hypothesize that the mutation to a smaller residue may relieve steric 
clash that prevents favorable binding of reactants. However, mutating the active site threonine to 
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valine, a residue that is similar in size, also produced a highly active variant with similar 
selectivity to P450BM3-T268A (Figure S2.5). Alternatively, enzyme inactivation may result from 
direct carbenoid insertion into the protein scaffold (e.g. O-H insertion into the threonine side 
chain). However, no change in protein mass was observed after incubating the enzyme with 
styrene and ethyl diazoacetate. While the mutation does not appear to cause significant changes 
to secondary and tertiary structure in P450BM3 (RMSD of 0.5 Å between the wild type and 
T268A structures, 2IJ2 and 1YQO, respectively), backbone rearrangements in this region have 
been observed in other P450 crystal structures.23-24 The mutation may induce subtle structural 
changes or alter hydrogen bonding networks, active site water composition, or protein dynamics 
that affect enzymatic cyclopropanation in a manner that has yet to be elucidated. 
Conclusion 
In summary, we have shown that natural P450 diversity provides a rich and rapid means for 
identifying biocatalysts with moderate to high selectivity for most cyclopropane diastereomers 
including cis-diastereomers that are traditionally difficult to produce. In addition, mutations 
identified in previous engineering experiments can guide library design, increasing the likelihood 
of isolating robust and stereoselective catalysts. Although the effects of the conserved threonine 
to alanine mutation are not universal, it provides an important target for engineering P450-based 
cyclopropanation catalysts. Importantly, incorporation of this mutation allowed the discovery of 
cis-selective catalysts that would not have been discovered by screening only the wild type 
enzymes. Although there remains room for improvements, this work shows that a diversity-based 
strategy incorporating key mutations can help create small, focused libraries that provide rapid 
access to selective starting points for further engineering and laboratory evolution. 
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Methods 
General. All chemicals and reagents were purchased from commercial suppliers (Acros, 
Fisher, Sigma). Silica gel chromatography was performed on an automated Biotage Isolera One 
using 10 g SNAP columns. Proton and carbon magnetic resonance spectra (1H NMR at 600 MHz 
and 13C NMR at 150 MHz) were recorded on a Bruker model DRX 600 spectrometer with 
solvent resonance as the internal standard (1H NMR: CDCl3 at 7.27 ppm; 
13C NMR: CDCl3 at 
77.0 ppm). Synthetic reactions were monitored by thin layer chromatography (EMD Millipore 
TLC silica gel 60 F254) using a UV-lamp for visualization. Gas chromatography analyses were 
carried out using an Agilent 7820A gas chromatograph, FID detector, and a J&W scientific 
cyclosil-B column (30m x 0.25 mm x 0.25 μm film). Cyclopropane product standards for the 
reaction of ethyl diazoacetate (EDA) with styrene (ethyl 2-phenylcyclopropane-1-carboxylate), 
α-methylstyrene (ethyl 2-methyl-2-phenylcyclopropane-1-carboxylate), 4-methoxystyrene (ethyl 
2-(4-methoxyphenyl)cyclopropane-1-carboxylate), and 4-trifluoromethylstyrene (ethyl 2-(4-
(trifluoromethyl)phenyl)cyclopropane-1-carboxylate) were prepared using purified P450BM3-
T268A and P450BM3-CIS-T438S as previously described.
16  
Library construction by functional site profiling. To guide library design we used the 
bioinformatics tool Deacon Active Site Profiler 2 (DASP2). This program allows the user to 
create a signature active site profile for protein(s) of known structure and then search for 
sequences in existing databases that contain similar features.19-21,25 We used the substrate-free 
and N-palmitoylglycine-bound structures of P450BM3 as well as a substrate-free structure of 
P450cam to create an active site profile (PDB: 2IJ2, 1JPZ, and 1PHC respectively).
23,26-27 We then 
chose 3 key residues that are highly conserved among P450s: T268, F393, and C400 in P450BM3 
(Figure 2.2); and T252, F350, and C357 in P450cam. Using these structures as input, DASP2 
extracted an active site signature for each protein consisting of the residues in the immediate 
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structural vicinity of each of the defined residues. These signatures were aligned by DASP2 to 
create an active site profile. The program then split the profile into small motifs based on 
continuous fragments in a protein sequence and searched the PDB and GenBank NR databases 
for proteins that share these characteristic motifs.  
From the DASP2 PDB and GenBank searches, hundreds of unique P450 sequences were 
identified with significant DASP search scores that could be potential candidates for library 
design.  Sequences with DASP search scores ≤ 1E-6 (PDB) or ≤ 1E-9 (GenBank) were selected 
for further evaluation.19 From these sequences the library was narrowed down to enzymes that fit 
into at least two of the following categories: 1) P450s derived from bacterial origin or previously 
produced in E. coli to facilitate heterologous expression, 2) P450s with available crystal 
structures to aid future protein engineering efforts, and 3) P450 sequences that shared < 20 % 
sequence identity to P450BM3 to maximize structural variation among P450 active sites. 
P450 gene sequences and cloning. Wild type and mutant variants of P450BM3 were obtained 
from the Arnold lab (Caltech). Wild type and threonine-to-alanine mutant genes for the P450 
scaffolds used in this study were obtained via commercial gene synthesis from Gen9 Inc. 
(Cambridge, MA). Gen9 Inc. gene sequences were codon optimized to facilitate gene synthesis. 
pET-21c(+) was used as a cloning and expression vector for all enzymes described in this study. 
P450 genes were cloned into pET-21c(+) using NdeI and XhoI restriction sites to provide 
constructs with a C-terminal 6xHis tag for protein purification. The P450 genes in pET-21c(+) 
were transformed into E. coli strain BL21(DE3) for subsequent expression. In addition to P450s 
identified by the DASP2 algorithm (above), the library was supplemented with two additional 
enzymes, P450eryF and CYP122A2, which are known in the literature and contain a native alanine 
and serine respectively in place of the active site threonine (Figure S2.1). 
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Gene sequence information. Codon optimized gene sequences purchased from Gen9 are listed 
below. The conserved active site threonine is in bold and underlined. For P450eryF and 
CYP122A2 the corresponding alanine and serine residues respectively are bolded and 
underlined. The optimized gene sequences for the threonine-to-alanine mutants are identical to 
wild type except for the codon encoding the active site threonine, which was changed to GCG 
for alanine. 
P450cam: Pseudomas putida 
ATGACGACTGAAACCATACAAAGCAACGCCAATCTTGCCCCTCTGCCACCCCATGTG
CCAGAGCACCTGGTATTCGACTTCGACATGTACAATCCGTCGAATCTGTCTGCCGGC
GTGCAGGAGGCCTGGGCAGTTCTGCAAGAATCAAACGTACCGGATCTGGTGTGGAC
TCGCTGCAACGGCGGACACTGGATCGCCACTCGCGGCCAACTGATCCGTGAGGCCT
ATGAAGATTACCGCCACTTTTCCAGCGAGTGCCCGTTCATCCCTCGTGAAGCCGGCG
AAGCCTACGACTTCATTCCCACCTCGATGGATCCGCCCGAGCAGCGCCAGTTTCGTG
CGCTGGCCAACCAAGTGGTTGGCATGCCGGTGGTGGATAAGCTGGAGAACCGGATC
CAGGAGCTGGCCTGCTCGCTGATCGAGAGCCTGCGCCCGCAAGGACAGTGCAACTT
CACCGAGGACTACGCCGAACCCTTCCCGATACGCATCTTCATGCTGCTCGCAGGTCT
ACCGGAAGAAGATATCCCGCACTTGAAATACCTAACGGATCAGATGACCCGTCCGG
ATGGCAGCATGACCTTCGCAGAGGCCAAGGAGGCGCTCTACGACTATCTGATACCG
ATCATCGAGCAACGCAGGCAGAAGCCGGGAACCGACGCTATCAGCATCGTTGCCAA
CGGCCAGGTCAATGGGCGACCGATCACCAGTGACGAAGCCAAGAGGATGTGTGGCC
TGTTACTGGTCGGCGGCCTGGATACGGTGGTCAATTTCCTCAGCTTCAGCATGGAGT
TCCTGGCCAAAAGCCCGGAGCATCGCCAGGAGCTGATCGAGCGTCCCGAGCGTATT
CCAGCCGCTTGCGAGGAACTACTCCGGCGCTTCTCGCTGGTTGCCGATGGCCGCATC
CTCACCTCCGATTACGAGTTTCATGGCGTGCAACTGAAGAAAGGTGACCAGATCCTG
CTACCGCAGATGCTGTCTGGCCTGGATGAGCGCGAAAACGCCTGCCCGATGCACGT
CGACTTCAGTCGCCAAAAGGTTTCACACACCACCTTTGGCCACGGCAGCCATCTGTG
CCTTGGCCAGCACCTGGCCCGCCGGGAAATCATCGTCACCCTCAAGGAATGGCTGA
CCAGGATTCCTGACTTCTCCATTGCCCCGGGTGCCCAGATTCAGCACAAGAGCGGCA
TCGTCAGCGGCGTGCAGGCACTCCCTCTGGTCTGGGATCCGGCGACTACCAAAGCG
GTA 
 
P450eryF: Saccharopolyspora erythraea 
ATGACGACCGTTCCCGATCTCGAAAGCGACTCCTTCCACGTCGACTGGTACCGCACC
TACGCCGAGCTGCGCGAGACCGCGCCGGTGACGCCGGTGCGCTTCCTCGGCCAGGA
CGCGTGGCTGGTCACCGGCTACGACGAGGCGAAGGCCGCGCTGAGCGACCTGCGCC
TGAGCAGCGACCCGAAGAAGAAGTACCCGGGCGTGGAGGTCGAGTTCCCGGCATAC
CTCGGTTTCCCCGAGGACGTGCGGAACTACTTCGCCACCAACATGGGCACCAGCGA
CCCGCCGACCCACACCCGGCTGCGCAAGCTGGTGTCGCAGGAGTTCACCGTCCGCC
GCGTGGAGGCGATGCGGCCCCGCGTCGAGCAGATCACCGCGGAGCTGCTCGACGAG
GTGGGCGACTCCGGCGTGGTCGACATCGTCGACCGCTTCGCCCACCCGCTGCCCATC
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AAGGTCATCTGCGAGCTGCTCGGCGTCGACGAGAAGTACCGCGGGGAGTTCGGGCG
GTGGAGCTCGGAGATCCTGGTCATGGACCCGGAGCGGGCCGAACAGCGCGGGCAGG
CGGCCAGGGAGGTCGTCAACTTCATCCTCGACCTGGTCGAGCGCCGCCGCACCGAG
CCCGGCGACGACCTGCTGTCCGCGCTGATCAGGGTCCAGGACGACGATGACGGTCG
GCTCAGCGCCGACGAGCTGACCTCCATCGCGCTGGTGCTGCTGCTGGCCGGTTTCGA
GGCGTCGGTGAGCCTCATCGGGATCGGCACCTACCTGCTGCTCACCCACCCGGACC
AGCTCGCGCTGGTGCGGCGGGACCCGTCGGCGCTGCCCAACGCCGTCGAGGAGATC
CTGCGCTACATCGCTCCGCCGGAGACCACCACGCGCTTCGCCGCGGAGGAGGTGGA
GATCGGCGGTGTCGCGATCCCCCAGTACAGCACGGTGCTGGTCGCGAACGGCGCGG
CCAACCGCGACCCGAAGCAGTTCCCGGACCCCCACCGCTTCGACGTCACCCGCGAC
ACCCGCGGCCACCTGTCGTTCGGGCAGGGCATCCACTTCTGCATGGGCCGGCCGCTG
GCCAAGCTGGAGGGCGAGGTGGCGCTGCGGGCGCTGTTCGGCCGCTTCCCCGCTCT
GTCGCTGGGAATCGACGCCGACGACGTGGTGTGGCGGCGTTCGCTGCTGCTGCGGG
GCATCGACCACCTACCGGTGCGGCTCGACGGA 
 
P450nor: Fusarium oxysporum 
ATGGCATCTGGCGCACCGAGCTTCCCTTTCTCGCGCGCCTCTGGTCCTGAGCCACCC
GCCGAGTTCGCCAAACTTCGAGCTACGAATCCCGTTTCCCAAGTCAAGCTTTTCGAT
GGCAGTCTCGCCTGGCTCGTCACTAAGCACAAAGATGTCTGCTTCGTAGCTACTTCT
GAAAAGCTCTCCAAGGTCCGCACTCGCCAAGGCTTCCCTGAGCTTAGCGCCAGTGG
AAAGCAAGCAGCCAAGGCAAAGCCGACATTTGTCGACATGGATCCCCCAGAGCACA
TGCATCAGAGGAGCATGGTGGAGCCGACCTTTACCCCCGAAGCTGTCAAGAATTTGC
AGCCTTACATCCAGAGGACTGTCGATGATCTACTGGAGCAGATGAAGCAGAAGGGG
TGTGCCAATGGTCCAGTTGACCTTGTCAAAGAGTTTGCTCTCCCTGTCCCCTCCTATA
TCATCTACACACTTCTCGGAGTTCCCTTCAATGATCTCGAATATCTTACGCAGCAGA
ACGCCATTCGGACAAATGGTAGCTCCACTGCCCGAGAGGCCTCTGCCGCTAACCAG
GAACTCCTTGATTACCTTGCAATTCTTGTCGAGCAGCGTCTCGTAGAGCCAAAGGAT
GATATCATCAGCAAGCTCTGCACTGAGCAAGTCAAGCCTGGAAATATCGACAAGTC
CGATGCTGTCCAGATTGCTTTCTTGCTCCTTGTCGCTGGCAACGCAACCATGGTAAA
CATGATTGCTCTGGGCGTCGCCACTCTGGCTCAGCACCCTGATCAGCTGGCGCAACT
CAAGGCCAACCCATCCCTTGCGCCCCAGTTTGTCGAGGAACTCTGTCGCTACCATAC
TGCTTCTGCACTAGCTATCAAGCGTACTGCCAAGGAGGATGTCATGATCGGTGACAA
GCTGGTCCGGGCGAATGAAGGCATTATCGCATCCAACCAGTCAGCCAACAGAGATG
AAGAAGTCTTCGAGAATCCCGATGAGTTCAACATGAACCGCAAGTGGCCTCCTCAA
GATCCTCTTGGCTTTGGCTTTGGTGATCACAGATGTATCGCTGAGCATCTTGCAAAG
GCTGAACTCACAACTGTGTTCTCAACACTGTATCAGAAGTTCCCAGATCTCAAGGTT
GCGGTTCCATTGGGAAAGATCAACTACACGCCTCTGAACCGAGATGTCGGAATCGT
GGATCTTCCTGTCATTTTT 
 
P450TxtE: Streptomyces scabiei 87.22 
ATGACCGTCCCCTCGCCGCTCGCCGACCCGTCCATCGTGCCCGACCCCTACCCTGTC
TACGCCGACCTGGCCCAGCGCCGCCCCGTCCACTGGGTCGAGCGCCTGAACGCCTG
GGCGGTCTTGACGTACGCCGACTGCGCCGCCGGGCTGAAGGATCCCCGGCTCACCG
CCGACCGGGGGACGGAAGTGCTGGCCGCGAAGTTCCCCGGACAGCCGCTGCCGCCG
GACAACATCTTCCACCGCTGGACCAAGAACGTGGTGATGTACACGGACCCGCCGCT
CCACGACGCGCTACGCCGGTCCGTCCGCGCAGGCTTCACCCGTGCCGCGCACCAGC
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ACTACGACCAAGTCCTCCAGAAGGTCGCGCACGACCTGGTCGCTTCCATCCCGGCCG
GTGCCACCGAGATCGACGCCGTCCCCGCCCTGGCTGCCGAACTCCCCGTACGCTCCG
CCGTGCACGCCTTCGGGGTCCCCGAGGAGGACCTCGGATTCCTCATCCCGCGCGTGA
ATACGATCATGACGTACCACTCCGGTCCGAAGGATCAGCCGGTGACGCAGGAGATA
ATCCTGGAAAAGCTCACCGACCTGCACACGTACGCCTCCGAACTCCTCCAGGGCATG
CGGGGCAAGGTCCTGCCGGACACCGTCATCGCCCGCCTGGCAGCCGCCCAGGACGG
CCTGACCGAGACCACGCCGGAACAGACCGTGCACCAGCTGGCGCTGGTGTTCATCG
CGTTGTTCGCGCCCACGACGCCGGGCTCTCTCAGCAGCGGCACGCTCGCGTTCGCCC
GCAACCCGCGGCAGGTCGAACGCTTCCTGGCGGACCAGGCGTGCGTGGACAACACG
GCGAACGAGGTCCTCCGCTACAACGCCTCGAACCAGTTCACCTGGCGCGTCGCGGC
CAAGGACGTCGAGATGGGCGGCGTACGGATCGAGGCCGGGCAGACTCTCGCCCTGT
TCCTGGGCTCGGCCAACCGGGACGCCAACATGTTCGAGCGACCGAACGACTTCGAC
CTCGACCGTCCCAACAGCGCTCGGCACCTGTCGTTCGGCCAAGGGGTGCACGCCTGT
CTCGCCGCGCAGCTCATCTCCCTGCAGCTGAAGTGGTTCTACGTCGCCCTGCTGAAC
CGCTTCCCGGGCATCCGGACGGCGGGCGAGCCGATCTGGAACGAGAACCTCGAATT
CCGCTCCCTTCGCTCCCTGCCGCTCAGCCTCCGC 
 
P450RhF: Rhodococcus sp.NCIMB9784 
ATGAGTGCATCAGTTCCGGCGTCGGCGCCGGCGTGTCCCGTCGACCACGCGGCCCTG
GCGGGCGGCTGCCCGGTGTCGGCGAACGCCGCGGCGTTCGATCCGTTCGGTTCCGCG
TACCAGACCGATCCGGCCGAGTCGCTGCGCTGGTCCCGCGACGAGGAGCCGGTGTT
CTACAGCCCCGAACTCGGCTACTGGGTCGTCACCCGGTACGAGGATGTGAAGGCGG
TGTTCCGCGACAACATCCTGTTCTCGCCGGCGATCGCGCTGGAGAAGATCACTCCCG
TCTCGGCGGAGGCCACCGCCACCCTCGCCCGGTACGACTACGCCATGGCCCGGACC
CTCGTGAACGAGGACGAGCCCGCCCACATGCCGCGCCGCCGCGCGCTCATGGATCC
GTTCACCCCGAAGGAACTGGCGCACCACGAGGCGATGGTGCGACGGCTCACGCGCG
AATACGTCGACCGCTTCGTCGAATCCGGCAAGGCCGACCTGGTGGACGAGATGCTG
TGGGAGGTTCCGCTCACCGTCGCCCTGCACTTCCTCGGCGTGCCGGAGGAGGACATG
GCGACGATGCGCAAGTACTCGATCGCGCACACCGTGAACACCTGGGGCCGCCCCGC
GCCCGAGGAGCAGGTGGCCGTCGCCGAGGCGGTCGGCAGGTTCTGGCAGTACGCGG
GCACGGTGCTCGAGAAGATGCGGCAGGACCCGTCGGGACACGGCTGGATGCCCTAC
GGGATCCGCAAGCAGCGGGAGATGCCGGACGTCGTCACCGACTCCTACCTGCACTC
GATGATGATGGCCGGCATCGTCGCCGCGCACGAGACCACGGCCAACGCGTCCGCGA
ACGCGTTCAAGCTGCTGCTCGAGAACCGCGCGGTGTGGGAGGAGATCTGCGCGGAT
CCGTCGCTGATCCCCAACGCCGTCGAGGAGTGCCTGCGCCACTCCGGGTCCGTGGCG
GCGTGGCGACGGGTGGCCACCGCCGACACCCGCATCGGCGACGTCGACATCCCCGC
CGGCGCCAAGCTGCTCGTCGTCAACGCGTCCGCCAACCACGACGAGCGCCACTTCG
AGCGCCCCGACGAGTTCGACATCCGGCGCCCGAACTCGAGCGACCATCTCACCTTCG
GGTACGGCAGCCACCAGTGCATGGGCAAGAACCTGGCCCGCATGGAGATGCAGATC
TTCCTCGAGGAACTCACCACGCGGCTTCCCCACATGGAACTCGTACCCGATCAGGAG
TTCACCTACCTGCCGAATACGTCCTTCCGCGGACCCGACCACGTGTGGGTGCAGTGG
GATCCGCAGGCGAATCCCGAGCGCACCGATCCTGCTGTGCTGCACCGGCATCAACC
GGTCACCATCGGAGAACCCGCCGCCCGGGCGGTGTCCCGCACCGTCACCGTCGAGC
GCCTGGACCGGATCGCCGACGACGTGCTGCGCCTCGTCCTGCGCGACGCCGGCGGA
AAGACATTACCCACGTGGACTCCCGGCGCCCATATCGACCTCGACCTCGGCGCGCTG
TCGCGCCAGTACTCCCTGTGCGGCGCGCCCGATGCGCCGAGCTACGAGATTGCCGTG
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CACCTGGATCCCGAGAGCCGCGGCGGTTCGCGCTACATCCACGAACAGCTCGAGGT
GGGAAGCCCGCTCCGGATGCGCGGCCCTCGGAACCATTTCGCGCTCGACCCCGGCG
CCGAGCACTACGTGTTCGTCGCCGGCGGCATCGGCATCACCCCAGTCCTGGCCATGG
CCGACCACGCCCGCGCCCGGGGGTGGAGCTACGAACTGCACTACTGCGGCCGAAAC
CGTTCCGGCATGGCCTATCTCGAGCGTGTCGCCGGGCACGGTGACCGGGCCGCCCTG
CACGTGTCCGAGGAAGGCACCCGGATCGACCTCGCCGCCCTCCTCGCCGAGCCCGC
CCCCGGCGTCCAGATCTACGCGTGCGGGCCCGGGCGGCTGCTCGCCGGACTCGAGG
ACGCGAGCCGGAACTGGCCCGACGGGGCGCTGCACGTCGAGCACTTCACCTCGTCC
CTCGCGGCGCTCGATCCGGACGTCGAGCACGCCTTCGACCTCGAACTGCGTGACTCG
GGGCTGACCGTGCGGGTCGAACCCACCCAGACCGTCCTCGACGCGTTGCGCGCCAA
CAACATCGACGTGCCCAGCGACTGCGAGGAAGGCCTCTGCGGCTCGTGCGAGGTCG
CCGTCCTCGACGGCGAGGTCGACCATCGCGACACGGTGCTGACCAAGGCCGAGCGG
GCGGCGAACCGGCAGATGATGACCTGCTGCTCGCGTGCCTGTGGCGACCGGCTGGC
CCTGCGACTC 
 
P450PikC: Streptomyces venezuelae 
ATGCGCCGTACCCAGCAGGGAACGACCGCTTCTCCCCCGGTACTCGACCTCGGGGCC
CTGGGGCAGGATTTCGCGGCCGATCCGTATCCGACGTACGCGAGACTGCGTGCCGA
GGGTCCGGCCCACCGGGTGCGCACCCCCGAGGGGGACGAGGTGTGGCTGGTCGTCG
GCTACGACCGGGCGCGGGCGGTCCTCGCCGATCCCCGGTTCAGCAAGGACTGGCGC
AACTCCACGACTCCCCTGACCGAGGCCGAGGCCGCGCTCAACCACAACATGCTGGA
GTCCGACCCGCCGCGGCACACCCGGCTGCGCAAGCTGGTGGCCCGTGAGTTCACCA
TGCGCCGGGTCGAGTTGCTGCGGCCCCGGGTCCAGGAGATCGTCGACGGGCTCGTG
GACGCCATGCTGGCGGCGCCCGACGGCCGCGCCGATCTGATGGAGTCCCTGGCCTG
GCCGCTGCCGATCACCGTGATCTCCGAACTCCTCGGCGTGCCCGAGCCGGACCGCGC
CGCCTTCCGCGTCTGGACCGACGCCTTCGTCTTCCCGGACGATCCCGCCCAGGCCCA
GACCGCCATGGCCGAGATGAGCGGCTATCTCTCCCGGCTCATCGACTCCAAGCGCG
GGCAGGACGGCGAGGACCTGCTCAGCGCGCTCGTGCGGACCAGCGACGAGGACGG
CTCCCGGCTGACCTCCGAGGAGCTGCTCGGTATGGCCCACATCCTGCTCGTCGCGGG
GCACGAGACCACGGTCAATCTGATCGCCAACGGCATGTACGCGCTGCTCTCGCACC
CCGACCAGCTGGCCGCCCTGCGGGCCGACATGACGCTCTTGGACGGCGCGGTGGAG
GAGATGTTGCGCTACGAGGGCCCGGTGGAATCCGCGACCTACCGCTTCCCGGTCGA
GCCCGTCGACCTGGACGGCACGGTCATCCCGGCCGGTGACACGGTCCTCGTCGTCCT
GGCCGACGCCCACCGCACCCCCGAGCGCTTCCCGGACCCGCACCGCTTCGACATCCG
CCGGGACACCGCCGGCCATCTCGCCTTCGGCCACGGCATCCACTTCTGCATCGGCGC
CCCCTTGGCCCGGTTGGAGGCCCGGATCGCCGTCCGCGCCCTTCTCGAACGCTGCCC
GGACCTCGCCCTGGACGTCTCCCCCGGCGAACTCGTGTGGTATCCGAACCCGATGAT
TCGCGGGCTCAAGGCCCTGCCGATCCGCTGGCGGCGAGGACGGGAGGCGGGCCGCC
GTACCGGT 
 
P450BioI: Bacillus subtilis 
ATGACAATTGCATCGTCAACTGCATCTTCTGAGTTTTTGAAAAACCCATATTCTTTTT
ACGACACATTGCGAGCTGTTCATCCTATCTATAAAGGGAGTTTCTTAAAATACCCGG
GCTGGTATGTCACAGGATATGAAGAAACGGCTGCTATTTTGAAAGATGCGAGATTC
AAAGTCCGCACCCCGCTGCCTGAGAGCTCAACCAAATATCAGGACCTTTCACATGTG
CAAAATCAAATGATGCTGTTTCAGAACCAGCCTGATCATAGACGATTGCGGACGCTT
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GCCAGCGGAGCGTTTACGCCGAGAACGACAGAGAGTTATCAGCCGTATATCATTGA
AACTGTCCATCATTTGCTTGATCAAGTGCAAGGTAAAAAAAAGATGGAGGTCATTTC
GGACTTTGCTTTTCCTTTAGCAAGTTTTGTCATAGCTAACATTATAGGTGTACCGGAG
GAAGATAGGGAGCAATTAAAGGAGTGGGCTGCGAGTCTCATTCAAACGATTGATTT
TACCCGCTCAAGAAAGGCATTAACAGAGGGCAATATTATGGCTGTGCAGGCTATGG
CATATTTCAAAGAGCTGATTCAAAAGAGAAAACGCCACCCTCAACAGGATATGATC
AGCATGCTCTTGAAGGGGAGAGAAAAGGATAAGCTGACGGAAGAGGAGGCGGCAT
CTACGTGCATATTGCTGGCGATCGCCGGACATGAGACAACGGTCAATCTCATCAGCA
ATTCAGTCCTTTGTCTGCTGCAGCATCCAGAACAGCTTTTGAAACTGAGAGAAAATC
CAGATCTTATTGGTACCGCAGTCGAGGAATGTTTACGCTATGAAAGCCCCACGCAAA
TGACAGCCAGAGTTGCGTCAGAGGATATTGACATCTGCGGGGTGACGATCCGTCAA
GGAGAACAAGTCTATCTTTTGTTAGGAGCGGCTAATCGAGACCCTAGCATATTCACG
AACCCCGATGTCTTCGATATTACGAGAAGTCCTAATCCGCATCTTTCATTCGGGCAT
GGCCATCATGTTTGCTTAGGGTCCTCGCTGGCACGATTAGAAGCGCAAATTGCGATT
AACACTCTTCTGCAGCGAATGCCCAGCCTTAATCTTGCGGATTTTGAATGGCGGTAT
CGGCCGCTTTTTGGATTTCGGGCGCTTGAGGAGCTGCCGGTGACTTTTGAA 
 
CYP164A2: Mycobacterium Smegmatis str.MC2-155 
ATGCACAATGGGTGGATGTCGACCGCCGCGACAGCCCAAGAGGCGCAGGGACTGCT
GCTCCAACTGCTCGACCCTGCCACCCGTGCCGACCCGTACCCGATCTATGACCGCAT
CCGCCGCGGCGGACCGCTTGCGCTCCCCGAGGCGAATCTCGCGGTGTTCTCCAGCTT
TTCCGATTGCGACGACGTTCTGCGGCACCCCTCGTCGTGCAGCGACCGCACGAAATC
GACCATCTTTCAACGGCAACTCGCCGCCGAGACGCAGCCGCGACCGCAGGGGCCCG
CCAGCTTCCTGTTCCTCGACCCGCCCGATCACACGAGGCTGCGCGGCCTGGTCAGCA
AGGCGTTCGCGCCGCGCGTGATCAAGCGGCTCGAACCCGAGATCACCGCGCTGGTC
GACCAACTGCTCGACGCTGTCGACGGGCCGGAGTTCAACCTCATCGACAACCTCGCC
TACCCGCTGCCGGTCGCGGTGATCTGCCGACTGCTCGGCGTGCCGATCGAGGACGA
ACCGAAGTTCAGCCGCGCGTCGGCGCTGCTGGCCGCGGCCCTGGACCCGTTCCTGGC
GCTCACCGGCGAGACGTCGGATCTGTTCGACGAACAGATGAAGGCCGGGATGTGGC
TGCGCGACTATCTGCGAGCCCTCATCGACGAGCGGCGCCGCACACCGGGTGAGGAC
CTCATGTCCGGTTTGGTCGCGGTCGAGGAGTCGGGCGATCAGCTCACCGAGGACGA
GATCATCGCGACCTGCAACCTGCTGCTGATCGCGGGCCACGAAACGACGGTGAACC
TGATCGCCAACGCGGCCCTGGCCATGTTGCGCACCCCCGGACAGTGGGCCGCGCTG
GCCGCCGACGGATCCCGGGCCTCCGCGGTCATCGAGGAGACCATGCGGTACGACCC
GCCCGTGCAGTTGGTGTCGCGGTACGCAGGCGACGACCTGACCATCGGGACGCACA
CGGTGCCCAAGGGCGACACCATGTTGCTGCTGCTCGCCGCGGCGCACCGCGACCCG
ACGATCGTCGGCGCCCCCGACCGGTTCGATCCGGACCGCGCTCAGATCCGGCACCTC
GGCTTCGGCAAGGGGGCGCACTTCTGTCTGGGGGCACCTCTGGCCCGACTCGAGGC
GACCGTGGCGTTGCCCGCGCTCGCGGCCCGGTTCCCCGAGGCCCGGCTCAGCGGCG
AACCGGAGTACAAGCGGAATTTGACGCTGCGCGGCATGTCTACGTTATCCATCGCGG
TA 
 
CYP107N1: Streptomyces lavendulae 
ATGACCGGCCCCGAGGCCGCGGTGCGCGGGTGCCCCTTCGGCGCCGGCGAGGCGCC
CGCGTACCCCTTCCACGCCCCCGACCGGCTGGAGCCCGACCCGTACTGGGAGCCGCT
GCGCCGCGAGCGGCCGCTGCAACGCGTCACGCTGCCGTACGGCGGCGAGGCGTGGC
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TCGCCACCCGCTATCAGGACGTGCGCGCGGTCTTCGCCGACCGCAGGTTCTCCCGGC
AGCTCGCCGTCGCGCCCGGCGCTCCGCGCTTCCTCCCGCACCAGCCGCCGCCGGACG
CCGTCCTGAGCGTCGAGGGCCCCGACCACGCGCGGCTGCGCCGGCTGGTCGGGAAG
GTCTTCACGCCGCGCCGCGTGGAGGACATGCGTCCGCTCATCCAGCGCACCGCCGAC
GGACTCCTCGACGCGATGGAGGAGATGGGGCCGCCCGCGGACCTGGTCGAGGACTT
CTCCCTGCCCTTCGCCGTGTCCATGATCTGCGAGCTGCTCGGCGTGCCGCCCGAGGA
CCGCAAGCGGTTCTGCGTCTGGTCGGACGCGCTGCTGACGACCACCGCGCACACCCC
CGCCCAGGTGCGCGACTACATGATGCAGATGCACGACTACCTCGGCGGGCTCGTCG
CGCAGCGCCGGGTGCGGCCCACCGCGGACCTGATCGGCTCCCTCGTGACCGCGCGC
GACGAGGAGGACAAGCTCACCGAGGGCGAGCTGGTGCGGCTGGCCGAGGCCATCCT
CATCGCCGGCTACGAGACCTCGGCGAGCCAGATCCCCAACTTCCTCTACGTCCTCTT
CCGCCACCCGCAGCTGCTGGAGCGGATCAGGAACGACCACGACCTCATCCCCGACG
CCGTCGAGGAACTGCTGCGCTTCGTGCCCATCGGCACCGTGGACGGCTTTCCCCGTA
CGGCCACCGAGGACGTCGAGCTCGGGGGAGTCCTGGTCAGGGCCGGGGAGACGGTC
GTGCCGTCGATGGGCGCCGCCAACCGCGACCCCGAGCTGTTCACGGACCCCGACGA
GCTGGACCTCGCGCGGCGGCCGAATCCGCACCTGGGCTTCGGCGCGGGACCGCACC
ACTGCCTGGGCGCCCAACTGGCCCGGGTGGAGCTCCAGATCACGCTCACGACGCTG
TTCCGCAGATACCCCCGCCTGCGGCTGGCCGTGCCGGAGGAGAGCCTCTCGTGGAA
GGAGGGGCTGATGGTCCGCGGCATGCACACCATGCCGGTCACCTGG 
 
CYP142: Mycobacterium tuberculosis UT205 
ATGACTGAAGCTCCGGACGTGGATCTGGCCGACGGCAACTTCTACGCCAGCCGCGA
GGCGCGGGCCGCGTACCGGTGGATGCGGGCCAACCAACCGGTGTTCCGCGATCGCA
ACGGCCTGGCGGCCGCGTCGACGTACCAGGCGGTGATCGACGCCGAACGTCAACCC
GAGCTGTTCTCCAACGCCGGCGGCATCCGCCCCGACCAGCCCGCCCTGCCGATGATG
ATCGACATGGACGATCCCGCACATCTGTTGCGGCGCAAGCTGGTTAACGCCGGCTTC
ACCCGCAAGCGGGTGAAGGACAAGGAGGCGTCGATTGCCGCGCTGTGTGACACCCT
GATCGACGCCGTGTGCGAACGCGGCGAGTGTGACTTCGTGCGGGACCTGGCCGCGC
CGCTACCGATGGCGGTGATCGGCGACATGCTCGGGGTGCGTCCAGAGCAGCGGGAC
ATGTTCTTGCGGTGGTCCGACGATCTGGTGACATTCCTCAGTTCGCATGTGTCTCAAG
AGGATTTCCAGATCACCATGGACGCCTTCGCGGCCTACAACGACTTCACCCGGGCCA
CCATTGCGGCACGGCGAGCGGACCCCACCGACGACCTGGTCAGCGTGCTGGTGAGT
TCCGAAGTTGACGGCGAGCGGCTAAGCGACGACGAGCTGGTCATGGAGACGCTGCT
GATCCTGATCGGCGGCGACGAGACCACGCGGCATACCTTGAGCGGTGGTACCGAGC
AGCTGCTGCGCAACCGTGACCAGTGGGACCTGCTGCAGCGCGACCCGTCGTTGCTGC
CCGGGGCCATCGAGGAGATGCTACGTTGGACCGCCCCGGTAAAGAACATGTGCCGG
GTGTTGACCGCGGATACCGAGTTTCACGGCACGGCGTTGTGTGCCGGCGAGAAGAT
GATGCTGCTCTTCGAGTCGGCGAACTTCGACGAGGCGGTTTTCTGTGAACCGGAAAA
GTTTGATGTTCAGCGAAATCCAAACAGCCACTTGGCGTTTGGCTTCGGCACGCATTT
CTGCCTGGGCAATCAGCTGGCCCGGTTGGAGCTGTCGTTGATGACGGAACGGGTGTT
GCGGCGGCTACCCGACCTGCGGTTGGTCGCCGATGACTCCGTGTTGCCGCTGCGGCC
GGCGAACTTTGTCAGCGGCCTGGAATCCATGCCGGTGGTGTTCACGCCGAGCCCGCC
GCTGGGC 
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P450TylH1: Streptomyces fradiae 
ATGGCCTGGGCACCGGACACGGTGTTTTCGTTGAGGCCGCAGCGAGTCGTGTCCTCG
TCCGGGGACGCCCGCCCGTCACAAAAGGGGATTCTGTTGCCCGCAGCACGCGCCAA
CGACACCGACGAGGCCGCAGGCCGGCGCAGCATCGCCTGGCCGGTCGCCCGCACCT
GTCCCTTCAGCCCTCCCGAGCAGTACGCCGCCCTCCGGGCGGAGGAGCCGATCGCCC
GGGCCGAGCTGTGGGACGGGGCGCCGGTCTGGCTGATCTCCCGCCAGGATCACGTC
CGGGCGCTGCTGGCCGACCCCCGGGTCAGCATCCATCCCGCGAAGCTCCCGCGGCTC
TCACCCTCCGACGGTGAGGCCGAGGCGTCCCGTTCGCTGCTGACACTGGACCCGCCC
GACCACGGAGCGCTCCGCGGCCACTTCATCCCCGAGTTCGGCCTGCGGCGGGTGCG
GGAGCTGCGCCCCTCCGTCGAACAGATCGTCACCGGCCTGCTGGATGACCTCACCGC
CCGCGGCGACGAGGCGGATCTGCTGGCCGACTTCGCGCTCCCCATGGCGACCCAGG
TGATCTGCCGGCTGCTCGACATCCCCTACGAGGACCGGGACTACTTCCAGGAGCGCA
CCGAACAGGCCACCCGCCCCGCGGCCGGCGAGGAGGCGCTGGAGGCGCTGCTGGAG
CTGCGCGACTACCTCGACCGGCTGATCAGCGGCAAGACCGGCCGGGAATCCGGCGA
CGGGATGCTCGGCAGCATGGTGGCGCAGGCCCGCGGTGGCGGGCTGTCGCACGCCG
ACGTCCTGGACAACGCGGTGCTCCTGCTGGCCGCCGGGCACGAGACCACGGCCAGC
ATGGTCACGATGAGCGTGCTCGTTCTGCTACAGCACCCCACGGCCTGGCGCGAACTC
ACCGTGAATCCCGGCCTGTTGCCGGGCGCGGTGGACGAACTGCTGCGCTATCTGTCG
ATCGCCGACGGGCTGCGCCGCTCGGCCACCGCGGACATCGAGATCGACGGCCACAC
CATCCGCGCCGGCGACGGCCTGGTCTTCCTGCTGGCCGCGGCCAACCGGGACGAGG
CCGTCTTCTCCGAACCGGAGGCCTTCGACATCCACCGGTCCGCGAGGCGGCATGTCG
CCTTCGGCTACGGACCCCACCAGTGCCTGGGACAGAACCTCGCCCGGATGGAACTG
GAAGTGGCCCTCGGCGCCGTGCTGGAGAGGCTGCCCGCACTGCGGCCGACCACGGA
CGTCGCCGGGCTGCGGCTCAAGAGCGACTCCGCGGTCTTCGGGGTGTACGAGCTGC
CCGTCGCCTGG 
 
P450NovI: Streptomyces niveus 
ATGAGCACCCGTCCCACGGTGTCCCCCAGCGAACTCGAACAGATCGACCTGGCATC
ACCGGTCCTGCACGCCGAGTACGAACTGGACGAGATCTTCCGCCACCTGCGCGCCG
ATGAGCCGGTGTACTGGCAGCAGCCACGGAACGAGCAGCCCGGCTTCTGGGTGATC
AGTCGCCACGCCGACGTGAACGAGGTGTACAAGGACAAGGAGCACTTCACGACGGA
GCACGGCAACGCGCTGGCCACTTTGCTGACCGGCGGTGACTCTGCCTCGGGCGCCAT
GCTCGCCGTCACCGACGGAGTGCGCCACCATCAGGTGCGCAACGTGTTGTCCAGGG
GCTTCTCGGCGCGGATGCTCGACCTCATCGCCCACACGCTGCAGGAAACCGTGGAC
GGTCTGCTGCTGGCGGCACTGGAGCGAGGCGAATGCGACGCCGCGCAGGACATCGC
GGCGGACGTGCCACTCGGGGCGATCTGCGACCTGCTGGAGATTCCCCACGCGGACC
GGAAGTACCTGCTCGGTCTGACCTCGCACGCGTGGAGCACGGACTACGCGGACGAG
CCTCCCGAGGAGAGCTGGGTCGCCAAGAACGAGATCCTGCTGTACTTCAGCAAGCT
GCTCAAGGAGCGTCGCGGTGGAGTCCGGGAGGACATGGTCAGCCTGCTGGCGAACT
GCCGGATCGACGGCGATCCGCTCAAGGCGGCCGAGCAGATGGCCAACTGCTACGGG
CTGATGATCGGCGGCGACGAGACCGGCAGGCACGCCATCACCGGCACGATCCTCGC
GTTGATCCAGAACCCCGACCAGTGGCGTGCGCTGAAGAACGGCGACGTCGATCTGA
ACACGGCGACCGAGGAGGCCCTGCGCTGGACCGTGCCGTCGCTGCACGGAGGCCGG
AAGGCGACCGGAGACGTCGTGATCAACGGCCGGCGGATCAACGCCGGCGATGTGGT
CAGTGTGTGGATCTCCTCGGCCAACCGTGACGAGACCGTCTTCGACGCGCCGGACG
AGTTCAACCTCGCCCGCACCCCGAACAAGCACTTCACCTTCGCGTACGGCTCGCACT
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ACTGCCTCGGCCACTACCTCGGCCGGATGGAGGTCTACGCCGTGCTCGACGGGCTGC
GCCGGCTGGTGGGCGACCTGGAGCAGATCGGCGAGGAGCGATGGATCTACTCCAGC
ATCCTGCACGGGATGAGCTCACTGCCGATCAGGATCACGGGC 
 
P450EpoK: Sorangium cellulosum 
ATGACACAGGAGCAAGCGAATCAGAGTGAGACGAAGCCTGCTTTCGACTTCAAGCC
GTTCGCGCCTGGGTACGCGGAGGACCCGTTCCCCGCGATCGAGCGCCTGAGAGAGG
CAACCCCCATCTTCTACTGGGATGAAGGCCGCTCCTGGGTCCTCACCCGATACCACG
ACGTGTCGGCGGTGTTCCGCGACGAACGCTTCGCGGTCAGTCGAGAAGAGTGGGAA
TCGAGCGCGGAGTACTCGTCGGCCATTCCCGAGCTCAGCGATATGAAGAAGTACGG
ATTGTTCGGGCTGCCGCCGGAGGATCACGCTCGGGTCCGCAAGCTCGTCAACCCGTC
GTTTACGTCACGCGCCATCGACCTGCTGCGCGCCGAAATACAGCGCACCGTCGACCA
GCTGCTCGATGCTCGCTCCGGACAAGAGGAGTTCGACGTTGTGCGGGATTACGCGG
AGGGAATCCCGATGCGCGCGATCAGCGCTCTGTTGAAGGTTCCGGCCGAGTGTGAC
GAGAAGTTCCGTCGCTTCGGCTCGGCGACTGCGCGCGCGCTCGGCGTGGGTTTGGTG
CCCCAGGTCGATGAGGAGACCAAGACCCTGGTCGCGTCCGTCACCGAGGGGCTCGC
GCTGCTCCATGACGTCCTCGATGAGCGGCGCAGGAACCCGCTCGAAAATGACGTCTT
GACGATGCTGCTTCAGGCCGAGGCCGACGGCAGCAGGCTGAGCACGAAGGAGCTGG
TCGCGCTCGTGGGTGCGATTATCGCTGCTGGCACCGATACCACGATCTACCTTATCG
CGTTCGCTGTGCTCAACCTGCTGCGGTCGCCCGAGGCGCTCGAGCTGGTGAAGGCCG
AGCCCGGGCTCATGAGGAACGCGCTCGATGAGGTGCTCCGCTTCGACAATATCCTCA
GAATAGGAACTGTGCGTTTCGCCAGGCAGGACCTGGAGTACTGCGGGGCATCGATC
AAGAAAGGGGAGATGGTCTTTCTCCTGATCCCGAGCGCCCTGAGAGATGGGACTGT
ATTCTCCAGGCCAGACGTGTTTGATGTGCGACGGGACACGGGCGCGAGCCTCGCGT
ACGGTAGAGGCCCCCATGTCTGCCCCGGGGTGTCCCTTGCTCGCCTCGAGGCGGAGA
TCGCCGTGGGCACCATCTTCCGTAGGTTCCCCGAGATGAAGCTGAAAGAAACTCCCG
TGTTTGGATACCACCCCGCGTTCCGGAACATCGAATCACTCAACGTCATCTTGAAGC
CCTCCAAAGCTGGA 
 
Protein expression. BL21(DE3) E. coli cells harboring a pET-21c(+) plasmid encoding 
the P450 of interest were grown from glycerol stocks overnight (37 °C, 225 rpm) in 5 mL of LB 
media containing 100 ug/mL ampicillin. The saturated overnight culture was used to inoculate 1 
L of terrific broth supplemented with trace metal mix (1000 × = 50 mM FeCl3, 20 mM CaCl2, 10 
mM MnSO4, 10 mM ZnSO4, 2 mM CoSO4, 2 mM CuCl2, 2 mM NiCl2, 2 mM Na2MoO4, and 2 
mM H3BO3) and 100 μg/mL ampicillin. The culture was grown at 37 °C and 225 rpm to an O.D. 
of 1.2 – 1.8 (3.5 – 4 hours). The temperature was lowered to 25 °C, and the culture was shaken 
for 20 min at the reduced temperature. Isopropyl β-D-1-thiogalactopyranoside (IPTG) and 5-
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aminolevulinic acid (ALA) were then added to a final concentration of 0.5 mM and the cells 
were allowed to shake at 25 °C and 225 rpm for 16 – 20 hours. The cells were harvested by 
centrifugation (4 °C, 10 min, 4400 xg) and subsequently frozen at -20 °C for at least two hours.  
Protein purification. Frozen cell pellets were thawed on ice, resuspended in 25 mL of 
lysis solution containing 0.5 mg/mL lysozyme in buffer A (50 mM NaH2PO4, 10 mM imidazole, 
0.3 M NaCl, pH 8.0), incubated for 30 min on ice, and sonicated (8 min, 20% amplitude, pulse 
on 0.5s, pulse off 0.8s; Sonic Dismembrator Model 500, Fisher Scientific). Cell debris was 
removed by centrifugation for 45 min at 27000 xg, and the supernatant was filtered through a 
0.45 μm syringe filter before loading onto a pre-equilibrated Ni-NTA HisTrap HP column (5 mL 
HisTrap HP, GE Healthcare, Piscataway, NJ) using an AKTA Purifier or AKTAxpress (GE 
Healthcare). The column was washed with buffer A until the signal from the detector reached ≤ 
60 mAU. P450 was then eluted with 55% buffer B (50 mM NaH2PO4, 0.3 M imidazole, 0.3 M 
NaCl, pH 8.0). The combined P450 fractions were concentrated and exchanged into 0.1 M 
potassium phosphate buffer (pH 8.0) using a 30 kDa molecular weight cut-off Amicon 
centrifugal filter (EMD Millipore). P450 concentrations were determined by carbon monoxide 
binding assay (vide infra), portioned into 50-100 μL aliquots, and frozen at -80 °C until further 
use. 
P450 concentration determination. The concentration of cytochrome P450s was 
determined using a standard carbon monoxide binding assay. In a polystyrene 96-well plate 
(Evergreen Scientific) 50 μL of 0.4 M sodium dithionite in 1 M potassium phosphate buffer (pH 
8.0) was added to a 200 μL solution of cytochrome P450 (0.1 M potassium phosphate, pH 8.0.)  
The absorbance at 450 nm and 490 nm was recorded using a Tecan M1000 PRO UV/Vis plate 
reader. The 96-well plate was then placed in a vacuum chamber in a fume hood. The chamber 
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was evacuated to approximately -15 mmHg, backfilled with carbon monoxide gas, and incubated 
for 25 min. The plate was removed, and the absorbance at 450 nm and 490 nm was measured 
again using the plate reader. The P450 concentration was determined from the ferrous carbon 
monoxide binding difference spectrum by using previously reported extinction coefficient for 
P450cam (ε450-490=91,000 M-1cm-1).28  
Typical procedure for small-scale cyclopropanation bioconversions under anaerobic 
conditions. Milli-Q water and 0.1 M Na2S2O4 were placed into a separate sealed vial and 
degassed with argon for at least 10 minutes prior to use. Small-scale reactions (400 μL) were 
conducted in 2-mL crimp vials (Agilent Technologies, San Diego, CA). The headspace of a 
crimp vial containing P450 and a stir bar was similarly flushed with argon to remove oxygen, 
however with no bubbling to minimize protein denaturation. Using glass syringes, water and 
P450 were added under argon to a final volume of 340 μL followed by 40 μL of 0.1 M Na2S2O4. 
10 μL of olefin solution (1.2 M in MeOH) was added and allowed to mix for at least 30 sec 
before adding 10 μL of EDA (0.4 M in MeOH). The argon lines were subsequently removed, and 
the reactions were left to stir overnight. The final concentration of reagents in the reactions were 
as follows: 30 mM olefin, 10 mM EDA, 10 mM Na2S2O4, and 20 μM P450. After 12 hours, 15 
μL of 6 M HCl was added by syringe to the crimp vials to quench the reaction. The vials were 
opened and supplemented with 20 μL of internal standard (20 mM 2-phenylethanol in MeOH). 
The reaction was extracted with 1 mL of ethyl acetate, transferred to a 1.7 mL eppendorf tube, 
and centrifuged for 5 min at 18400 xg to remove precipitated protein. The organic layer was 
transferred to a separate eppendorf tube containing anhydrous sodium sulfate for drying. After 10 
minutes, the organic layer was filtered through a Pasteur pipette packed with glass wool into a 
glass vial for chiral GC analysis. 
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Synthesis of cyclopropane product standards. Product standards for the cyclopropanation 
of styrene, α-methylstyrene, 4-methoxystyrene, and 4-(trifluoromethyl)styrene were synthesized 
on a preparative scale as previously reported using P450BM3-T268A and P450BM3-CIS-T438S.
16  
Ethyl 2-phenylcyclopropane-1-carboxylate (3a-d) was synthesized from styrene with 
EDA and isolated as predominately trans isomers. Diagnostic data for the E cyclopropanes: 1H 
NMR (600 MHz, CDCl3):  7.30 (m, 2H), 7.22 (m, 1H), 7.11 (m, 2H), 4.18 (q, 7.2 Hz, 2H), 2.53 
(m, 1H), 1.92 (m, 1H), 1.62 (m, 1H), 1.33 (m, 1H), 1.30 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, 
CDCl3):  173.4, 140.1, 128.4, 126.4, 126.1, 60.7, 26.2, 24.2, 17.1, 14.2. 
Ethyl 2-methyl-2-phenylcyclopropane-1-carboxylate (4a) was synthesized from α-
methylstyrene with EDA and isolated as predominately trans isomers. Diagnostic data for the E 
cyclopropanes: 1H NMR (600 MHz, CDCl3):  7.31 (m, 4H), 7.22 (m, 1H), 4.20 (q, J = 7.1 Hz, 
2H), 1.98 (dd, J = 8.3, 6.0 Hz, 1H), 1.54 (s, 3H), 1.44 (m, 2H), 1.31 (t, J = 7.1 Hz, 3H); 13C NMR 
(150 MHz, CDCl3):  172.2, 145.8, 128.4, 127.3, 126.4, 60.5, 30.6, 27.9, 20.8, 19.9, 14.4. 
Ethyl 2-(4-methoxyphenyl)cyclopropane-1-carboxylate (4b) was synthesized from 4-
methoxystyrene with EDA and isolated as exclusively trans isomers. Diagnostic data for the E 
cyclopropanes: 1H NMR (600 MHz, CDCl3):  7.04 (d, J = 8.9 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 
4.18 (q, J = 7.2 Hz, 2H), 3.79 (s, 3H), 2.49 (m, 1H), 1.83 (m, 1H), 1.57 (m, 1H), 1.29 (t, J = 7.2 
Hz, 3H), 1.26 (m, 1H); 13C NMR (150 MHz, CDCl3):  173.6, 158.3, 132.0, 127.3, 113.8, 60.7, 
55.3, 25.7, 23.9, 16.8, 14.3. 
Ethyl 2-(4-trifluoromethylphenyl)cyclopropane-1-carboxylate (4c) was synthesized 
from 4-(trifluoromethyl)styrene with EDA and isolated as a mixture of cis and trans isomers. 
Diagnostic data for the E cyclopropanes: 1H NMR (600 MHz, CDCl3):  7.53 (d, J = 7.8 Hz, 2H), 
7.20 (d, J = 8.1 Hz, 2H), 4.19 (q, J = 6.9 Hz, 2H), 2.56 (m, 1H), 1.95 (m, 1H), 1.67 (m, 1H), 1.35 
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(m, 1H), 1.30 (t, J = 7.1 Hz, 3H). 13C NMR (150 MHz, CDCl3):  172.9, 144.4, 126.3, 125.3, 
60.9, 25.7, 24.5, 17.3, 14.2. Diagnostic data for the Z cyclopropanes: 1H NMR (600 MHz, 
CDCl3):  7.53 (d, J = 7.8 Hz, 2H), 7.39 (d, J = 8.2 Hz, 2H), 3.90 (q, J = 7.1 Hz, 2H), 2.58 (m, 
1H), 2.15 (m, 1H), 1.74 (m, 1H), 1.40 (m, 1H), 1.00 (t, J = 7.2 Hz, 3H). 
Calibration curves. Yields of cyclopropane products were determined using calibration 
curves made with independently synthesized product standards. A 0.2 M stock solution of 
product standard was used to prepare samples of product standard at 2 mM, 4 mM, 6 mM, 8 mM, 
and 10 mM in 0.1 M potassium phosphate (pH 8.0) containing 0.4 mM internal standard (2-
phenylethanol) and 5% methanol. The samples were extracted with 1 mL of ethyl acetate, 
transferred to a 1.7 mL eppendorf tube, and centrifuged for 5 min at 18400 xg. The organic layer 
was transferred to a separate eppendorf tube containing anhydrous sodium sulfate for drying. 
After 10 minutes, the organic layer was filtered through a Pasteur pipette packed with glass wool 
into a glass vial for GC analysis. 
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Supporting Information 
Figure S2.1. ClustalOmega alignment of the P450 library protein sequences. The conserved 
active-site threonine is highlighted in yellow, and amino acid substitutions that differ from the 
highly conserved threonine are highlighted in red. 
 
BM3h          -----------------------------------------------MTIKEMPQPKTFG 13 
cam           MTT-----------ETIQSNANLAPL-----------PPHVPEHLVFDFDMYNPSNLSAG 38 
TxtE          ---------------------------------------------MTVPSPLADPSIVPD 15 
NovI          MST---------------------------------RPTVSPSELEQIDLASPVLHAEYE 27 
RhF           MSA------------SVPASAPACPVD------HAALAGGCPVSANAAAFDPFGSAYQTD 42 
terp          ----------------------------------MDARATIPEHIARTVILPQGYADDEV 26 
CYP122A2      ------------------------------------------MSTEAQQESTPTARCPFS 18 
EpoK          MTQ---------------------------------EQANQSETKPAFDFKPFAPGYAED 27 
CYP142        -----------------------------------------MTEAPDVDLADGNFYASRE 19 
nor           -------------------------------------------MASGAPSFPFSRASGPE 17 
TylH1         MAWAPDTVFSLRPQRVVSSSGDARPSQKGILLPAARANDTDEAAGRRSIAWPVARTCPFS 60 
BioI          ---------------------------------------------MTIASSTASSEFLKN 15 
CYP107N1      MTG------------------------------PEAAVRGCPFGAGEAPAYPFHAPDRLE 30 
CYP164A2      MHN------------------------------GWMSTAATAQEAQGLLLQLLDPATRAD 30 
PikC          MRR------------------------------T---QQGTTASPPVLDLGALGQDFAAD 27 
eryF          ---------------------------------------------MTTVPDLESDSFHVD 15 
                                                                           
 
BM3h          ELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESRFDKNLS 73 
cam           VQEAWAVLQESNVPDLVWTRC-N-------GGHWIATRGQLIRE----AYEDYRHFSSEC 86 
TxtE          PYPVYADLAQRRPVHWVE----R-------LNAWAVLTYADCAA----GLKDPRLTADRG 60 
NovI          LDEIFRHLRADEPVYWQQPRNEQ-------PGFWVISRHADVNE----VYKDKEHFTTEH 76 
RhF           PAESLRWSRDEEPVFYSP----E-------LGYWVVTRYEDVKA----VFRDNILFSPAI 87 
terp          IYPAFKWLRDEQPLAMAHIEG-Y-------DPMWIATKHADVMQ----IGKQPGLFSNAE 74 
CYP122A2      IQDGHRTILETGTVGAHELF--G-------VKQWLVAAAEDVKL----VTNDPRFSSAAP 65 
EpoK          PFPAIERLREATPIFY---WD-E-------GRSWVLTRYHDVSA----VFRDERFAVSRE 72 
CYP142        ARAAYRWMRANQPVFRD-----R-------NGLAAASTYQAVID----AERQPELFSNAG 63 
nor           PPAEFAKLRATNPVSQVKLFD-G-------SLAWLVTKHKDVCF----VATSEKLSKVRT 65 
TylH1         PPEQYAALRAEEPIARAELWD-G-------APVWLISRQDHVRA----LLADPRVSIHPA 108 
BioI          PYSFYDTLRAVHPIYKGSFL--K-------YPGWYVTGYEETAA----ILKDARFKVRTP 62 
CYP107N1      PDPYWEPLRRERPLQRVTLPY-G-------GEAWLATRYQDVRA----VFADRRFSRQLA 78 
CYP164A2      PYPIYDRIRRGGPLALP-----E-------ANLAVFSSFSDCDD----VLRHPSSCSDRT 74 
PikC          PYPTYARLRAEGPAHRVRTPE-G-------DEVWLVVGYDRARA----VLADPRFSKDWR 75 
eryF          WYRTYAELRETAPVTPVRFL--G-------QDAWLVTGYDEAKA----ALSDLRLSSDPK 62 
                                                                           
 
BM3h          QALKF-------------VRDFAGDGLFTSWTHEKNWKKAHNILLPSFSQQAMKGYHAMM 120 
cam           PFIPR-------------EAGEAYDF-IPTSMDPPEQRQFRALANQVVGMPVVDKLENRI 132 
TxtE          TEVLA-AKFPGQPLPPDNIFHRWTKN-VVMYTDPPLHDALRRSVRAGFTRAAHQHYDQVL 118 
NovI          GNALA----------TLLTGGDSASGAMLAVTDGVRHHQVRNVLSRGFSARMLDLIAHTL 126 
RhF           ALEKITPVS-AEATATLARYDYAMAR-TLVNEDEPAHMPRRRALMDPFTPKELAHHEAMV 145 
terp          GSEILYDQNNEAFMRSISGGCPHVID-SLTSMDPPTHTAYRGLTLNWFQPASIRKLEENI 133 
CYP122A2      SG----------------ILGDRRPG-WFSGMDSPEHNRYRQKIARDFTLRAARKQEEFI 108 
EpoK          EWESS-----AEYSSAIPELSDMKKY-GLFGLPPEDHARVRKLVNPSFTSRAIDLLRAEI 126 
CYP142        ----------------GIRPDQPALP-MMIDMDDPAHLLRRKLVNAGFTRKRVKDKEASI 106 
nor           RQGFP-------ELSASGKQAAKAKP-TFVDMDPPEHMHQRSMVEPTFTPEAVKNLQPYI 117 
TylH1         KLPRL----------SPSDGEAEASR-SLLTLDPPDHGALRGHFIPEFGLRRVRELRPSV 157 
BioI          LPE---------SSTKYQDLSHVQNQ-MMLFQNQPDHRRLRTLASGAFTPRTTESYQPYI 112 
CYP107N1      VAPGA-----P-----RFLPHQPPPD-AVLSVEGPDHARLRRLVGKVFTPRRVEDMRPLI 127 
CYP164A2      KSTI-----FQRQLAAETQPRPQGPA-SFLFLDPPDHTRLRGLVSKAFAPRVIKRLEPEI 128 
PikC          NSTTP-----------LTEAEAALNH-NMLESDPPRHTRLRKLVAREFTMRRVELLRPRV 123 
eryF          KKYPGVEVEFPAYLGFPEDVRNYFAT-NMGTSDPPTHTRLRKLVSQEFTVRRVEAMRPRV 121 
                                                      :      .           : 
 
BM3h          VDIAVQLVQKWERL-NADEHIEVPEDMTRLTLDTIGLCGFNYRFNSFYRDQPHPFITSMV 179 
60 
cam           QELACSLIESLRPQ----GQCNF--------------------TEDYAEPFPIRIFMLLA 168 
TxtE          QKVAHDLVASIPAGA---TEIDA--------------------VPALAAELPVRSAVHAF 155 
NovI          QETVDGLLLAALER----GECDA--------------------AQDIAADVPLGAICDLL 162 
RhF           RRLTREYVDRFVES----GKADL--------------------VDEMLWEVPLTVALHFL 181 
terp          RRIAQASVQRLLDFD---GECDF--------------------MTDCALYYPLHVVMTAL 170 
CYP122A2      VRAADSCLDDIEASG---PGTDL--------------------VPGYAKRLASLAIHDLY 145 
EpoK          QRTVDQLLDARSGQ----EEFDV--------------------VRDYAEGIPMRAISALL 162 
CYP142        AALCDTLIDAVCER----GECDF--------------------VRDLAAPLPMAVIGDML 142 
nor           QRTVDDLLEQMKQKGCANGPVDL--------------------VKEFALPVPSYIIYTLL 157 
TylH1         EQIVTGLLDDLTARG---DEADL--------------------LADFALPMATQVICRLL 194 
BioI          IETVHHLLDQVQGK----KKMEV--------------------ISDFAFPLASFVIANII 148 
CYP107N1      QRTADGLLDAMEEMG---PPADL--------------------VEDFSLPFAVSMICELL 164 
CYP164A2      TALVDQLLDAVDG-----PEFNL--------------------IDNLAYPLPVAVICRLL 163 
PikC          QEIVDGLVDAMLAAP--DGRADL--------------------MESLAWPLPITVISELL 161 
eryF          EQITAELLDEVGDS----GVVDI--------------------VDRFAHPLPIKVICELL 157 
                     :             :                                       
 
BM3h          RALDEAMNKLQRANPDDPAY---------------DENKRQFQEDIKVMNDLVDKIIADR 224 
cam           GLPEEDIPHLKYLTDQMTR----------------PDGSMTFAEAKEALYDYLIPIIEQR 212 
TxtE          GVPEEDLGFLIPRVNTIMTYHSGPK--------DQPVTQEIILEKLTDLHTYASELLQGM 207 
NovI          EIPHADRKYLLGLTSHAWST------------DYADEPPEESWVAKNEILLYFSKLLKER 210 
RhF           GVPEEDMATMRKYSIAHTVNTWG---------RPAPEEQVAVAEAVGRFWQYAGTVLEKM 232 
terp          GVPEDDEPLMLKLTQDFFGVHEPDEQAVAAPRQSADEAARRFHETIATFYDYFNGFTVDR 230 
CYP122A2      GLNEEGPVLEGQMRAM---------------------EGGTDMESIKRLTDEFGHVLALV 184 
EpoK          KVPAECDEKFRRFGSATARALGVGLV------PRVDEETKTLVASVTEGLALLHGVLDER 216 
CYP142        GVRPEQRDMFLRWSDDLVTFLSSHVS---------QEDFQITMDAFAAYNDFTRATIAAR 193 
nor           GVPFNDLEYLTQQNAIRTNG---------------SSTAREASAANQELLDYLAILVEQR 202 
TylH1         DIPYEDRDYFQERTEQATR----------------PAAGEEALEALLELRDYLDRLISGK 238 
BioI          GVPEEDREQLKEWAASLIQTIDFTRS----R-----KALTEGNIMAVQAMAYFKELIQKR 199 
CYP107N1      GVPPEDRKRFCVWSDALLTT--------------TAHTPAQVRDYMMQMHDYLGGLVAQR 210 
CYP164A2      GVPIEDEPKFSRASALLAAALDPFLA----LTGETSDLFDEQMKAGMWLRDYLRALIDER 219 
PikC          GVPEPDRAAFRVWTDAFVF----------------PDDPAQAQTAMAEMSGYLSRLIDSK 205 
eryF          GVDEKYRGEFGRWSSEILVM--------------DPERAEQRGQAAREVVNFILDLVERR 203 
                                                                           
 
BM3h          KASGEQSD-DLLTHMLNGKDPETGEPLDDENIRYQIITFLIAGHETTSGLLSFALYFLVK 283 
cam           R--QKPGT-DAISIVANGQ--VNGRPITSDEAKRMCGLLLVGGLDTVVNFLSFSMEFLAK 267 
TxtE          R--GKVLPDTVIARLAAAQD-GLTETTPEQTVHQLALVFIALFAPTTPGSLSSGTLAFAR 264 
NovI          R--GGVRE-DMVSLLANCR--IDGDPLKAAEQMANCYGLMIGGDETGRHAITGTILALIQ 265 
RhF           R--QDPSGHGWMPYGIRKQR-EMPDVVTDSYLHSMMMAGIVAAHETTANASANAFKLLLE 289 
terp          R--SCPKD-DVMSLLANSK--LDGNYIDDKYINAYYVAIATAGHDTTSSSSGGAIIGLSR 285 
CYP122A2      RAKRDEAGDRLLHRLAESG--EDEILLSDEEATGVFATLLFAGHDSMQQMVGYSLYALLS 242 
EpoK          R--RNPLENDVLTMLLQAE--ADGSRLSTKELVALVGAIIAAGTDTTIYLIAFAVLNLLR 272 
CYP142        R--ADPTD-DLVSVLVSSE--VDGERLSDDELVMETLLILIGGDETTRHTLSGGTEQLLR 248 
nor           L--VEPKD-DIISKLCTEQ--VKPGNIDKSDAVQIAFLLLVAGNATMVNMIALGVATLAQ 257 
TylH1         T--GRESGDGMLGSMVAQA---RGGGLSHADVLDNAVLLLAAGHETTASMVTMSVLVLLQ 293 
BioI          K--RHPQQ-DMISMLLKGR---EKDKLTEEEAASTCILLAIAGHETTVNLISNSVLCLLQ 253 
CYP107N1      R--VRPTA-DLIGSLVTAR--DEEDKLTEGELVRLAEAILIAGYETSASQIPNFLYVLFR 265 
CYP164A2      R--RTPGE-DLMSGLVAVE--ESGDQLTEDEIIATCNLLLIAGHETTVNLIANAALAMLR 274 
PikC          R--GQDGE-DLLSALVRTSD-EDGSRLTSEELLGMAHILLVAGHETTVNLIANGMYALLS 261 
eryF          R--TEPGD-DLLSALIRVQD-DDDGRLSADELTSIALVLLLAGFEASVSLIGIGTYLLLT 259 
                         :                                 :           :   
 
BM3h          NPHVLQKAAEEAARVLVDPVPSYKQVKQLKYVGMVLNEALRLWPTA--PAFSLYAKEDTV 341 
cam           SPEHRQELIERPER-----------------IPAACEELLRRFSLV---ADGRILTSDYE 307 
TxtE          NPRQVERFLADQAC-----------------VDNTANEVLRYNASN--QFTWRVAAKDVE 305 
NovI          NPDQWRALKNGDVD-----------------LNTATEEALRWTVPS--LHGGRKATGDVV 306 
RhF           NRAVWEEICADPSL-----------------IPNAVEECLRHSGSV--AAWRRVATADTR 330 
terp          NPEQLALAKSDPAL-----------------IPRLVDEAVRWTAPV--KSFMRTALADTE 326 
CYP122A2      HPEQRAALRENPDL-----------------IDGAVEELLRFLPLNQ-LGVPRVCVEDVE 284 
EpoK          SPEALELVKAEPGL-----------------MRNALDEVLRFDNILR-IGTVRFARQDLE 314 
CYP142        NRDQWDLLQRDPSL-----------------LPGAIEEMLRWTAPV--KNMCRVLTADTE 289 
nor           HPDQLAQLKANPSL-----------------APQFVEELCRYHTASA-LAIKRTAKEDVM 299 
61 
TylH1         HPTAWRELTVNPGL-----------------LPGAVDELLRYLSIA--DGLRRSATADIE 334 
BioI          HPEQLLKLRENPDL-----------------IGTAVEECLRYESPT--QMTARVASEDID 294 
CYP107N1      HPQLLERIRNDHDL-----------------IPDAVEELLRFVPIGTVDGFPRTATEDVE 308 
CYP164A2      TPGQWAALAADGSR-----------------ASAVIEETMRYDPPV--QLVSRYAGDDLT 315 
PikC          HPDQLAALRADMTL-----------------LDGAVEEMLRYEGPVE-SATYRFPVEPVD 303 
eryF          HPDQLALVRRDPSA-----------------LPNAVEEILRYIAPP--ETTTRFAAEEVE 300 
                                                  :*  *                    
 
BM3h          LGGEYPLEKGDELMVLIPQLHRDKTIWGDDVEEFRPERFENPSAIPQHAFKPFGNGQRAC 401 
cam           FHGV-QLKKGDQILLPQMLSGLDERENA------CPMHVDFSRQ--KVSHTTFGHGSHLC 358 
TxtE          MGGV-RIEAGQTLALFLGSANRDANMFE------RPNDFDLDRP-NSARHLSFGQGVHAC 357 
NovI          INGR-RINAGDVVSVWISSANRDETVFD------APDEFNLART--PNKHFTFAYGSHYC 357 
RhF           IGDV-DIPAGAKLLVVNASANHDERHFE------RPDEFDIRRP-NSSDHLTFGYGSHQC 382 
terp          VRGQ-NIKRGDRIMLSYPSANRDEEVFS------NPDEFDITRF--PNRHLGFGWGAHMC 377 
CYP122A2      LHGQ-TISAGDNVIPLYSTANRDPGVFA------DPDTFDITRK--PEHNFAFGYGIHGC 335 
EpoK          YCGA-SIKKGEMVFLLIPSALRDGTVFS------RPDVFDVRRD--TSASLAYGRGPHVC 365 
CYP142        FHGT-ALCAGEKMMLLFESANFDEAVFC------EPEKFDVQRN--PNSHLAFGFGTHFC 340 
nor           IGDK-LVRANEGIIASNQSANRDEEVFE------NPDEFNMNRKWPPQDPLGFGFGDHRC 352 
TylH1         IDGH-TIRAGDGLVFLLAAANRDEAVFS------EPEAFDIHRS--ARRHVAFGYGPHQC 385 
BioI          ICGV-TIRQGEQVYLLLGAANRDPSIFT------NPDVFDITRS--PNPHLSFGHGHHVC 345 
CYP107N1      LGGV-LVRAGETVVPSMGAANRDPELFT------DPDELDLARR--PNPHLGFGAGPHHC 359 
CYP164A2      IGTH-TVPKGDTMLLLLAAAHRDPTIVG------APDRFDPDRA--QIRHLGFGKGAHFC 366 
PikC          LDGT-VIPAGDTVLVVLADAHRTPERFP------DPHRFDIRRD--TAGHLAFGHGIHFC 354 
eryF          IGGV-AIPQYSTVLVANGAANRDPKQFP------DPHRFDVTRD--TRGHLSFGQGIHFC 351 
                    :     :                      *  .:            :. * : * 
 
BM3h          IGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKETLTLKPEGFVVKAKSKKIPLGGIPS 461 
cam           LGQHLARREIIVTLKEWLTRIPDFSIAP------GAQIQHKSGIVSGVQ-------ALPL 405 
TxtE          LAAQLISLQLKWFYVALLNRFPGIRTAGE-------PIWNENLEFRSLR-------SLPL 403 
NovI          LGHYLGRMEVYAVLDGLRRLVGDLEQIGE-------ERWIYSSILHGMS-------SLPI 403 
RhF           MGKNLARMEMQIFLEELTTRLPHMELVPD-----QEFTYLPNTSFRGPD-------HVWV 430 
terp          LGQHLAKLEMKIFFEELLPKLKSVELSGP-------PRLVATNFVGGPK-------NVPI 423 
CYP122A2      PGQHLARVLIKVATVRLFERFPDVRLAGD-------VPMNEGLGLFSPA-------ELRV 381 
EpoK          PGVSLARLEAEIAVGTIFRRFPEMKLKET-------PVFGYHPAFRNIE-------SLNV 411 
CYP142        LGNQLARLELSLMTERVLRRLPDLRLVADD----SVLPLRPANFVSGLE-------SMPV 389 
nor           IAEHLAKAELTTVFSTLYQKFPDLKVAVPL----GKINYTPLNRDVGIV-------DLPV 401 
TylH1         LGQNLARMELEVALGAVLERLPALRPTTDV----AGLRLKSDSAVFGVY-------ELPV 434 
BioI          LGSSLARLEAQIAINTLLQRMPSLNLAD------FEWRYRPLFGFRALE-------ELPV 392 
CYP107N1      LGAQLARVELQITLTTLFRRYPRLRLAVPE----ESLSWKEGLMVRGMH-------TMPV 408 
CYP164A2      LGAPLARLEATVALPALAARFPEARLSGE-------PEYKRNLTLRGMS-------TLSI 412 
PikC          IGAPLARLEARIAVRALLERCPDLALDVSP----GELVWYPNPMIRGLK-------ALPI 403 
eryF          MGRPLAKLEGEVALRALFGRFPALSLGIDA----DDVVWRRSLLLRGID-------HLPV 400 
               .  :                                                    :   
 
BM3h          PST--------------------------------------------------------- 464 
cam           VWDPATTKAV-------------------------------------------------- 415 
TxtE          SLR--------------------------------------------------------- 406 
NovI          RITG-------------------------------------------------------- 407 
RhF           QWDPQANPERTDPAVLHRHQPVTIGEPAARAVSRTVTVERLDRIADDVLRLVLRDAGGKT 490 
terp          RFTKA------------------------------------------------------- 428 
CYP122A2      TWGAE------------------------------------------------------- 386 
EpoK          ILKPSKAG---------------------------------------------------- 419 
CYP142        VFTPSPPLG--------------------------------------------------- 398 
nor           IF---------------------------------------------------------- 403 
TylH1         AW---------------------------------------------------------- 436 
BioI          TFE--------------------------------------------------------- 395 
CYP107N1      TW---------------------------------------------------------- 410 
CYP164A2      AV---------------------------------------------------------- 414 
PikC          RWRRGREAGRRTG----------------------------------------------- 416 
eryF          RLDG-------------------------------------------------------- 404 
                                                                           
 
BM3h          ------------------------------------------------------------ 464 
62 
cam           ------------------------------------------------------------ 415 
TxtE          ------------------------------------------------------------ 406 
NovI          ------------------------------------------------------------ 407 
RhF           LPTWTPGAHIDLDLGALSRQYSLCGAPDAPSYEIAVHLDPESRGGSRYIHEQLEVGSPLR 550 
terp          ------------------------------------------------------------ 428 
CYP122A2      ------------------------------------------------------------ 386 
EpoK          ------------------------------------------------------------ 419 
CYP142        ------------------------------------------------------------ 398 
nor           ------------------------------------------------------------ 403 
TylH1         ------------------------------------------------------------ 436 
BioI          ------------------------------------------------------------ 395 
CYP107N1      ------------------------------------------------------------ 410 
CYP164A2      ------------------------------------------------------------ 414 
PikC          ------------------------------------------------------------ 416 
eryF          ------------------------------------------------------------ 404 
                                                                           
 
BM3h          ------------------------------------------------------------ 464 
cam           ------------------------------------------------------------ 415 
TxtE          ------------------------------------------------------------ 406 
NovI          ------------------------------------------------------------ 407 
RhF           MRGPRNHFALDPGAEHYVFVAGGIGITPVLAMADHARARGWSYELHYCGRNRSGMAYLER 610 
terp          ------------------------------------------------------------ 428 
CYP122A2      ------------------------------------------------------------ 386 
EpoK          ------------------------------------------------------------ 419 
CYP142        ------------------------------------------------------------ 398 
nor           ------------------------------------------------------------ 403 
TylH1         ------------------------------------------------------------ 436 
BioI          ------------------------------------------------------------ 395 
CYP107N1      ------------------------------------------------------------ 410 
CYP164A2      ------------------------------------------------------------ 414 
PikC          ------------------------------------------------------------ 416 
eryF          ------------------------------------------------------------ 404 
                                                                           
 
BM3h          ------------------------------------------------------------ 464 
cam           ------------------------------------------------------------ 415 
TxtE          ------------------------------------------------------------ 406 
NovI          ------------------------------------------------------------ 407 
RhF           VAGHGDRAALHVSEEGTRIDLAALLAEPAPGVQIYACGPGRLLAGLEDASRNWPDGALHV 670 
terp          ------------------------------------------------------------ 428 
CYP122A2      ------------------------------------------------------------ 386 
EpoK          ------------------------------------------------------------ 419 
CYP142        ------------------------------------------------------------ 398 
nor           ------------------------------------------------------------ 403 
TylH1         ------------------------------------------------------------ 436 
BioI          ------------------------------------------------------------ 395 
CYP107N1      ------------------------------------------------------------ 410 
CYP164A2      ------------------------------------------------------------ 414 
PikC          ------------------------------------------------------------ 416 
eryF          ------------------------------------------------------------ 404 
                                                                           
 
BM3h          ------------------------------------------------------------ 464 
cam           ------------------------------------------------------------ 415 
TxtE          ------------------------------------------------------------ 406 
NovI          ------------------------------------------------------------ 407 
RhF           EHFTSSLAALDPDVEHAFDLELRDSGLTVRVEPTQTVLDALRANNIDVPSDCEEGLCGSC 730 
terp          ------------------------------------------------------------ 428 
CYP122A2      ------------------------------------------------------------ 386 
EpoK          ------------------------------------------------------------ 419 
CYP142        ------------------------------------------------------------ 398 
nor           ------------------------------------------------------------ 403 
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TylH1         ------------------------------------------------------------ 436 
BioI          ------------------------------------------------------------ 395 
CYP107N1      ------------------------------------------------------------ 410 
CYP164A2      ------------------------------------------------------------ 414 
PikC          ------------------------------------------------------------ 416 
eryF          ------------------------------------------------------------ 404 
                                                                           
 
BM3h          ------------------------------------------- 464 
cam           ------------------------------------------- 415 
TxtE          ------------------------------------------- 406 
NovI          ------------------------------------------- 407 
RhF           EVAVLDGEVDHRDTVLTKAERAANRQMMTCCSRACGDRLALRL 773 
terp          ------------------------------------------- 428 
CYP122A2      ------------------------------------------- 386 
EpoK          ------------------------------------------- 419 
CYP142        ------------------------------------------- 398 
nor           ------------------------------------------- 403 
TylH1         ------------------------------------------- 436 
BioI          ------------------------------------------- 395 
CYP107N1      ------------------------------------------- 410 
CYP164A2      ------------------------------------------- 414 
PikC          ------------------------------------------- 416 
eryF          ------------------------------------------- 404 
 
 
 
Figure S2.2. Percent identity matrix generated by Clustal 12.1. 
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Figure S2.3. Actives sites of P450s from the library with known structure. The position of the 
conserved threonine is shown (except for in eryF where this residue is alanine). In the structures 
of the P450s that perform monooxygenation, a conserved glutamate/aspartate precedes the 
threonine. P450TxtE and P450nor, which do not perform monooxygenation, have unusual residues 
in this position. 
 
      
P450BM3, PDB: 2IJ2         P450cam, PDB: 1PHC 
 
 
      
P450eryF, PDB: 1OXA     P450nor, PDB: 1XQD 
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P450terp, PDB: 1CPT         P450TxtE, PDB: 4TPN 
 
 
      
P450PikC, PDB: 2BVJ         P450BioI, PDB: 3EJB 
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      CYP164A2, PDB: 3R9B        CYP142, PDB: 2XKR 
 
 
 
         P450EpoK, PDB: 1Q5E 
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Figure S2.4. SDS‐polyacrylamide gel electrophoresis analysis of his-tag purified P450 variants. 
The 40 kDa and 50 kDa protein markers are indicated with white text in each gel image. 
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Table S2.1. % Identity to P450BM3, representative PDB accession numbers (PDB#), and 
expression level in E. coli of each P450 library member.27,29-44 
Name % Identity PDB# Expression level in E. coli 
P450cam 13.25 1PHC High, mostly folded P450 
P450eryF 12.87 1OXA High, mostly folded P450 
P450nor 14.39 1XQD Low, mostly folded P450 
P450terp 15.65 1CPT Low, mostly misligated P420** 
P450TxtE 11.33 4TPN High, mostly folded P450 
P450RhF* 12.42 N/A High, some misligated P420** 
P450PikC 17.79 2BVJ High, mostly folded P450 
P450BioI 16.46 3EJB High, mostly folded P450 
CYP164A2 16.51 3R9B High, mostly folded P450 
CYP107N1 14.39 N/A High, mostly folded P450 
CYP122A2 12.44 N/A None 
CYP142 16.33 2XKR High, mostly folded P450 
P450TylH1 12.39 N/A Low, some misligated P420 
P450NovI 11.30 N/A None 
P450EpoK 16.47 1Q5E High, mostly misligated P420** 
*P450-reductase fusion 
**P420, shown by the presence of an absorbance maximum at 420 nm for the carbon 
monoxide-bound ferrous enzyme, indicates a misligated heme state and possible protein 
misfolding. See Figure S1 for CO-bound absorbance traces.45 
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Table S2.2. Representative substrates and reactions for P450 library members.29,33,35-44 
 
Name Organism Substrate/ Reaction 
P450cam  Pseudomonas putida camphor/hydroxylation 
 
 
P450eryF 
 
Saccharopolyspora erythraea 
 
6-deoxyerythronolide B/hydroxylation 
  
 
P450nor 
 
Fusarium oxysporum 
 
nitric oxide and NADH/reduction 
 
 
P450TxtE 
 
Streptomyces turgidiscabies Car8 
 
tryptophan/nitration 
 
 
 
 
  
   
P450RhF  Rhodococcus sp. NCIMB 9784 unknown/various oxidations 
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P450PikC 
 
Streptomyces venezuelae 
 
pikromycin precursor/hydroxylation 
 
 
P450BioI 
 
Bacillus subtilis 
 
fatty acyl-ACP/oxidative cleavage 
 
 
CYP164A2 
 
Mycobacterium smegmatis 
 
fatty acid oxidation (hypothesized) 
 
CYP107N1 
 
Streptomyces lavendulae 
 
mitomycin precursor/oxidation 
(not fully characterized) 
 
CYP142 
  
 
 
Mycobacterium tuberculosis 
 
cholesterol/oxidation 
 
 
P450TylH1  Streptomyces fradiae tylsoin precursor/hydroxylation 
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P450EpoK 
 
Sorangium cellulosum 
 
epothilone precursor/epoxidation 
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Figure S2.5. Chiral GC traces from enzymatic cyclopropanations of styrene with EDA. 
 
 
 
Constant pressure; GC Oven temperature = 100 °C for 30 min, 1 °C/min to 135 °C, 135 
for 10 min, 10 °C/min to 200 °C, 200 °C for 5 min. Inset: UV/vis spectra for ferric P450 (blue), 
ferrous P450 (orange), and ferrous-carbon monoxide-bound P450 (gray). The ferrous-carbon 
monoxide-bound spectra show qualitative compositions of folded (450 nm peak) and misligated 
(420 nm peak) protein. Elution times: 3a (35.0min), 3b (37.5 min), 3c (41.6 min), and 3d (42.7 
min). Variable dilutions and injection volumes were used to attempt separation of cyclopropane 
isomers; product peaks can be compared within the same chromatogram but not between 
chromatograms. 
 
P450cam 
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P450cam-T252A 
 
 
 
 
P450eryF 
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P450nor 
 
 
 
 
 
 
P450nor-T243A 
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P450TxtE 
 
 
 
 
 
P450TxtE-T250A 
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P450RhF 
 
 
 
 
 
P450RhF-T275A 
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P450PikC 
 
 
 
 
P450PikC-T247A 
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P450BioI 
 
 
 
 
P450BioI-T238A 
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CYP164A2 
 
 
 
 
 
CYP164A2-T260A 
 
 
 
 
 
 
 
 
 
 
 
81 
CYP107N1 
 
 
 
 
 
CYP107N1-T251A 
 
 
 
 
 
 
 
 
 
 
 
82 
CYP142 
 
 
 
 
 
CYP142-T234A 
 
 
 
 
 
 
 
 
 
 
 
83 
P450TylH1 
 
 
 
 
 
P450TylH1-T279A 
 
 
 
 
 
 
 
 
 
 
 
84 
P450EpoK 
 
 
 
 
P450EpoK-T258A 
 
  
85 
P450BM3-T268V 
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Figure S2.6. Chiral GC traces from enzymatic cyclopropanations of α-methylstyrene with EDA. 
 
 
Constant pressure; GC Oven temperature = 100 °C for 30 min, 1 °C/min to 135 °C, 135 
for 10 min, 10 °C/min to 200 °C, 200 °C for 5 min. Elution times: Z isomers (25.0 min, 26.5 
min); E isomers (34.3 min, 35.4 min). Variable dilutions and injection volumes were used to 
attempt separation of cyclopropane isomers; product peaks can be compared within the same 
chromatogram but not between chromatograms. 
 
 
FePP 
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P450BM3-T268A 
 
 
 
 
 
P450BM3-CIS-T438S 
 
 
 
 
 
 
 
 
 
 
 
88 
P450eryF 
 
 
 
P450PikC-T247A 
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P450BioI-T238A 
 
 
 
 
CYP142-T234A 
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Figure S2.7. Chiral GC traces from enzymatic cyclopropanations of 4-methoxystyrene with 
EDA. 
 
 
Constant pressure; GC Oven temperature = 100 °C for 5 min, 1 °C/min to 135 °C, 135 
for 10 min, 10 °C/min to 200 °C, 200 °C for 5 min. Elution times:  Z isomers (47.9 min, 50.9 
min); E isomers (54.1 min). Variable dilutions and injection volumes were used to attempt 
separation of cyclopropane isomers; product peaks can be compared within the same 
chromatogram but not between chromatograms. 
 
 
 
FePP 
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P450BM3-T268A 
 
 
 
P450BM3-CIS-T438S 
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P450eryF 
 
 
 
 
P450PikC-T247A 
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P450BioI-T238A 
 
 
 
CYP142-T234A 
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Figure S2.8. Chiral GC traces from enzymatic cyclopropanations of 4-(trifluoromethyl)styrene 
with EDA. 
 
 
Pressure = 10 psi; GC Oven temperature = 100 °C for 40 min, 1.5 °C/min to 140 °C, 140 
for 10 min, 10 °C/min to 200 °C, 200 °C for 5 min. Elution times: Z isomers (65.7 min, 67.4 
min); E isomers (72.0 min, 72.4 min). Variable dilutions and injection volumes were used to 
attempt separation of cyclopropane isomers; product peaks can be compared within the same 
chromatogram but not between chromatograms. 
 
FePP 
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P450BM3-T268A 
 
 
P450BM3-CIS-T438S 
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P450eryF 
 
P450PikC-T247A 
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P450BioI-T238A 
 
 
CYP142-T234A 
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CHAPTER 3: P450-MEDIATED NON-NATURAL CYCLOPROPANATION OF 
DEHYDROALANINE-CONTAINING THIOPEPTIDES3 
 
Introduction 
Cytochrome P450s are versatile biocatalysts that are of synthetic importance due to their 
ability to catalyze late-stage modifications of small molecules and natural products.1-4 For 
example, P450s identified from S. bungoensis A-1544 have been instrumental in preparing C16-
hydroxylated pladienolide analogs for clinical trials.5,6 More recently, Arnold, Fasan, and others 
have shown that P450s and other heme proteins catalyze non-native metallocarbenoid and 
metallonitrenoid insertion reactions, providing novel biosynthetic routes to the formation of C-C, 
C-N, and other bonds.4,7-14 P450-mediated cyclopropanation of aryl olefins using diazoacetate 
reagents has garnered attention due to the high turnover and diastereoselectivities displayed by 
native and engineered P450s.7,15 This reaction has been adapted for the enzymatic synthesis of 
precursors to pharmaceuticals such as levomilnacipran and ticagrelor.16,17 In addition, tuning 
P450 reactivity through mutations of the proximal Cys heme-ligand to Ser or His has led to 
efficient whole cell cyclopropanation catalysts.15,16 Due to the prevalent role of P450s in natural 
product biosynthesis, non-natural P450-mediated reactions may be adaptable to the 
diversification of complex molecules. Notably, Fasan and colleagues have demonstrated that 
engineered P450s catalyze intramolecular C-H amination of modified-terpenes covalently  
_________________________ 
3Edited with permission from: Gober, J. G.; Ghodge, S. V.; Bogart, J. W.; Wever, W. J.; 
Watkins, R. R.; Brustad, E. M.; and Bowers, A. A. Submitted, 2017. Under revision at J. Am. 
Chem. Soc. 
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decorated with carbonazidate metallonitrenoid precursors.4 
We hypothesized that P450s may be capable of intermolecular carbenoid-mediated 
cyclopropanations of natural products bearing native or engineered olefins. In particular, 
dehydroalanines (Dhas) and related olefins, are common features of ribosomally-produced cyclic 
peptides, including lantipeptide and thiopeptide antibiotics.18 Despite the fact that hemoprotein-
catalyzed cyclopropanation reactions have typically been limited to aryl olefins (e.g. styrenes), 
we speculated that the geminal push-pull olefin present in Dhas would be sufficiently electron 
rich to permit modification by P450-metallocarbenoids. On small molecule Dhas, this chemistry 
would allow access to 1-amino-2-cyclopropane carboxylic acids (ACCAs), important motifs in 
natural products and pharmaceuticals.19-21 Alternatively, Dhas might provide reactive handles for 
ACCA incorporation into natural products. 
Results and Discussion 
We began our investigations by targeting cyclopropanation of two model compounds 
representative of Dhas observed in lantipeptides (1) and thiopeptides (2). For our first survey of 
this chemistry, we employed a panel of diverse P450 variants which we previously identified as 
highly active and/or stereoselective for cyclopropanation of styrene with ethyl diazoacetate 
(EDA, 3).22 To enrich activity, we also added an active site ThrAla mutation that has been 
found to be generally activating with respect to carbenoid transfer. As summarized in Table 3.1 
(and Figure S3.1, Figure S3.2, and Table S3.1), each variant screened was active for 
cyclopropanation against 1 and 2, to yield cyclopropane products 4 and 5, respectively. 
Conversions and diastereoselectivities were determined based on UV absorbance compared to 
authentic standards that were isolated and fully characterized by NMR. Diastereomers of 4 have 
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been previously described in the literature;23 key NOEs were used to discern diastereomers of 
compound 5 (see Supporting Methods). A number of trends can be observed in these results. 
Most notably, thiazole Dha, 2, was cyclopropanated more readily when compared to the more 
electron-deficient Dha ester (1); N-H insertion, a preferred target for P450-generated carbenoids 
with olefin-substituted anilines,11 was not observed for either substrate. While conversions in 
excess of 60% could be obtained with 2 (Table 3.1, Figures S3.1 and S3.2), cyclopropanation of 
1 gave low conversion (2 – 29 %) even in the presence of excess olefin. In reactions with 
compound 1, reduced cyclopropanation is accompanied by competing EDA dimerization, which 
proceeds in 14 – 71 % conversion (Figures S3.3 and Table S3.1). This result suggests that slow 
insertion into more electron-deficient Dha olefins may enhance off-path dimerization products.  
Table 3.1. Dha cyclopropanation with P450 variants. 
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As anticipated, the ThrAla mutation proved generally helpful. However, addition of an 
axial CysSer mutation, which is activating in aryl olefin cyclopropanation,15,22 led to variable 
improvements across both substrates. Interestingly, the CysSer mutation had a profound effect 
on stereoselectivity in CYP119. In general, the C-C cys diastereomer comprised the preferred 
product for either substrate 2 (see Supporting Methods), with moderate dr observed for 1 and 
very good dr for 2 (Table 3.1). With CYP119-T213A-C317S, a loss of stereoselectivity was 
observed for compound 1, whereas, against compound 2, the catalyst showed a significant 
inversion of diastereoselectivity (dr: 84:16  10:90).  
We next expanded our P450 library in order to examine enzymes that evolved to oxidize 
natural products containing motifs analogous to compounds 1 and 2. Many thiopeptides undergo 
post-translational monooxygenation by P450s. For example, thiomuracin and related 
thiopeptides have hydroxyls and/or epoxides installed on side chains (Figure 3.1).24-27 
Mutagenesis experiments have tied these modifications to P450s, but there have been no reports 
of in vitro reconstitution to date.27,28  We chose to pursue two such P450s, P450TbtJ1 and 
P450TbtJ2, identified from the recently reported thiomuracin GZ pathway from T. bispora DSM 
43833 (Figure 3.1).29 P450TbtJ1 and P450TbtJ2 variants bearing conserved activating mutations 
were screened for cyclopropanation of 1 and 2 with EDA. P450TbtJ1 and P450TbtJ2 variants gave 
similar efficiencies to library constituents on 1 (Table 3.2, and Figure S3.1 and S3.2) and showed 
enhanced activity against Dha-thiazole, 2. Notably, P450TbtJ2-T247A provided the best 
conversion (79 %), turnovers, and dr of any of the biocatalysts surveyed against 2. These results 
suggested that P450TbtJ1 and P450TbtJ2 variants might be suitable candidates to carry out similar 
chemistry on Dha-containing analogues of native substrates. In effort to better understand the 
differences in activities observed among P450 catalysts for 2, we determined the crystal structure 
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of substrate-free P450TbtJ1 (Table S3.2, Figure S3.4, 2.4 Å resolution, PDB: t.b.d.). Initial efforts 
to obtain structures for P450TbtJ2 did not yield diffraction-quality crystals. Nevertheless, the 
P450TbtJ1 structure allows a visual comparison of X-ray crystal structures for P450 biocatalysts 
tested herein. P450TbtJ1 exhibits the typical triangular prism-shaped P450 fold with the heme 
prosthetic group embedded adjacent to the central I helix (Figure S3.5). The surface of the 
protein shows a deep but narrow channel that may accommodate its preferred linear peptide  
 
Figure 3.1. Key post-translational modifications of thiomuracin GZ core. A. Cyclization of the 
TbtA precursor by TbtD leads to the pyridine core (orange) of Thiomuracin GZ. LP = leader 
peptide B. Two monooxygenations, highlighted in yellow, are predicted to be carried out by 
P450 gene products of tbtJ1 and tbtJ2. 
 
Table 3.2. Dha cyclopropanation with P450TbtJ1 and P450TbtJ2 variants 
 
106 
substrate. This large substrate-binding cavity is flanked by the distinctive B-C and F-G loops 
shared by many P450s.1 Common to substrate-free crystal structures of other P450s, the B-C 
loop appears partially disordered (Figure S3.6 and S3.7). Dynamic interactions with the B-C loop 
play an important role in P450 substrate recognition, and substrate binding typically results in 
organization of the B-C loop in other P450 crystal structures.30 
Qualitatively, P450s that show high activity against substrate 2 (i.e. P450PikC (PDB: 
2C7Z), P450TbtJ1 (PDB: t.b.d.), and CYP119 (PDB:1IO7)) are marked by large, solvent-
accessible heme binding pockets in their ligand-free form (Figure S3.8). Alternatively, the hemin 
of poorly active P450s, including P450BM3 and CYP142 (PDB: 1YQO and 3EJB, respectively), 
is buried within the protein, with only narrow solvent channels leading to the cofactor. This 
observation is supported by calculations of accessible channel volumes (see Figure S3.8 for 
details), which suggest highly active P450s possess large channels that facilitate substrate access 
to the metallocarbenoid intermediate. A notable structural difference for P450TbtJ1 is the presence 
of several phenylalanines (F70, F277, and F300, Figure S5) near the active site. These aromatic 
residues may be involved in pi-pi interactions that bind and/or orient native polythiazole 
substrates and may contribute to the enriched activity observed for P450TbtJ1 variants on thiazole 
Dha, 2. A similar motif has been proposed for thiazole recognition by EpoK, a P450 involved in 
epothilone biosynthesis, and similar residues can be found in alignments with P450TbtJ2 (Figure 
S9 and S10).31 Further structural and biochemical studies to confirm the importance of these 
features for substrate recognition, as well as P450TbtJ2 structural investigations, are ongoing; 
however, we anticipate that the substrate-free structure will facilitate further engineering and 
applications of this chemistry on thiomuracin and other thiopeptides. 
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Figure 3.2. P450-mediated cyclopropanation of linear I8Dha thiopeptide core substrates bearing 
either one (7, panel A) or three (9, panel F) Dha olefins. B-E. UV traces of cyclopropanation 
reactions on 7 show starting material (blue) and monosubstituted cyclopropane products (8, red). 
G-H. UV traces of reactions on 9 show starting material (blue) and tri-substituted cyclopropane 
products (10, red). Reaction conditions: 20 μM catalyst, 100 μM thiomuracin derivative, 10 mM 
EDA, 10 mM Na2S2O4, 0.1 M KPi pH 8, 7.5% co-solvent, argon, 16 h. 
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With thiomuracin P450 variants in hand, we turned to the synthesis of putative substrates. 
Based on prior mutagenesis work, it seemed likely that these enzymes would function on linear 
thiopeptide cores prior to installation of the central pyridine core (Figure 3.1).28 We exploited a 
recently disclosed solid-phase route to thiopeptide cores to prepare a substrate analog in which 
Ile8, which is monooxygenated in a number of thiomuracin variants, was replaced with a Cys 
residue that could be eliminated to yield a Dha at this position; all other Dhas normally present in 
this core were replaced with alanine to reduce potential complexity (Figure S3.11).32,33 
Compound 7 (I8-1Dha, Figure 3.2A and Table 3.3) was separately incubated with three of the 
best biocatalysts for cyclopropanation of 1 and 2 (P450PikC-T247A, P450TbtJ1-T234A/C340S and 
P450TbtJ2-T247A), as well as free hemin. Due to the limited solubility of 7, the maximum peptide 
concentration investigated was 100 μM. Catalyst concentrations were maintained at 20 μM, 
consistent with small molecule reactions. P450PikC-T247A, P450TbtJ1-T234A/C340S, and hemin 
all gave very low levels of modified products exhibiting different retention times (Figure 3.2B-
D, Table 3.3). These peaks likely correspond to multiple diastereomers of the expected 
cyclopropanation product, which are generated in low yields by these catalysts. In contrast, 
P450TbtJ2-T247A provides robust conversion to a single major peak in the LC trace (8, Figures 
3.2A and 3.2E, Figures S3.12 and S3.13); a few minor peaks can also be observed near the 
baseline. To confirm that this product was the expected cyclopropane and to investigate 
diastereoselectivity, we repeated the reaction on scale using 13C-labeled EDA in order to 
facilitate subsequent characterization by NMR. 1H and 13C NMRs of the purified major product 
confirm that it is a single diastereomer of the cyclopropanation product (See Supporting 
Methods). A trace amount (<5% based on integration) of an unidentified compound with 
resonance at ~40 ppm can also be observed in the 13C NMR. Together, these results show that 
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P450TbtJ2-T247A catalyzes robust and diastereoselective cyclopropanation on an engineered 
variant of its natural substrate. As P450TbtJ2-T247A exhibits proclivity towards modification of 
an I8-1Dha core (7), this may indicate P450TbtJ2’s role in native modifications at the I8 position. 
We further investigated the potential for site-specific cyclopropanation on thiopeptide 
substrates exhibiting multiple Dhas. Substrates F5-3Dha (Figure S3.14 and S3.15) and I8-3Dha 
(9, Figure 3.2F and S3.16) display three Dhas: one Dha at one of the two different positions that 
Table 3.3. Dha cyclopropanation on linear thiopeptide cores 
 
normally undergo P450-mediated monooxygenation (Phe5 or Ile8) and two Dhas at positions 1 
and 11, which are natively used as handles for pyridine formation en route to the macrocyclic 
thiopeptide. Variants of P450TbtJ1 and P450TbtJ2 provided cyclopropane products (i.e. 10 in Figure 
3.2F) with improved conversion relative to P450PikC-T247A or hemin alone (Table 3.3, Figure 
3.2G and 3.2H; Figure S3.17-S3.22). Somewhat surprisingly, the major products exhibit 
modifications at all three olefins (Figures 3.2, S3.21 and S3.22); mono- and di-cyclopropanation 
products are only detectable in the baseline of the mass spectra. Again, P450TbtJ2-T247A shows 
particularly strong conversion (~68%, Figure 3.2H and Table 3.3) from substrate 9 and yields 
primarily 4a single peak in the UV trace. 
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In order to investigate site selectivity for enzymatic cyclopropanations by P450TbtJ2-
T247A, product formation in the presence of 9 was monitored over time. Notably, the reaction 
nears completion in under an hour, and the tri-cyclopropanated species was the major product 
observed even at early time points (Figures S3.23 and S3.24). Accumulation of mono- and di-
modified product was not observed. These results suggest that the native binding affinity of 
P450TbtJ1 and P450TbtJ2 may permit processive scanning of the substrate, transiently orienting 
 
Figure 3.3 Non-natural enzymatic modification of a cyclic thiopeptide. A. Cyclic F5Dha peptide 
precursor (11) and cyclopropane product (12). B. Extracted ion chromatograms from P450TbtJ1-
T234A/C340S cyclopropanation reaction with cyclo-F5Dha C. Extracted ion chromatograms 
from P450TbtJ2-T247A cyclopropanation reaction with cyclo-F5Dha. Cyclo-F5Dha is shown in 
blue, and the cyclopropane product is shown in red. Reaction conditions: 20 μM P450, 100 μM 
thiomuracin derivative, 10 mM EDA, 10 mM Na2S2O4, 0.1 M KPi pH 8, 7.5% co-solvent, argon, 
16 h. 
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each olefin within the active site for modification. A broader analysis of substrate promiscuity 
with additional analogs will be necessary to confirm this mechanism. 
For comparison, we investigated modification of Dha modified peptides using standard 
metal catalysts. Rhodium catalysts have been used by Romo and colleagues to catalyze 
microscale intermolecular C-H amination and olefin cyclopropanation of natural products.34,35 
Attempts to cyclopropanate I8-3Dha (9) using a panel of Rh catalysts provided only trace 
amounts of product (Figure S25). This data may suggest an inhibitory interaction between the 
peptide and catalyst. In addition, poor peptide solubility prevents high substrate concentrations 
typically used for Rh-mediated cyclopropanations. Alternatively, catalysis by FeIII-
tetraphenylporphyrin provided a complex mixture of cyclopropanation products enriched for one 
or two cyclopropane modifications (Figure S3.25). Finally, in order to access cyclopropanated 
thiopeptides, we sought to determine whether P450TbtJ1 or P450TbtJ2 variants can modify a 
macrocyclic thiopeptide. This would provide a unique enzymatic opportunity for late-stage 
introduction of new C-C bonds, functional handles, and structural diversity into a natural product 
or natural product-like molecule. Accordingly, both the F5-3Dha and I8-3Dha core substrates 
were elaborated with a 15-residue fragment of the thiomuracin leader peptide. In previous work, 
we have reported that a pyridine synthase recognition sequence is located in this region of the 
thiomuracin leader peptide (Figure S3.26 and S3.27).33,36 Treatment of the F5-3Dha core with the 
thiomuracin pyridine synthase, TbtD (Figure 1), yielded the pyridine macrocycle (11, Figure 3.3 
and S3.28). In contrast, no cyclization was observed with the I8-3Dha core, suggesting that TbtD 
is intolerant to this modification. Incubation of the cyclic F5-Dha thiomuracin analog (11, Figure 
3.3A) and EDA with P450TbtJ1-T234A/C340S or P450TbtJ2-T247A afforded the cyclopropanated 
thiopeptide product (12, Figure 3B and 3C; confirmation by LCMS/MS in Figure S3.29 and 
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S3.30). We additionally screened P450TbtJ1 and P450TbtJ2 variants against two olefin-containing 
thiopeptides, nosiheptide and thiostrepton, derived from alternative biosynthetic pathways. Only 
baseline detection of cyclopropanated nosiheptide was observed, whereas thiostrepton showed 
no modification (data not shown). These results suggest that P450TbtJ1 and P450TbtJ2 variants 
show preference for linear and cyclic thiopeptide analogs of their natural substrate for 
cyclopropanation. 
Conclusion 
In conclusion, we have demonstrated that P450 mediated cyclopropanation can be 
extended to modification of Dhas, resulting in enzymatic synthesis of ACCAs. Both electron-rich 
and electron-deficient Dhas can be transformed in this way, although further catalyst tuning will 
be necessary to obtain appreciable yields from the latter. Additionally, we characterized two new 
P450s, P450TbtJ1 and P450TbtJ2 from the thiomuracin pathway in T. bispora DSM 43833. Both 
P450s were able to affect cyclopropanation of Dhas at multiple sites on thiopeptide precursors. 
Significantly, engineered variants of P450TbtJ1 and P450TbtJ2, which displayed weak activity on 
model Dha 1, were more efficient catalysts on thiopeptides resembling their native substrates. In 
addition, these thiopeptide substrates were poorly tolerated by hemin and other P450s (i.e. PikC). 
These results suggest that innate substrate recognition motifs can be exploited to enhance non-
natural enzymatic modifications on natural products and their analogues. Furthermore P450TbtJ1, 
which we structurally characterized, is able to carry out ACCA incorporation on a cyclic 
thiomuracin analog, thereby demonstrating that P450s can carry out non-natural, late-stage 
modification of complex molecules and natural products, in addition to monooxygenation. 
Beyond cyclopropanation, a diverse array of metallocarbenoid and metallonitrenoid chemistries 
have been demonstrated in P450s4,7,8,10-14 and Ir-substituted heme proteins,37,38 suggesting that 
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P450-mediated modification of natural products can be extended to other non-natural C-C, C-N, 
and C-X modifications. Future efforts in our labs will focus on investigating the substrate scope 
for P450TbtJ1 and P450TbtJ2, engineering enzyme variants for improved activity and selectivity on 
small molecule or peptide Dhas, and assessing the biological activity of analogs prepared by this 
method. 
Methods 
General 
All reactions were carried out in an oven-dried round-bottomed-flask under an inert 
nitrogen atmosphere with stirring. Solvents, reagents, and chemicals were purchased from 
commercial suppliers (Acros, Fisher, Sigma, ChemPep) and used as received unless otherwise 
noted. Spectra for 1H and 13C NMR were recorded at room temperature with a Varian Inova 400 
spectrometer (400 MHz and 100 MHz, respectively), Varian Inova 500 spectrometer (500 MHz 
and 125 MHz, respectively), a Bruker model DRX 600 spectrometer (600 MHz and 151 MHz 
respectively) and a Bruker 700 Avance3E spectrometer (700 MHz and 176 MHz respectively). 
Chemical shifts are reported in δ (ppm) relative units to residual solvent peaks CDCl3 (7.26 ppm 
for 1H and 77.0 ppm for 13C) and CD3OD (3.35 ppm and 4.78 ppm for 
1H; 49.32 ppm for 13C). 
Splitting patterns are assigned as s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), 
multiplet (m), dd (doublet of doublets), and td (triplet of doublets). LC-MS and LC-MS/MS 
measurements were recorded using an Agilent 6520 Accurate-Mass Q-TOF ESI positive in high 
resolution mode (350 °C, 250 V fragmentor for peptides; 310 °C, 130 V fragmentor for small 
molecules). Analytical columns used in LC-MS analysis were a Phenomenex Kinetex® 2.6 µ 
C18 100 Å column (50 x 2.1 mm), a Thermo Scientific™ 2.6 µ Accucore™ RP-MS LC Column 
(50 x 3 mm), and a Restek 5 µ Ultra Biphenyl Column (50 x 2.1 mm). MS-MS was performed 
with collision energy of 45 V or 55 V. Predicted masses were extracted to ±5 ppm. Semi-
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preparatory HPLC was carried out using a Shimadzu UFLC CBM-20A with a dual channel 
wavelength detector at 220 nm and 254 nm with a Phenomenex LUNA 10 µ C18(2) 100 Å, 
AXIA semi-preparatory column or a Restek 5 µ Ultra Biphenyl Prep Column (50 x 21.2 mm). 
Gas chromatography analyses were carried out using an Agilent 7820A gas chromatograph, FID 
detector, and a J&W scientific cyclosil-B column (30m x 0.25 mm x 0.25 μm film). 
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Cloning 
TbtJ1 and TbtJ2 were cloned into pMCSG7 using a standard ligation independent cloning 
(LIC) protocol.  The codon optimized genes for expression in E.coli were obtained from 
Integrated DNA Technologies (IDT) and amplified by PCR using Q5 High-Fidelity DNA 
polymerase (NEB) according to the manufacturer’s instructions. The codon optimized gene 
sequences and the primer sequences used for gene amplification are below: 
tbtJ1 
ATGATGGAATTGCCCGGACAACCTTCCTTAACGGATGGAGGAGCAGCTCTGTTTGCT
TGGTTACGCACAATGCGTAATGAACATCCGGTGTGGCGCGACCAGTTCGGAATTTAC
CATGTTTTTCGTTATGACGATGTACGCCAGATCCTGGGGGACTATCAGACCTTCAGT
TCTGACCGCACGCGCCTGATGCCGACAGCCCAGGGCTTCGGAAAAGGGGGTATCAC
AATGATTGATCCCCCGGAGCACCGCCATCAACGCCGTCTGATCACACATGCGTTCAC
ACCCCAGTCAATCTCAGCCATGGAACCACGCATCCGTCAAATCGCCGATCATCTTCT
TGATGAGCTTCCGGGACCAGAGTTCGACTTAGTAGAACATTTTGCATACCCTTTGCC
AGTCATTGTAATTGCTGAGTTGCTTGGCGTGCCCCCAGGAGACCGCCACTTATTCCG
CACTTGGTCAGACCGCCTTATGAGCTTACAAGTTGAGAACTACGCTGATCCTGAACT
GGCGCGCACCGTCGCTGCAGCGATGACGGAGATGAACGATTACCTTCGTGAACATT
GTCGTAGTCGCCGTACCCATCCCCGCGACGACTTGTTAACTCGCTTAGTCCAGGCAG
AAGTCGAAGGCAAGCGCTTAGATCTGGAAGAGGTGGTCAATACAGCTAGTTTACTTT
TGCTGGCCGGCCATTTAACCACTACCGTTCTGATCGGCAATACCATGTTGTGCTTGTG
GGACCATCCAGAAGCAGAAAAAGCGGTGCGTGCTGACCCCTCCTTAATCCCCGCAG
CATTGGAGGAGTCGCTGCGTTTACGTTCGCCATTCCTGCAGGCTGGACGTGTTACTA
CCCGCGATGTAACAATCGCCGGTGAGACAATTCCAGCAAATCGCTTCGTGATGGCCT
GGATTTTAAGCGCAAACCACGACGACCGTCGTTTTCCCGATCCGGAGCGCTTTGACC
TGCACCGTCAAACCACTGGTCACATCGCATTCGGACACGGGGTCCATTTTTGTTTAG
GAGCTCAGCTGGGGCGTCTTGAGGGTCGCATCGCGCTGGAACGCTTGTTAGGTCGTT
TTACTGAAATTCACCCCTGGCCCCGTGAAGGCATTTCCTTCTACCAATCTGCTATCTT
CGGGGCCAGTCGTATGCCTGTTCGTTGCGGATGA 
 
tbtJ2 
ATGAATGAACCCCTGACCGCGCAGGGCACGCCTACAATGACGATGCCTGCCGCTCA
ACGTCCACGCATCTCTCACGGGGGGCAGGCTTTGCTTAAGTGGCTGGATGAGATGCG
TGAATCCCAACCCGTATGGCGTGATGGATTCGGCATCTTCCATGTTTTCCGTCATGCG
GATGTTCAGCGCGTAATGGCAGATTATGCAACTTTCTCTTCCGACATCAATCGCTTG
CGCCCAGGGGGTGATCCGTTCAGCGCAGGATCATTAATGCTGACTGATCCTCCGGAG
CACCGTAAACTTCGCCGTCTGATCTCGCAAGCCTTCAGTCCAAAGATGAGTGCAGAC
ATGAAGCCGCGCATCGCAGAGCTGACAGAGGAACTTTTAGATGATATTGAGGAAGA
CGAGTTCGATCTGGTCGAAAAATTCGCTCACCCCTTACCCATCATGGTTATCGCTGA
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GTTACTGGGTATTCCTATTCATGATCGTGGTTTGTTTCGTACTTGGGCTGATCGTTTG
ATTGCGTTGCACGTGGATGACCCTACGGATGTAGAGATTGGACGCATGGTCGGCGA
AGCAATGCGTGAGATGGGAGAATACGTGCAAACCCACGTGCGCAAACGCCGCGCAG
ATCCTCAAGATGACCTTGTAAGCAAATTAATCGCAGCAGAAGTAGACGGCGAGCGT
CTGACGGATGCAGAGATCGTCAACACTTCTTGTCTGCTGCTTTTAGCGGGACAGATT
ACCTCTACAATGGCGCTTGGAAACACCTTCCTTTGCTTTCGTGACGCCCCGGATGCA
GAACGTGCGGTCCGCGCCGACTTTAGTTTGTTAGGCCCGGCCTTCGAAGAAGTGCTG
CGTTTGCGCCCTCCACTGACACAGGCCGCACGTTTGACCACAACAGATGTCGAGGTG
GCAGGGACGTTGATTCCAGCAGGGAGTCTTGTGATTAACTGGCTGTTAAGCGCTAAC
TACGATGAGCGCCAGTTCCCGAACCCGTATCGCTTTGATTTAACACGTTCGCCAAAC
CGCCACTTCGCCTTTGGTCATGGTATTCACCATTGTCTTGGTGCACCTTTGGCGCGTG
TAGAGGGCCGTGTTGCTTTAGAGCTTTTGTTACGCCGTTTCTCCGAGATTACTATTGA
TCCCGATGCCGAGTTGAGCTACTATGAGGACCCGATGTTTGGAGTCAAATCCCTGCC
AGTCCGTGTTCGCCGTGCAGCGTAG 
 
TbtJ1_F: 5´-TACTTCCAATCCAATGCGATGATGGAATTGCCCGGACAACCTTCC-3´ 
TbtJ1_R: 5´-TTATCCACTTCCAATGCGCTATCATCCGCAACGAACAGGCATACG-3´ 
TbtJ2_F: 5´-TACTTCCAATCCAATGCGATGAATGAACCCCTGACCGCGCAG-3´ 
TbtJ2_R: 5´-TTATCCACTTCCAATGCGCTACTACGCTGCACGGCGAACACGGAC-3´ 
The purified PCR product was phosphorylated with T4-PNK and then treated with T4-
DNA polymerase to create LIC overhangs.  pMCSG7 was linearized with SSp1, 
dephosphorylated with Antarctic Phosphatase, and then treated with T4-DNA polymerase to 
create LIC overhangs.  Treated PCR product and vector were combined in 1:1 ratio by volume 
and transformed into One-Shot Top10™ competent cells (Agilent) and plated onto LB-agar 
plates containing 100 µg/mL ampicillin. Individual colonies were picked and grown overnight in 
5 mL LB-medium containing 100 µg/mL ampicillin. Cells were spun down and DNA was 
extracted using plasmid purification (Life Technologies).  The plasmid was transformed into 
BL21-DE3 competent cells (Agilent). 
Site-directed mutagenesis of TbtJ1 and TbtJ2 was carried out by the QuikChange 
mutagenesis protocol using PfuTurbo DNA polymerase.   The template DNA was digested after 
PCR with the restriction enzyme DpnI. The PCR product was then transformed into One-Shot 
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Top10™ Competent cells and grown on LB-agar plates containing ampicillin.  Primer sequences 
used in the mutagenesis PCR reactions are given below: 
TbtJ1_T234A_F: 5´-CTGGCCGGCCATTTAGCCACTACCGTTCTGATC-3´ 
TbtJ1_T234A_R: 5´-GATCAGAACGGTAGTGGCTAAATGGCCGGCCAG-3´ 
TbtJ1_C340S_F: 5´-CACGGGGTCCATTTTAGTTTAGGAGCTCAGCTG-3´ 
TbtJ1_C340S_R: 5´-CAGCTGAGCTCCTAAACTAAAATGGACCCCGTG-3´ 
TbtJ2_T247A_F: 5´-TTAGCGGGACAGATTGCCTCTACAATGGCGCTT-3´ 
TbtJ2_T247A_R: 5´-AAGCGCCATTGTAGAGGCAATCTGTCCCGCTAA-3´ 
TbtJ2_C353S_F: 5´-CATGGTATTCACCATAGTCTTGGTGCACCTTTG-3´ 
TbtJ2_C353S_R: 5´- CAAAGGTGCACCAAGACTATGGTGAATACCATG-3´ 
pCYP119 was a gift from Stephen Sligar (Addgene plasmid # 50771). The CYP119 gene 
contains the recognition sequence for the restriction enzyme NdeI (CATATG). A single point 
mutation was introduced to remove the NdeI recognition sequence by a Golden Gate assembly 
protocol. Whole plasmid PCR with Phusion polymerase (NEB) was performed using the primers 
below (BsaI recognition sequence is underlined): 
CYP119_NdeI_OUT_F: 5´-
GATGTTGGTCTCTGAAACACATGGCAGGTGTTTTCCTATAG-3´ 
CYP119_NdeI_OUT_R: 5´-GATGTTGGTCTCTTTTCCGTCATAATACACTGG-3´ 
The PCR product was digested with the restriction enzyme DpnI (NEB) overnight, 
column purified, and digested with the restriction enzyme BsaI HF (NEB) for 6 hours. The 
digested PCR product was then column purified and ligated with T4 DNA ligase (NEB). The 
ligation mixture was column purified and transformed into E. coli strain BL21-GOLD (DE3) 
competent cells (Agilent). 
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The modified CYP119 gene was amplified from purified plasmid DNA using Phusion 
polymerase and the following primers (restriction enzyme recognition sequences are underlined): 
CYP119_NdeI_F: 5´-GATGTTCATATGTATGACTGGTTTAGTGAGATG-3´ 
CYP119_XhoI_R: 5´-GATGTTCTCGAGTTCATTACTCTTCAACCTGACCAC-3´ 
The PCR product was digested with NdeI, XhoI, and DpnI and then ligated into pET21c+ 
(digested with NdeI and XhoI and treated with Calf Intestinal Alkaline Phosphatase) using T4 
DNA ligase. The ligation mixture was column purified and then transformed into E. coli strain 
BL21-GOLD (DE3) competent cells. 
Site-directed mutagenesis to introduce mutations to the conserved threonine and cysteine 
residues was performed using the whole plasmid Golden Gate assembly method described 
above. Primer sequences used in the mutagenesis PCR reactions are given below (BsaI 
recognition sequence is underlined): 
CYP119_T213A_BsaI_F: 5´-GATGTTGGTCTCTTGAGGCTACAACTAACTTAATATCAAACTCTG-3´ 
CYP119_T213A_BsaI_R: 5´-GATGTTGGTCTCTCTCATTACCCGCTATGAGAAG-3´ 
CYP119_C317S_BsaI_F: 5´-GATGTTGGTCTCTTCTGTCTTTAGGTGCTCCTTTGGCTAG-3´ 
CYP119_C317S_BsaI_R: 5´-GATGTTGGTCTCTCAGATGTATTCCAGACCCAAAG-3´ 
The sequences and cloning for all other P450s under investigation in this study were reported 
previously.1 
Protein expression and purification 
The cytochrome P450s used in this study, as well as TbtD, were expressed and purified 
as previously described.22,33 SDS-PAGE analysis of purified P450s is shown in Figure S30. 
TbtJ1 used for crystallography was purified using a HisTrap HP column (GE Healthcare Life 
Sciences) and then purified to homogeneity using an S200 gel filtration column on an 
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ÄKTAxpress (GE Healthcare Life Sciences) after removal of the N-terminal his-tag by TEV 
protease. Purified TbtJ1 was stored in 10 mM Tris pH 8, 10 mM NaCl at 4 °C prior to 
crystallography. 
Crystallization conditions for TbtJ1 
TbtJ1 was crystallized by vapor diffusion in 96-well sitting drop plates (Hampton 
Research) using an automated Phoenix liquid handling robot (Art Robbins Instruments) and 
sampling conditions from the commercial MCSG crystallization suite screen (Anatrace). A 0.2 
µL:0.1 µL mixture of protein stock (15 mg/mL in 10 mM Tris pH 8, 10 mM NaCl) to mother 
liquor was combined in each drop. Optimal crystallization conditions for TbtJ1 were 1 M 
(NH4)2SO4, 1 % w/v PEG 3350, and 0.1 M Bis-tris pH 5.5. Crystals typically grew over a span 
of 1 − 3 days at room temperature under these conditions.  
X-ray data collection and protein structure determination 
X-ray diffraction data were collected at Southeast Regional Collaborative Access Team 
(SER-CAT) at the Advanced Photon Source (Argonne National Laboratory) using beamline 22-
ID and a MAR300HS CCD detector. Data were collected at 100 K. Statistics for data collection 
and refinement are listed in Table S3.2. Diffraction data sets were integrated and scaled with the 
automated data processing software KYLIN provided by SER-CAT.39 Initial phases for TbtJ1 
were determined by molecular replacement using Phenix Phaser.40 The ligand free form of P450 
EryK from Saccharopolyspora erythraea (54% identity to TbtJ1, deposited under PDB code 
2WIO) was used as a molecular replacement model.41 Refinement was accomplished by iterative 
cycles of manual model building with Coot and automated refinement using Phenix Refine.40,42 
Model quality was assessed with the Phenix Validation tool.40 All protein structure figures were 
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generated using PyMOL software (The PyMOL Molecular Graphics System, Version 1.6, 
Schrödinger LLC.). 
Synthetic Procedures 
Synthesis and characterization of methyl 2-benzamidoacrylate (1) 
 
 
Compound 1 was prepared according to a literature procedure.43 (800 mg, 67% yield, 2 
steps). 1H NMR (400 MHz, CDCl3): δ 8.52 (broad, s, 1H), 7.80 – 7.83 (m, 2H), 7.42 – 7.54 (m, 
3H), 6.77 (s, 1H), 5.97 (d, J = 1.6 Hz, 1H), 3.85 (s, 3H). 
 
Synthesis and characterization of 2-ethyl 1-methyl 1-benzamidocyclopropane-1,2-dicarboxylate 
 
Inside a glove box under nitrogen atmosphere, compound 1 (98.8 mg, 0.482 mmol) was 
dissolved in CH2Cl2 (2 mL). Ethyl diazoacetate (87%, 87.4 μL, 0.723 mmol) was added dropwise 
followed by addition of [Rh(OAc)]2 (4.26 mg, 9.64 μmol). The reaction was stirred under N2 for 
12 h, after which an additional 87.4 μL of ethyl diazoacetate was added and stirred for an 
additional 4 h. The reaction was concentrated under reduced pressure and purified by silica gel 
(~60 mesh) using a hexanes : ethyl acetate system (1:1, Rf = 0.45) to afford compound 4 (52.3 
mg) in 37% yield as a mixture of diastereomers (dr = 1.1 : 1, major : minor). The diastereomers 
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were separated using Semi-Prep HPLC Method A. The structure of the diastereomers was 
determined based on comparison to previously reported 1H NMR spectra for diethyl 1-
benzamidocyclopropane-1,2-dicarboxylate diastereomers.23 1H NMR (600 MHz, CDCl3, 4a): δ 
7.77-7.79 (m, 2H), 7.51-7.54 (m, 1H), 7.43-7.46 (m, 2H), 6.80 (broad, s, 1H), 4.13-4.19 (dq, J = 
1.6, 7.2 Hz, 2H), 3.76 (s, 3H), 2.79 (dd, J = 7.2, 9.0 Hz, 1H), 2.04 (dd, J = 5.2, 9.4 Hz, 1H),  1.79 
(dd, J = 5.2, 8.6 Hz, 1H ), 1.26 (t, J = 7.2 Hz, 3H). 1H NMR (600 MHz, CDCl3, 4b): δ 7.78-7.80 
(m, 2H), 7.53-7.56 (m, 1H), 7.45-7.47 (m, 2H), 6.85 (broad, s, 1H), 4.21 (q, J = 7.2 Hz, 2H), 
3.74 (s, 3H), 2.43 (dd, J = 8.1, 9.6 Hz, 1H), 2.35 (dd, J = 6, 8.2 Hz, 1H), 1.77 (dd, J = 5.9, 9.6 
Hz, 1H), 1.30 (t, J = 7.2 Hz, 3H). 13C NMR (125 MHz, CDCl3, mixture of diastereomers): δ 
14.00, 14.06, 20.67, 21.81, 28.53, 31.27, 39.80, 40.03, 52.92, 53.18, 61.62, 61.67, 127.16, 
127.19, 128.64, 128.67, 132.14, 132.31, 132.89, 133.22, 168.40, 168.63, 169.33, 169.37, 169.56, 
170.13. Expected [M+H]+ = 292.1179; Observed [M+H]+ = 292.1198. 
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Synthesis of and characterization of ethyl 2-(1-acetylaminoethenyl)thiazole-4-carboxylate (2). 
 
Ethyl 2-(1-acetylaminoethenyl)thiazole-4-carboxylate was synthesized according to the 
procedure published by Hughes et al.44 A brief description of the adopted procedure is provided 
here. Potassium hydrogen carbonate (2.16 g, 21.6 mmol) and L-cysteine ethyl ester (4.0 g, 21.6 
mmol) were mixed in water (200 mL) and ethanol (200 mL) in a 1000 mL flask.  The reaction 
mixture was stirred under nitrogen at room temperature for 18 hours.  The reaction mixture was 
concentrated to half its original volume, sodium chloride was added to saturate the aqueous 
mixture, which was then extracted with chloroform (4 x 100 mL).  The combined organic phase 
was dried over magnesium sulfate and concentrated in vacuo using  a rotary evaporator to yield 
ethyl 2-acetylthiazolidine-4-carboxylate (4.0 g) as a red oil, which was used in the next step 
without purification. 
Manganese dioxide (31.2 g, 0.36 mol) was added to ethyl 2-acetylthiazolidine-4-
carboxylate (4.0 g) in dry acetonitrile (160 mL).  The reaction mixture was heated to 60 °C under 
nitrogen for 18 hours.  The reaction mixture was filtered through Celite and the filter cake was 
washed thoroughly with acetonitrile (3 x 50 mL).  The combined organic filtrate was 
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concentrated in vacuo to give a brown oil.  Purification by column chromatography gave ethyl 2-
acetylthiazole-4-carboxylate as a yellow solid (0.35 g, 8% over two steps). 
Sodium acetate (0.139 g, 1.708 mmol) was added to a suspension of hydroxylamine 
hydrochloride (0.118 g, 1.708 mmol) in ethanol (2 mL).  After stirring for 30 minutes, a solution 
of ethyl 2-acetylthiazole-4-carboxylate (0.34 mg, 1.708 mmol) in ethanol (4 mL) was added 
dropwise over an hour using dropping funnel, and then the reaction mixture was stirred at room 
temperature under nitrogen for 12 hours.  Water (15 mL) was added and the mixture was 
extracted with dichloromethane (3 x 15 mL).  The combined organic layer was dried over 
magnesium sulfate and concentrated in vacuo to give ethyl 2-(1-hydroxyiminoethyl)thiazole-4-
carboxylate, which was used in the next step without purification. 
Acetic anhydride (0.445 mL, 4.74 mmol) was added in portions to a solution of ethyl 2-
(1-hydroxyiminoethyl)thiazole-4-carboxylate (0.34 g, 1.58 mmol) in toluene (4 mL) under 
nitrogen.  Glacial acetic acid (0.27 mL, 4.74 mmol) was added followed by iron powder (0.177 
g, 3.16 mmol), and the reaction mixture was heated to 70 °C for three hours.  The reaction 
mixture was allowed to cool to room temperature and filtered through Celite.  The filter cake was 
washed with toluene (3 x 5 mL).  The combined filtrates were cooled in an ice bath and washed 
with aqueous sodium hydroxide solution (2 M, 3 x 15 mL).  The organic phase was separated, 
dried over magnesium sulfate, and the solvents were removed using rotary evaporator.  The 
product was then dissolved in dimethyl sulfoxide and diluted with an equal volume of water, and 
purified using semi-preparatory reverse-phase HPLC using Phenomenex C18 column as 
described above.  Water was used as solvent A and acetonitrile was used as solvent B.  Eluent 
fractions were analyzed by LC-MS and the solvent was removed using freeze-drying.  Ethyl 2-
(1-acetylaminoethenyl)thiazole-4-carboxylate (0.094 g, 24% over two steps) was obtained as a 
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white solid.  1H NMR (400 MHz; CDCl3, 298 K) δ 8.38 (1H, br s, NH), 8.07 (1H, s, 5-H), 6.51 
(1H, s, =CHH), 5.47 (1H, s, =CHH), 4.40 (2H, q, J 7.1, OCH2Me), 2.20 (3H, s, COMe), 1.40 
(3H, t, J 7.1, OCH2Me); 
13C NMR (400 MHz, CDCl3, 298 K) δ 169.2, 166.0, 160.8, 146.6, 
133.7, 127.7, 103.2, 61.6, 24.9, 14.3. Expected [M+H]+: 241.0641; Observed [M+H]+: 241.0655. 
Synthesis and characterization of ethyl 2-(1-acetamido-2-(ethoxycarbonyl)cyclopropyl)thiazole-
4-carboxylate (5). 
 
Compound 5a was synthesized on a preparative scale according to a previously reported 
procedure using P450TbtJ2-T247A and purified using Semi-Prep HPLC Method D.
7 1H NMR 
(600 MHz, CDCl3) δ 1.28 (t, J=7.2 Hz, 3 H), 1.38 (t, J=7.2 Hz, 4 H), 1.88 (dd, J=7.2, 5.3 Hz, 1 
H), 2.06 (s, 3 H), 2.24 (q, J=5.2 Hz, 1 H), 2.98 (dd, J=9.2, 7.3 Hz, 1 H), 4.11 - 4.18 (m, 2 H), 
4.35 - 4.41 (m, 2 H), 6.51 (s, 1 H), 8.02 (s, 1 H); 13C NMR (151 MHz, CDCl3) δ 14.05, 14.30, 
23.05, 24.71, 31.38, 41.22, 61.35 (2 C), 127.27, 146.87, 161.17, 169.72, 171.3, 172.36. Expected 
[M+H]+ = 327.1009; Observed [M+H]+ = 327.1057. 
Compound 5b was synthesized on a preparative scale according to a previously reported 
procedure using CYP119-T213A-C317S and purified using Semi-Prep HPLC Method D.7 1H 
NMR (600 MHz, CDCl3) δ 1.14 (t, J=7.2 Hz, 3 H), 1.38 (t, J=7.2 Hz, 4 H), 1.83 (dd, J=8.8, 5.9 
Hz, 1 H), 1.94, (s, 3 H), 2.29 (t, J=6.3 Hz, 1 H), 2.35 (dd, J=8.9, 7.2 Hz, 1 H), 4.00 (q, J=7.2 Hz, 
2 H), 4.39 (q, J=7.2 Hz, 2 H), 7.19 (br. s, 1 H), 8.12 (s, 1 H); 13C NMR (151 MHz, CDCl3) δ 
14.07, 14.39, 21.79, 23.07, 30.16, 39.59, 61.19, 61.37, 128.79, 145.91, 161.19, 167.78, 169.22, 
170.59. Expected [M+H]+ = 327.1009; Observed [M+H]+ = 327.1068. 
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Synthesis of and characterization of 13C-labelled EDA. 
 
Ethyl 2-13C-diazoacetate was synthesized by adapting the procedure described by 
Ranocchiari and Mezzeti.45 2-13C-glycine (Sigma, 0.30 g, 4.21 mmol) was suspended in 30 mL 
ethanol under nitrogen, and the suspension was cooled in an ice-water-salt bath.  Thionyl 
chloride (5.47 mmol, 0.397 mL) was added dropwise using a syringe and a needle.  The flask 
was allowed to warm to room temperature.  The mixture was then refluxed for 2 hours.  After 
cooling the reaction mixture to room temperature, the solvent was removed under reduced 
pressure.  The resulting white solid (ethyl 2-13C-glycine hydrochloride) was dried in vacuo and 
recrystallized from ethanol. Yield: 0.22 g (40%).  
Ethyl 2-13C-glycine hydrochloride (0.21 g, 1.49 mmol) was mixed with water (2 mL) and 
dichloromethane (3 mL) in a 10-mL flask with a magnetic stirrer under nitrogen.  The flask was 
placed in a freezing mixture of ice, water and salt.  Sodium nitrite (0.124 g, 1.8 mmol) was 
dissolved in 1 mL water and the solution was cooled to 0 °C separately, and then added to the 
flask dropwise.  After stirring the mixture for ~10 minutes after complete addition of sodium 
nitrite, 5% H2SO4 solution (0.143 mL, 0.073 mmol) was added slowly in a dropwise manner.  
The reaction mixture was allowed to stir for 30 minutes, during which it turns progressively 
yellow, while ensuring that the temperature of the bath was maintained below 0 °C throughout.  
The reaction mixture was then poured into an ice-cold separating funnel.  The yellow organic 
phase was recovered, and the aqueous phase was extracted with ice-cold dichloromethane (2 x 4 
mL).  The combined organic phase was then washed with 5% aqueous solution of sodium 
carbonate (3 x 4 mL).  The organic phase was set aside, and the aqueous phase was washed with 
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dichloromethane (2 x 4 mL).  Organic phases were combined and dried over Na2SO4.  The 
solvent was carefully removed under mildly reduced pressure in a rotary evaporator. The 
synthesized EDA was further purified using silica gel flash chromatography and eluted using 1:9 
ethyl acetate:hexane solvent mixture. Purified EDA was carefully concentrated in vacuo by 
repeated dilutions with dichloromethane.  Yield ~ 0.178 g of 50% EDA solution in CH2Cl2 (
1H-
NMR) (~52% yield).  1H-NMR (400 MHz; CDCl3) δ 4.72 (1H, d, 1JC-H 204 Hz, N213CH), 4.20 
(2H, q, 2JH,H’ 7.0 Hz, -OCH2Me), 1.26 (3H, t, 
2JH,H’ 7.1 Hz, -OCH2CH3); 
13C NMR (400 MHz, 
CDCl3, 298 K) δ 183.9, 60.82, 46.10 (s, N213CH), 14.39. 
Solid phase synthesis of linear thiopeptides 
Peptide synthesis was carried out using solid-phase peptide synthesis on a Biotage 
Initiator+ Alstra microwave peptide synthesizer using Rinkamide Chemmatrix resin (Biotage).  
Peptidic scaffolds were synthesized from the C-terminus to the N-terminus with a C-terminal 
amide functional group using standard fluorenylmethoxycarbonyl (Fmoc) chemistry.  The 
building blocks comprised of commercially available N-α-Fmoc-L-amino acids, and chemically 
synthesized N-Fmoc-L-amino acid-thiazole building blocks.  The detailed synthetic procedures 
for N-Fmoc-L-amino acid-thiazole building blocks are described elsewhere.33 The solid-phase 
synthesis involved swelling the resin (15 mg) in 1.5 mL DMF at 70 °C for 20 minutes. (i) 
Coupling: Fmoc-building block (5.0 equiv., 0.4 M in DMF), HATU (5.0 equiv., 0.2 M in DMF), 
and DIEA (10.0 equiv., 0.2 M in DMF) were added to the swollen resin in that order. The 
resulting suspension was heated under microwave irradiation: 5 min at 75 °C. The reaction 
vessel was then drained, and the resin was thoroughly washed with DMF four times.  Acetic 
anhydride was used for end-capping the N-terminus of core peptides.  Acetic anhydride (10 
equiv., 5 M in DMF) and DIEA (10 equiv., 0.5 M in DMF) were added to the reaction vial, and 
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the suspended resin was incubated at room temperature for 10 minutes followed by draining and 
washing as above. The bisthiazole-containing building block was coupled using TBTU (5 equiv., 
0.2 M in DMF) and HOBt (5 equiv., 0.2 M in DMF) instead of HATU.  (ii) Fmoc removal: 
Following coupling at each step, excess 20% piperidine was added to the reaction vessel and 
allowed to incubate for 3 min while stirring at room temperature. The reaction vessel was 
drained, washed with DMF, and excess 20% piperidine was introduced again and allowed to stir 
at room temperature for 10 min. The reaction vessel was drained, and the resin was thoroughly 
washed with DMF four times.  After the final deprotection to obtain a primary amine at the N-
terminus of the synthesized leader-peptide containing peptide or the end-capping of the core 
peptides using acetic anhydride, the resin was washed with dichloromethane and dried.  The final 
peptide product was cleaved using a cleavage cocktail containing 94 - 95% (v/v) TFA, 2.5% 
(v/v) water, 2.5% (v/v) triisopropylsilane (TIPS), and 1 or 0% (v/v) ethanedithiol (EDT).  EDT 
was added when the peptide sequence contained at least one methionine.  Cleavage reactions 
were carried out by shaking the resin with the cleavage cocktail at 37 °C for one hour followed 
by room temperature incubation for about 30 minutes in syringes fitted with frits.  The cleaved 
peptide was precipitated by the dropwise addition of the cleavage reaction mixture into cold 
diethyl ether.  The diethyl ether was evaporated under vacuum, and the dried solid was dissolved 
in DMSO and diluted with a mixture of 50% v/v acetonitrile-water.  This crude product was then 
purified using semi-preparatory scale HPLC, and the fractions were analyzed using the UV trace 
at 220 nm, 254 nm, and LC-MS.  In general, the synthesized peptides eluted in a range between 
50%-80% buffer B.  Fractions containing the relatively pure product were dried using 
lyophilization.  The dried product was then weighed and stored at -80 °C.  The peptide products 
were dissolved in DMSO to give a 2 mM stock solution for further use. 
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Conversion of thiopeptide cysteines to dehydroalanines 
The elimination of hydrogen sulfide from cysteine side chains to obtain dehydroalanines 
was adapted from a previously published procedure.46 In brief, cysteine-containing linear 
thiopeptide (1 mM) was incubated at 37 °C in an aqueous solution containing 50% DMSO, 4 
mM TCEP, and 100 mM K2CO3 for 15 minutes. 100 mM of 2,5-dibromopentanoic acid was then 
added to a final concentration of 100 mM, and the reaction mixture was incubated at 37 °C for 3 
hours with continuous shaking.  Excess unreacted dibromopentanoic acid was removed by 
washing the reaction with diethyl ether (6:1 ratio of volumes of diethyl ether to the reaction 
mixture, at least three washes per reaction), which included vortexing, centrifugation, and careful 
removal of the top diethyl ether layer.  Residual amounts of diethyl ether after the final wash 
were removed by keeping the reaction vial open at 37 °C for 10-15 minutes.  The remaining 
reaction mixture was then lyophilized overnight.  DMSO was added to the dried solid residue to 
yield a 2 mM stock solution of the peptide dehydroalanine product (based on the amount of 
peptide originally taken) followed by centrifugation to separate undissolved solids.  This stock 
solution was used as is for peptide characterization and enzymatic reactions. 
Enzymatic Reaction Protocols 
Enzymatic heterocyclization using pyridine synthase TbtD 
Dehydroalanine-containing linear substrate with the 15-residue leader peptide (20 μM) 
was incubated with 10 μM TbtD enzyme at room temperature for 16 hours in a solution 
containing 50 mM HEPES pH 7.5, and 250 mM NaCl.  The reaction mixture was frozen and 
lyophilized.  The solid residue was treated with methanol washes (250 μL x 2) with vortexing, 
followed by centrifugation to separate undissolved solids.  The methanolic solution was dried in 
vacuo, and the solid residue obtained was redissolved in DMSO to give a stock solution of the 
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dehydroalanine-containing analog of thiomuracin.  The aqueous reaction mixture, and the 
methanol and DMSO solutions were analyzed by LC-MS.  Impurities included the unreacted 
linear substrate as well as the cleaved leader peptide carboxamide, a known byproduct of the 
TbtD reaction. 
Small-scale cyclopropanation reaction setup 
Methyl 2-benzamidoacrylate 
Small-scale 400 µL reactions with methyl 2-benzamidoacrylate and EDA were setup 
following conditions previously reported for the cyclopropanation of styrene with EDA.22 A 1.2 
M stock solution of methyl 2-benzamidoacrylate was prepared in DMSO, and a 0.4 M stock 
solution of ethyl diazoacetate was prepared in ethanol. The final concentrations in 400 µL were 
as follows: 20 µM enzyme, 10 mM ethyl diazoacetate, 30 mM methyl 2-benzamidoacrylate, 10 
mM sodium dithionite, and 0.1 M KPi pH 8.0. After 16 h, 20 uL of  100 mM diethyl 
benzamidomalonate (internal standard) was added. The reaction mixture was extracted with 1 
mL of ethyl acetate, transferred to a 1.7 mL microcentrifuge tube, and centrifuged for 5 min at 
18400 xg. The organic layer was diluted 1:1 with 50% ethanol, and 20 μL of the solution was 
analyzed using LC-MS Method A. 
Ethyl 2-(1-acetylaminoethenyl)thiazole-4-carboxylate 
Small-scale 200 µL reactions with ethyl 2-(1-acetylaminoethenyl)thiazole-4-carboxylate 
and EDA were setup following conditions previously reported for the cyclopropanation of 
styrene with EDA.22 A 0.4 M stock solution of ethyl 2-(1-acetylaminoethenyl)thiazole-4-
carboxylate was prepared in DMSO, and a 0.4 M stock solution of ethyl diazoacetate was 
prepared in ethanol. The final concentrations in 200 µL were as follows: 20 µM enzyme, 10 mM 
ethyl diazoacetate, 10 mM ethyl 2-(1-acetylaminoethenyl)thiazole-4-carboxylate, 10 mM sodium 
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dithionite, and 0.1 M KPi pH 8.0. After 16 h, 10 uL of  100 mM diethyl benzamidomalonate 
(internal standard) was added. The reaction mixture was extracted with 1 mL of ethyl acetate, 
transferred to a 1.7 mL microcentrifuge tube, and centrifuged for 5 min at 18400 xg. The organic 
layer was collected in a separate microcentrifuge tube and evaporated to dryness. The dry 
material was dissolved in 1 mL of ethanol, and 1 μL of the solution was analyzed using LC-MS 
Method D. 
Thiomuracin derivatives 
Milli-Q water and 0.1 M Na2S2O4 in 1 M KPi (pH 8) were placed into a separate sealed 
vial and degassed with argon for at least 10 minutes prior to use. Small-scale reactions (200 μL) 
were conducted in 2-mL crimp vials (Agilent Technologies, San Diego, CA). The headspace of a 
crimp vial containing P450 and a stir bar was flushed with argon (no bubbling). Using glass 
syringes, water and P450 were added under argon to a final volume of 166 μL followed by 20 μL 
of 0.1 M Na2S2O4. 10 μL of a solution of thiomuracin derivative (2 mM in DMSO) was added 
and allowed to mix for at least 30 seconds before adding 5 μL of EDA (0.4 M in EtOH). The 
argon lines were subsequently removed, and the reactions were left to stir for at least 16 hours. 
The final concentration of reagents in the reactions were as follows: 20 μM P450, 100 μM 
thiomuracin derivative, 10 mM EDA, 10 mM Na2S2O4, 0.1 M KPi pH 8, and 7.5% cosolvent. 
The reactions with linear thiomuracin substrates were extracted with 1 mL of ethyl acetate, 
transferred to a 1.7 mL microcentrifuge tube, and centrifuged for 5 min at 18400 xg to remove 
precipitated protein. The organic layer was transferred to a separate microcentrifuge tube, 
evaporated to dryness, and dissolved in 200 μL of DMSO prior to analysis using LC-MS Method 
A. 
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Small-scale 200 μL reactions with traditional transition metal catalysts and I8Dha core 
were setup following a similar procedure to the one described above. The reaction with 
Rh2(OAc)2 in water was setup using previously reported reaction conditions.
13 Reactions with 
iron(III) tetraphenylporphyrin (FeTPP), Rh2(OAc)2, Rh2(Oct)2, and Rh2(esp)2 were setup under 
argon in dichloromethane with the following final concentrations: 100 μM rhodium (50 μM 
FeTPP), 100 μM thiomuracin derivative, 10 mM EDA, and 2.5% ethanol. For the reactions with 
rhodium catalysts, the thiomuracin derivative was added to the crimp vial in DMSO and then 
lyophilized prior to addition of catalyst and solvent (DMSO was found to be inhibitory). The 
aqueous reaction was worked up using the procedure described above for thiomuracin 
derivatives. For the reactions performed in dichloromethane, the reaction mixture was transferred 
to a microcentrifuge tube and evaporated to dryness. The remaining solid was dissolved in 200 
μL of DMSO prior to analysis using LC-MS Method A. 
For the reactions with cyclic thiomuracin substrates, an equal volume (200 μL) of 
methanol was added to precipitate protein. The mixture was centrifuged at 18400 xg for 5 min 
and then filtered through glass wool prior to analysis using LC-MS Method B. 
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NMR Spectra 
 
1H NMR (400 MHz) of compound 1 in CDCl3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (600 MHz) of compound 4a in CDCl3  
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1H NMR (600 MHz) of compound 4b in CDCl3 
 
 
13C NMR (125 MHz) of compound 4 (mixture of diastereomers) in CDCl3  
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1H NMR (600 MHz) of 5a in CDCl3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (151 MHz) of 5a in CDCl3.  
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11H-1H NOESY (600 MHz) of 5a in CDCl3.  
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1H NMR (600 MHz) of 5b in CDCl3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (151 MHz) of 5b in CDCl3.  
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1H-1H NOESY (600 MHz) of 5b in CDCl3.  
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Characterization of 13C-labelled cyclopropanated I8Dha mono core 
13C-labelled cyclopropanated I8-1Dha mono core was synthesized on a preparative scale 
according to a previously reported procedure using P450TbtJ2-T247A and 2-
13C-EDA.10 The 
isotopically labeled product was purified using Semi-Prep HPLC Method D. 
1H-NMR chemical shifts for 13C-labelled cyclopropanated I8Dha mono core 
Sr. no. Chemical shift (δ) Multiplicity Coupling constant (J, Hz)* 
1 9.33 s - 
2 9.19 d 9.0 
3 8.85 m 3.0 
4 8.845 d 7.5 
5 8.59 d 9.0 
6 8.52 d 8.0 
7 8 s - 
8 7.97 s - 
9 7.96 s - 
10 7.95 s - 
11 7.94 s - 
12 7.92 s - 
13 7.91 s - 
14 7.87 s - 
15 7.01 t  7.5 
16 7 d 7.3 
17 6.99 d 7.3 
18 6.98 t  7.5 
19 6.96 t  7.5 
20 6.74 d  8.5 
21 6.37 d  9.0 
22 5.56 m ND 
23 5.48 q  7.9 
24 5.35 m ND 
25 5.08 m ND 
26 4.58 s - 
27 3.99 q  7.3 
28 3.74 m ND 
29 3.3 m ND 
*ND: Not determined 
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1H-NMR chemical shifts for 13C-labelled cyclopropanated I8Dha mono core (continued) 
Sr. no. Chemical shift (δ) Multiplicity Coupling constant (J, Hz)* 
30 3.3 d 7.0 
31 3.28 d 7.0 
34 3.16 m ND 
35 3.15 m ND 
36 3.14 m ND 
37 2.98 quin 1.6 
38 2.89 d 6.8 
46 2.45 m ND 
47 2.41 m ND 
48 2.4 m ND 
49 2.34 m ND 
50 2.33 s - 
51 2.1 m ND 
52 1.79 s - 
*ND: Not determined 
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1H NMR (700 MHz, 298.2 K) of 13C-labelled cyclopropanated I8-1Dha mono core in CD3OD.  
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13C NMR (176 MHz, 298.2 K) of 13C-labelled cyclopropanated I8-1Dha mono core in CD3OD.  
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Calibration curves 
Calibration curves for 2-ethyl 1-methyl 1-benzamidocyclopropane-1,2-dicarboxylate and 
diethyl maleate were prepared according to the following procedure: A 0.2 M stock solution of 
product standard was used to prepare 400 μL samples of product standard at 0.1 mM, 0.2 mM, 
0.4 mM, 0.8 mM, 1.6 mM and 2 mM in 0.1 M potassium phosphate (pH 8.0) containing 2 mM 
internal standard (diethyl 2-benzamidomalonate) and 5% ethanol. The samples were extracted 
with 1 mL of ethyl acetate, transferred to a 1.7 mL microcentrifuge tube, and centrifuged for 5 
min at 18400 xg. The organic layer was diluted 1:1 with 50% ethanol, and 20 μL of the solution 
was analyzed using LC-MS Method A. The absorbance at 254 nm was used for integration. 
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The calibration curve for ethyl 2-(1-acetamido-2-(ethoxycarbonyl)cyclopropyl)thiazole-
4-carboxylate was prepared according to the following procedure: A 0.2 M stock solution of 
product standard was used to prepare 200 μL samples of product standard at 0.1 mM, 0.2 mM, 
0.4 mM, 0.8 mM, 1.6 mM and 2 mM in 0.1 M potassium phosphate (pH 8.0) containing 1 mM 
internal standard (diethyl 2-benzamidomalonate) and 5% DMSO. The samples were extracted 
with 1 mL of ethyl acetate, transferred to a 1.7 mL microcentrifuge tube, and centrifuged for 5 
min at 18400 xg. The organic layer was collected in a separate microcentrifuge tube and 
evaporated to dryness. The dry material was dissolved in 1 mL of ethanol, and 1 μL of the 
solution was analyzed using LC-MS Method D. The absorbance at 254 nm was used for 
integration. 
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Calibration curves for TbtA F5Dha core and TbtA I8Dha core were prepared according 
to the following procedure: A 2 mM stock solution of thiomuracin derivative was used to prepare 
200 μL samples at 100 μM, 50 μM, 25 μM, 12.5 μM, and 6.25 μM in 0.1 M potassium phosphate 
(pH 8.0) containing 5% ethanol and 20 μM hemin. The samples were extracted with 1 mL of 
ethyl acetate, transferred to a 1.7 mL microcentrifuge tube, and centrifuged for 5 min at 18400 
xg. The organic layer was then completely evaporated. The remaining pellet was dissolved in 
200 μL of DMSO, and 20 μL of the resulting solution was analyzed using LC-MS Method A. 
The absorbance at 254 nm was used for integration. 
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Supporting Information 
 
Figure S3.1. HPLC traces from enzymatic cyclopropanations of methyl 2-benzamidoacrylate (1) 
(N-Bz-Dha-COOMe). 
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P450BM3-T268A/C400S - N-Bz-Dha-COOMe
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P450BioI-T238A/C344S - N-Bz-Dha-COOMe 
 
 
 
 
P450EryF - N-Bz-Dha-COOMe 
 
 
 
 
 
CYP142-T234A - N-Bz-Dha-COOMe 
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CYP119-T213A - N-Bz-Dha-COOMe 
 
 
CYP119-T213A/C317S - N-Bz-Dha-COOMe
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P450TbtJ1 - N-Bz-Dha-COOMe 
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P450TbtJ1-T234A/C340S - N-Bz-Dha-COOMe 
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P450TbtJ2-C340S - N-Bz-Dha-COOMe 
 
 
 
 
P450TbtJ2-T247A/C353S - N-Bz-Dha-COOMe 
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Figure S3.2. HPLC traces from enzymatic cyclopropanations of ethyl 2-(1-
acetamidovinyl)thiazole-4-carboxylate (2) (N-Ac-ThzDha-COOEt). 
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P450BM3-CIS-C400S - N-Ac-ThzDha-COOEt 
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P450EryF - N-Ac-ThzDha-COOEt 
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CYP119-T213A/C317S - N-Ac-ThzDha-COOEt 
 
 
 
 
 
P450PikC-T247A - N-Ac-ThzDha-COOEt 
 
 
 
P450TbtJ1-T234A - N-Ac-ThzDha-COOEt 
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P450TbtJ1-T234A/C340S - N-Ac-ThzDha-COOEt 
 
 
  
P450TbtJ2-T247A - N-Ac-ThzDha-COOEt 
 
 
 
P450TbtJ2-T247A/C353S - N-Ac-ThzDha-COOEt 
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Figure S3.3. Chiral GC traces from cyclopropanations of methyl 2-benzamidoacrylate with 
EDA. 
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P450TbtJ2-T247A/C353S 
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Table S3.1. Conversions and turnovers for EDA dimer formation during cyclopropanation 
reactions with 1. 
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Table S3.2. Data collection and refinement statistics for TbtJ1 crystallography. 
 
 TbtJ1 
pdb accession # t.b.d. 
Data collection  
Space group P 41 21 2 
Wavelength 1.000 
Cell dimensions  
a, b, c (Å) 95.316, 95.316, 126.782 
a, b, g () 90 
Resolution (Å) 26.44 – 2.41 (2.50 – 2.41) * 
Rmerge 10.0 (47.9) 
I / σI 6.0 (2.0) 
Completeness (%) 91.2 (67.5) 
Redundancy 3.7 (2.4) 
  
Refinement  
Resolution (Å) 26.44 – 2.41 
No. reflections 21195 
Rwork / Rfree 0.21/ 0.28 
  
No. atoms  
Protein 3003 
Ligand/ion 43 
Water 96 
  
B-factors  
Protein 23.3 
Ligand/ion 12.8 
Water 20.3 
  
R.m.s. deviations  
Bond lengths (Å) 0.009 
Bond angles () 1.03 
  
Ramachandran outliers 1.6 % 
*All data sets were collected from single crystals. Highest-resolution shell is shown in parentheses. 
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Figure S3.4. TbtJ1 structure determination. (A) The structure of TbtJ1 was determined by X-ray 
crystallography to 2.4 Å via molecular replacement using P450 EryK (54% identity, PDB: 
2WIO) as a model template. The heme is shown as cyan sticks. Two regions of TbtJ1 were 
unstructured in the final structure including residues 64-70 (MPTAQGF) in the B-C loop and 
residues 165 and 166 (NY) in the F-G loop. Flanking residues for these missing regions are 
highlighted in orange. (B) Close up of the modeled heme from TbtJ1 overlaid with the 2Fo – Fc 
maximum likelihood weighted electron density map. (C) Structural alignments of TbtJ1 with the 
EryK structure used as a molecule replacement model. 
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Figure S3.5. X-ray crystal structure of ligand-free TbtJ1. The heme is shown as green sticks. 
The B-C loop that caps the active site is disordered in this structure. The B-C loop from ligand-
bound PikC has been superimposed in red, to provide a rough estimate of this capping 
interaction. Three Phe residues flank the active site. F280 and F303 (purple) are well resolved in 
the crystal structure. The side chain of F73 (olive) is poorly structure in the crystal structure, but 
modeled here (using coot) to show the approximate orientation with respect to the active site. 
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Figure S3.6. TbtJ1 alignment with the open and closed forms of PikC. (A) TbtJ1 alignment with 
the ligand-free, open form of PikC (PDB: 2BVJ). Residues flanking the missing, disordered 
regions of TbtJ1 are highlighted in orange. Similar disordered regions (highlighted in olive) are 
observed in the ligand-free form of PikC. (B) TbtJ1 alignment with the ligand-bound, closed 
form of PikC (PDB:2C7X). The disordered region of PikC is now well structured (olive) and 
provides a rough estimate of where missing residues in TbtJ1 may be located when bound to 
thiopeptide substrates. 
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Figure S3.7. Loop modeling of TbtJ1 based on the closed form of PikC. Structural alignment 
with the closed form of PikC provides a crude estimate of the location of unstructured residues in 
TbtJ1. These regions are shown as surface representations in panel A and, for clarity, as cartoons 
in panel B. Residues flanking this unstructured region in TbtJ1 are highlighted in orange. The 
ordered loop from the ligand-bound form of PikC (PDBL2C7X) is highlighted in pink and shows 
that missing residues in TbtJ1 likely form a cap over the deep heme-bound active site. 
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Figure S3.8. Comparison of P450 binding pockets for highly active cyclopropanation variants 
(A) P450TbtJ1 (PDB: t.b.d.), (B) P450PikC (PDB: 2BVJ), and (C) CYP119 (PDB: 1IO7) as well as 
poorly active variants (D) P450BM3 (PDB: 1YQO) and (E) CYP142 (PDB: 2XKR). Cavity 
volumes calculated using the 3V, volume calculator (http://3vee.molmovdb.org),14 are shown on 
the left. Surface representations of each crystal structure are shown in the middle. Regions 
identified in 3V are highlighted in yellow in the corresponding surface structures. Highly active 
variants show considerably larger cavities providing access to the heme cofactor. Structures of 
representative substrates for each P450 are shown to the right. 
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Figure S3.9. ClustalOmega alignment of P450 protein sequences. The conserved active-site 
threonine and ligating cysteine are highlighted in yellow, and amino acid substitutions that differ 
from the highly conserved threonine are highlighted in red. Active site phenylalanine residues 
are highlighted in green. 
 
BM3         MTIKEMPQPKT-FGELKNLPLLN---TD----KPVQALMKIADEL---GEIFKFEA---- 45 
CYP142      ---------------MTEAPDVDLADGNFYASREARA---AYRWMRANQPVFRDRN---- 38 
CYP119      -------------------------------------MYDWFSEMRKKDPVYYDG----- 18 
TbtJ1       ------------------MMELP---GQPSLTDGGAALFAWLRTMRNEHPVWRDQF---- 35 
TbtJ2       -----MNEPLTAQGTPTMTMPAA---QRPRISHGGQALLKWLDEMRESQPVWRDGF---- 48 
BioI        -------------------MTIA---SSTASSEFLKNPYSFYDTLRAVHPIYKGSF-LKY 37 
PikC        -------MRRTQQGTTASPPVLD---LGALGQDFAADPYPTYARLRAEGPAHRVRTPEGD 50 
EryF        ---------------MTTVP-------DLESDSFHVDWYRTYAELRETAPVTPVRF-LGQ 37 
                                                        :                
 
BM3         -PGRVTRYLSSQRLIKEACDESRFDKNLS-----------QALKFVRDFAG---DGLFTS 90 
CYP142      GLAAASTYQAVIDAERQP---ELFSN-AGGIR----------------PDQPALPMMIDM 78 
CYP119      NIWQVFSYRYTKEVLNNF---SKFSSDLTGYHERLEDLRNGKIR----FDIPTRYTMLTS 71 
TbtJ1       GIYHVFRYDDVRQILGDY---QTFSSDRTRLMPT--------------AQGFGKGGITMI 78 
TbtJ2       GIFHVFRHADVQRVMADY---ATFSSDINRLRPG--------------GDPFSAGSLMLT 91 
BioI        PGWYVTGYEETAAILKDA---R-FKVRTPLPE-----SSTK----YQDLSHVQNQMMLFQ 84 
PikC        EVWLVVGYDRARAVLADP---R-FSKDWRNSTTPL-----------TEAEAALNHNMLES 95 
EryF        DAWLVTGYDEAKAALSDL---R-LSSDPKKKYPGVEVEFPAYLGFPEDVRNYFATNMGTS 93 
                .  :        :      :.                               :    
 
BM3         WTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERLNADEHIEVPEDMTRLT 150 
CYP142      --DDPAHLLRRKLVNAGFTRKRVKDKEASIAALCDTLIDAV--CE--------------- 119 
CYP119      --DPPLHDELRSMSADIFSPQKLQTLETFIRETTRSLLDSI---D--------------- 111 
TbtJ1       --DPPEHRHQRRLITHAFTPQSISAMEPRIRQIADHLLDEL---P--------------- 118 
TbtJ2       --DPPEHRKLRRLISQAFSPKMSADMKPRIAELTEELLDDI---E--------------- 131 
BioI        --NQPDHRRLRTLASGAFTPRTTESYQPYIIETVHHLLDQV--QG--------------- 125 
PikC        --DPPRHTRLRKLVAREFTMRRVELLRPRVQEIVDGLVDAMLAAP--------------- 138 
EryF        --DPPTHTRLRKLVSQEFTVRRVEAMRPRVEQITAELLDEV--GD--------------- 134 
              .       : :    *: :     .  :      *::                      
 
BM3         LDTIGLCGFNYRFNSFYRDQPHPFITSMVRALDEAMNK-------LQRANPDDPAYDENK 203 
CYP142      ---RGECDFV---RDLAAPLPMAVIGDMLGVRPEQRDMFLRWSDDLVTFLSSHVSQ-EDF 172 
CYP119      ---PREDDIV---KKLAVPLPIIVISKILGLPIEDKEKFKEWSDLVAFRLGK----PGEI 161 
TbtJ1       ---GPEFDLV---EHFAYPLPVIVIAELLGVPPGDRHLFRTWSDRLMSLQVENYADPELA 172 
TbtJ2       ---EDEFDLV---EKFAHPLPIMVIAELLGIPIHDRGLFRTWADRLIALHVDDPTDVEIG 185 
BioI        ---KKKMEVI---SDFAFPLASFVIANIIGVPEEDREQLKEWAASLIQTIDFTRSR-KAL 178 
PikC        ---DGRADLM---ESLAWPLPITVISELLGVPEPDRAAFRVWTDAFVFPDD--P-----A 185 
EryF        ---SGVVDIV---DRFAHPLPIKVICELLGVDEKYRGEFGRWSSEILVMDPERA-----E 183 
                    .      :       .* .::                .               
 
BM3         RQFQEDIKVMNDLVDKIIADRKASGEQSDDLLTHMLNGKDPETGEPLDDENIRYQIITFL 263 
CYP142      QITMDAFAAYNDFTRATIAARR--ADPTDDLVSVLVSS-EV-DGERLSDDELVMETLLIL 228 
CYP119      FELGKKYLELIGYVKDHLNS-------GTEVVSRVV-------NSNLSDIEKLGYIILLL 207 
TbtJ1       RTVAAAMTEMNDYLREHCRSRR--THPRDDLLTRLVQA-EV-EGKRLDLEEVVNTASLLL 228 
TbtJ2       RMVGEAMREMGEYVQTHVRKRR--ADPQDDLVSKLIAA-EV-DGERLTDAEIVNTSCLLL 241 
BioI        TEGNIMAVQAMAYFKELIQKRK--RHPQQDMISMLLKGREK---DKLTEEEAASTCILLA 233 
PikC        Q-AQTAMAEMSGYLSRLIDSKR--GQDGEDLLSALVRTSDE-DGSRLTSEELLGMAHILL 241 
EryF        Q-RGQAAREVVNFILDLVERRR--TEPGDDLLSALIRVQDD-DDGRLSADELTSIALVLL 239 
                                         :::: ::          *   :       :  
 
BM3         IAGHETTSGLLSFALYFLVKNPHVLQKAAEEAARVLVDPVPSYKQVKQLKYVGMVLNEAL 323 
CYP142      IGGDETTRHTLSGGTEQLLRNRDQWDLLQRDP-----------------SLLPGAIEEML 271 
CYP119      IAGNETTTNLISNSVIDFTRFNLW--QRIREE-----------------NLYLKAIEEAL 248 
TbtJ1       LAGHLTTTVLIGNTMLCLWDHPEAEKAVRADP-----------------SLIPAALEESL 271 
TbtJ2       LAGQITSTMALGNTFLCFRDAPDAERAVRADF-----------------SLLGPAFEEVL 284 
BioI        IAGHETTVNLISNSVLCLLQHPEQLLKLRENP-----------------DLIGTAVEECL 276 
170 
PikC        VAGHETTVNLIANGMYALLSHPDQLAALRADM-----------------TLLDGAVEEML 284 
EryF        LAGFEASVSLIGIGTYLLLTHPDQLALVRRDP-----------------SALPNAVEEIL 282 
            :.*  ::   :.     :            :                       ..:* * 
 
BM3         RLWPTAPA-FSLYAKEDTVLGGEYPLEKGDELMVLIPQLHRDKTIWGDDVEEFRPERFEN 382 
CYP142      RWTAPVKN-MCRVLTADTEFHGT-ALCAGEKMMLLFESANFDEAVFCE------PEKFDV 323 
CYP119      RYSPPVMR-TVRKTKERVKLGDQ-TIEEGEYVRVWIASANRDEEVFHD------GEKFIP 300 
TbtJ1       RLRSPFLQ-AGRVTTRDVTIAGE-TIPANRFVMAWILSANHDDRRFPD------PERFDL 323 
TbtJ2       RLRPPLTQ-AARLTTTDVEVAGT-LIPAGSLVINWLLSANYDERQFPN------PYRFDL 336 
BioI        RYESPTQM-TARVASEDIDICGV-TIRQGEQVYLLLGAANRDPSIFTN------PDVFDI 328 
PikC        RYEGPVESATYRFPVEPVDLDGT-VIPAGDTVLVVLADAHRTPERFPD------PHRFDI 337 
EryF        RYIAPPET-TTRFAAEEVEIGGV-AIPQYSTVLVANGAANRDPKQFPD------PHRFDV 334 
            *                  . .   :     :       :     : :         *   
 
BM3         PSAIPQHAFKPFGNGQRACIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKE-TLTLK 441 
CYP142      QRN--PNSHLAFGFGTHFCLGNQLARLELSLMTERVLRRLPDLR-----LVADDSVLPLR 376 
CYP119      DRN--PNPHLSFGSGIHLCLGAPLARLEARIAIEEFSKRFRHIE-----ILDTE----KV 349 
TbtJ1       HRQ--TTGHIAFGHGVHFCLGAQLGRLEGRIALERLLGRFTEIH-----PWPRE-GISFY 375 
TbtJ2       TRS--PNRHFAFGHGIHHCLGAPLARVEGRVALELLLRRFSEIT-----IDPDA-ELSYY 388 
BioI        TRS--PNPHLSFGHGHHVCLGSSLARLEAQIAINTLLQRMPSLN-----LA----DFEWR 377 
PikC        RRD--TAGHLAFGHGIHFCIGAPLARLEARIAVRALLERCPDLA-----LDVSPGELVWY 390 
EryF        TRD--TRGHLSFGQGIHFCMGRPLAKLEGEVALRALFGRFPALS-----LGIDADDVVWR 387 
                    .  ** * : *:*  :.  *  :    .  :                      
 
BM3         PEGFVVKAKSKKIPLGGIPSPST----- 464 
CYP142      PA--NFVSGLESMPVVFTPSPPLG---- 398 
CYP119      PN--EVLNGYKRLVVRLKSNE------- 368 
TbtJ1       QSAIF---GASRMPVRCG---------- 390 
TbtJ2       EDPMF---GVKSLPVRVRRAA------- 406 
BioI        YRPLFGFRALEELPVTFE---------- 395 
PikC        PNP--MIRGLKALPIRWRRGREAGRRTG 416 
EryF        RSL--LLRGIDHLPVRLDG--------- 404 
 
 
 
 
 
Figure S3.10. Percent identity matrix for TbtJ1, TbtJ2, and P450 library (generated by Clustal 
12.1). 
 
1: BM3         100.00   19.35   18.66   19.35   19.37   18.21   19.47   16.98 
2: CYP142       19.35  100.00   28.77   32.02   33.07   27.25   31.87   31.66 
3: CYP119       18.66   28.77  100.00   33.24   34.65   30.77   34.38   29.72 
4: TbtJ1        19.35   32.02   33.24  100.00   53.33   30.79   37.47   34.75 
5: TbtJ2        19.37   33.07   34.65   53.33  100.00   30.26   34.61   35.70 
6: BioI         18.21   27.25   30.77   30.79   30.26  100.00   35.43   33.85 
7: PikC         19.47   31.87   34.38   37.47   34.61   35.43  100.00   46.04 
8: EryF         16.98   31.66   29.72   34.75   35.70   33.85   46.04  100.00 
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Figure S3.11. LC-MS/MS of linear TbtA I8-1Dha core. 
LC-MS Method A; CID = 55 eV. Expected [M+H]+: 1278.2653; Observed [M+H]+: 1278.2667. 
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Figure S3.12. HPLC and extracted ion chromatogram (EIC) traces of enzymatic 
cyclopropanations of linear TbtA I8-1Dha core (analyzed by LC-MS Method A). 
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Figure S3.13. LC-MS/MS of cyclopropanated linear TbtA I8-1Dha core. 
LC-MS Method A; CID = 55 eV. Expected [M+H]+: 1364.3021; Observed [M+H]+: 1364.3090. 
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Figure S3.14. LC-MS/MS of linear TbtA core. 
LC-MS Method C; CID = 45.0 eV. Expected [M+H]+: 1318.2966, Observed [M+H]+: 
1318.2955. 
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Figure S3.15. LC-MS/MS of linear TbtA F5-3Dha core. 
LC-MS Method C; CID = 45 eV. Expected [M+H]+: 1240.2497; Observed [M+H]+: 1240.2509. 
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Figure S3.16. LC-MS/MS of linear TbtA I8-3Dha core (9). 
LC-MS Method C; CID = 45 eV. Expected [M+H]+: 1274.2340; Observed [M+H]+: 1274.2338. 
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Figure S3.17. HPLC and extracted ion chromatogram (EIC) traces of enzymatic 
cyclopropanations of linear TbtA core (analyzed by LC-MS Method A). 
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Figure S3.18. HPLC and extracted ion chromatogram (EIC) traces of enzymatic 
cyclopropanations of linear TbtA F5-3Dha core (analyzed by LC-MS Method A). 
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Figure S3.19. HPLC and extracted ion chromatogram (EIC) traces of enzymatic 
cyclopropanations of linear TbtA I8-3Dha core (analyzed by LC-MS Method A).
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Figure S3.20. LC-MS/MS of cyclopropanated linear TbtA core. 
LC-MS Method A; CID = 55 eV. Expected [M+H]+: 1490.3702; Observed [M+H]+: 1490.3722. 
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Figure S3.21. LC-MS/MS of cyclopropanated linear TbtA F5-3Dha core. 
LC-MS Method A; CID = 55 eV. Expected [M+H]+: 1498.3600; Observed [M+H]+: 1498.3620. 
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Figure S3.22. LC-MS/MS of cyclopropanated linear TbtA I8-3Dha core. 
LC-MS Method A; CID = 55 eV. Expected [M+H]+: 1532.3444; Observed [M+H]+: 1532.3485. 
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Figure S3.23. HPLC traces for time course experiments with TbtJ2-T247A and I8-3Dha core. 
Reactions were setup following the procedure for small-scale cyclopropanation of thiomuracin 
derivatives described above. Percent conversion was measured after 5 min, 30 min, 1 h, and 2 h. 
The starting material peak (I8Dha) is colored blue, and the 3 cyclopropane product peaks are 
colored red. 
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Figure S3.24. HPLC traces for catalyst loading experiments with TbtJ2-T247A and I8-3Dha 
core. Reactions were setup following the procedure for small-scale cyclopropanation of 
thiomuracin derivatives described above. Percent conversion was measured at enzyme loadings 
of 2 mol% (2 µM), 5 mol% (5 µM), and 10 mol% (10 µM) after 16 hours. The starting material 
peak (I8Dha) is colored blue, and the 3 cyclopropane product peaks are colored red. 
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Figure S3.25. HPLC and extracted ion chromatogram (EIC) traces of cyclopropanations of 
linear TbtA I8-3Dha core with traditional catalysts (analyzed by LC-MS Method A). 
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Figure S3.26. LC-MS/MS of 15LP-TbtA F5Dha. 
LC-MS Method C; CID = 45 eV. Expected [M+2H]+2: 1319.4589; Observed [M+2H]+2: 
1319.4849. 
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Figure S3.27. LC-MS/MS of 15LP-TbtA I8Dha. 
LC-MS Method C; CID = 45 eV. Expected [M+2H]+2: 1336.4511; Observed [M+2H]+2: 
1336.4737. 
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Figure S3.28. LC-MS/MS of cyclized TbtA F5Dha. 
LC-MS Method B; CID = 55 eV. Expected [M+H]+: 1163.2020; Observed [M+H]+: 1163.2010. 
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Figure S3.29. LC-MS/MS of cyclopropanated cyclized TbtA F5Dha. 
LC-MS Method B; CID = 55 eV. Expected [M+H]+: 1249.2388; Observed [M+H]+: 1249.2337. 
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Figure S3.30. SDS‐polyacrylamide gel electrophoresis analysis of his-tag purified P450 variants. 
The 40 kDa and 50 kDa protein markers are indicated with white text in each gel image. 
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